

EXHIBIT 5



EXHIBIT C

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1	AVMDL04089532	AVMDL04089533	6/4/1998	Email from H. Ross to G. Campion, cc J. Balcarek
2	AVMDL00006962	AVMDL00006964	8/6/1996	Message to Team from H. Ross
3	AVMDL04090206	AVMDL04090206	7/30/1998	Email from R. Price to L. Menci et al.
4	AVMDL03971471	AVMDL03971474	9/25/1998	Email from M. Freed to A. Rebuck, et al.
5	AVMDL01869186	AVMDL01869189	3/17/1998	Internal GSK Document Entitled "Additional Analysis for Monotherapy Studies in Light of New Developments"
6	AVMDL01860309	AVMDL01860319	1/4/1998	R&D Avandia Update
7	AVMDL03974745	AVMDL03974746	3/16/1998	Email from N. Jones to A. Salzman, et al.
8	AVMDL04090061	AVMDL04090064	7/20/1998	Email from A. Rutt to J. Balcarek
9	AVMDL03972878	AVMDL03972881	8/6/1998	Email from M. Freed to H. Ross, et al.
10	AVMDL04089075	AVMDL04089077	4/8/1998	Email from M. Freed to M. McCoy, et al.
11	AVMDL01428993	AVMDL01428995	12/16/1998	Email from W. Nickerson to S. Weill, et al.
12	AVMDL00076892	AVMDL00076893	7/20/2001	Email from M. Freed to R. Berry, cc D. Garrison
13	AVMDL00296565	AVMDL00296566	3/29/2001	Email from M. Freed to S. Dollow, et al.
14	AVMDL00067833	AVMDL00067833	10/23/2000	Email from D. Fuell to D. Krause, cc M. Freed
15	AVMDL06691125	AVMDL06691125	6/25/1999	Email from T. Yamada to W. Claypool, cc D. Stout/ JP Garnier
16	AVMDL01620682	AVMDL01620684	3/12/2000	Letter from Dr. J. Buse to J. Henney
17	AVMDL00312843	AVMDL00312843	6/25/1999	Email from JP Garnier to M. Freed, cc T. Yamada
18	AVMDL10619942	AVMDL10619945	6/25/1999	Memo from M. Freed to JP Garnier, et al.
19	AVMDL04090236	AVMDL04090237	7/30/1998	Email from M. Freed to R. Price, et al.
20	AVMDL00001643	AVMDL00001644	4/22/1994	U.S. Regulatory Affairs, FDA Conversation Record
21	AVMDL00003067	AVMDL00003073	4/21/2000	Study Proposal (Freezer Study)
22	AVMDL00003085	AVMDL00003087	8/28/2000	Analysis Plan for Study 243
23	AVMDL00074584	AVMDL00074585	11/6/2001	Email from M. Freed to D. Brand/P. Letendre
24	AVMDL04096034	AVMDL04096036	6/25/1999	Email from C. Depew to M. Freed, et al.
25	AVMDL00080185	AVMDL00080187	12/14/2000	Email from P. Letendre to R. Buckingham, et al.
26	AVMDL00140865	AVMDL00140867	11/21/2003	Email from M. Freed to S. Shaoival
27	AVMDL00260397	AVMDL00260418	9/16/2001	Email/Attachments from B. Blakely to M. Freed
28	AVMDL00295388	AVMDL00295389	4/20/2001	Email from M. Freed to B. Mansi, et al.
29	AVMDL00428692	AVMDL00428697	8/10/1999	HPB's Request for the Addition of Cardiac Disease to the Avandia Product Monograph (Canada)
30	AVMDL00430169-R	AVMDL00430170-R	6/30/1999	Email from S. Shapowal to M. McCoy
31	AVMDL00493269	AVMDL00493270	5/13/2007	Email from R. Krall to S. Nissen
32	AVMDL00670375	AVMDL00670393	10/1/2001	Avandia and Myocardial Infarction
33	AVMDL01470467	AVMDL1470467	12/14/2000	Email from M. Freed to N. Biswas et al.
34	AVMDL03438258	AVMDL03438645	3/7/1999	Avandia Launch Plan
35	AVMDL04090206	AVMDL04090206	7/30/1998	Email from R. Price to L. Menci/M. Freed, et al.
36	AVMDL06694101	AVMDL06694102	10/19/1999	SKB Memo from JP Garnier re: 3/1 Plan Presentations for 2000 to 2002
37	AVMDL07714294	AVMDL07714295	5/8/2007	Email from M. Shaout to L. Macarthy, et al.
38	AVMDL00471372	AVMDL00471389	12/7/2001	Avandia Lipid Publication Strategy

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
39	AVMDL001715686	AVMDL001715708	1999	Avandia 1999 Publication Plan
40	AVMDL00539526	AVMDL00539526	11/16/2001	Email from L. Caponi to A. Cobitz
41				Time to Onset for Cardiovascular Adverse Events in Studies 49653/082 and 49653/085
42	AVMDL00007336	AVMDL00007339	3/25/1996	U.S. Regulatory Affairs, FDA Conversation Record
43	AVMDL00007354-R*	AVMDL00007362-R	?/?/1996	Regulatory Affairs Document
44	AVMDL00007378	AVMDL00007382	NA	Handwritten Notes re 49653C
45	AVMDL00007976	AVMDL00008031	NA	"Avandia Safety Profile" By, E. Rappaport
46	AVMDL00009822	AVMDL00009825	3/15/2000	UNC Health Care Letter to Dr. Henney
47	AVMDL00011308	AVMDL00011308	6/28/1999	Letter from J. Buse dated 06/28/1999
48	AVMDL00011391	AVMDL00011395	10/31/2001	Letter from Dept. of Health & Human Services to D. Wheadon
49	AVMDL00012436	AVMDL00012464	?/?/?/01	"Avandia for the Metabolic Syndrome: STP for the CVU TAST" slide set
50	AVMDL00013964	AVMDL00013964	8/20/2001	FDA/SB Meeting Record
51	AVMDL00016321	AVMDL00016326	10/22/1998	Excerpt from Study 024, Clinical Report - "5.3.5 Lipid Parameters"
52	AVMDL00016818	AVMDL00016820	5/31/2001	Email from F. Lowry to S. Weill et al.
53	AVMDL00017293	AVMDL00017295	7/12/2001	Email from S. Shapowal to S. Weill
54	AVMDL00031588	AVMDL00031589	6/25/1999	Email from M. Freed to J. Garnier
55	AVMDL00033862	AVMDL00033871	3/12/2002	Letter from S. Haffner to Dr. J. Wilerson
56	AVMDL00035027	AVMDL00035028	2/7/2002	Email from J. Osborne to M. Freed
57	AVMDL00051851	AVMDL00051853	7/6/2001	Email from M. Stewart to M. Freed
58	AVMDL00054279	AVMDL00054282	3/15/2000	UNC Health Care - J. Buse letter to Dr. Henney
59	AVMDL00057759-R	AVMDL00057766-R	5/2/2001	Email from A. Nathwani to B. Cole
60	AVMDL00057948	AVMDL00057950	4/26/2001	Email from S. Calmels to M. Freed
61	AVMDL00058426	AVMDL00058431	4/12/2001	Email from S. Calmels to M. Freed
62	AVMDL00058501	AVMDL00058502	4/10/2001	Email from Mansi to Cobitz, et. all, cc: Nigel Jones
63	AVMDL00060388	AVMDL00060388	3/15/2001	Email from M. Stewart to J. Dole, et.al.
64	AVMDL00063317	AVMDL00063318	1/24/2001	Email from A. Cobitz to M. DiMatteo
65	AVMDL00065696	AVMDL00065700	11/30/2000	Email from J. Freid to A. Cobitz et al.
66	AVMDL00065701	AVMDL00065719	12/?/00	Avandia and Hypertriglyceridemia
67	AVMDL00066432	AVMDL00066437	NA	Study 175 Headline Results Summary
68	AVMDL00066910	AVMDL00066913	11/3/2000	Email from M. DiMatteo to M. Freed
69	AVMDL00067683	AVMDL00067686	10/25/2000	Email from P. Letendre to J. Balcarek et al.
70	AVMDL00067819	AVMDL00067819	10/23/2000	Lp PLA2 Results of Assay of Frozen Samples from Avandia Study 01
71	AVMDL00067833	AVMDL00067833	10/23/2000	Email from D. Fuell to D. Krause
72	AVMDL00070848	AVMDL00070851	8/29/2000	Email from H. Chen to D. Fuell
73	AVMDL00070849	AVMDL00070851	08/?/00	DRAFT Analysis Plan for Study 243
74	AVMDL00071047	AVMDL00071048	8/23/2000	Email from W. Tucker to A. Berg et al.
75	AVMDL00072643	AVMDL00072646	2/12/2002	Email from M. Freed to N. Jones re 096 manuscript
76	AVMDL00072766	AVMDL00072774	1/28/2002	Draft - "Comparison of Rosiglitazone and Pioglitazone for Filing in Support of the Japanese NDA"

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
77	AVMDL00074584	AVMDL00074585	11/16/2001	Email from M. Freed to D. Brand and P. Letendre
78	AVMDL00074681	AVMDL00074683	10/30/2001	Email from M. Freed to A. Cobitz
79	AVMDL00075892	AVMDL00076893	7/20/2001	Email from M. Freed to R. Berry
80	AVMDL00078549	AVMDL00078551	5/18/2001	Email from M. Freed to S. Dollow
81	AVMDL00080185	AVMDL00080187	12/14/2000	Email from P. Letendre to R. Buckingham et al.
82	AVMDL00080343	AVMDL00080348	11/21/2000	Email from M. Freed to P. Letendre
83	AVMDL00080400	AVMDL00080402	11/12/2000	Email from M. Freed to P. Letendre
84	AVMDL00080436	AVMDL00080437	10/26/2000	Email from M. Freed to D. Brooks
85	AVMDL00080461	AVMDL00080464	10/24/2000	Email from M. Freed to D. Brooks
86	AVMDL00081405	AVMDL00081528	8/23/2000	Rosiglitazone BRL 49653C, Report 12, Phase IIIB: Final Clinical Report
87	AVMDL00082107-R	AVMDL00082109-R	8/1/2000	Email from P. Letendre to M. Freed
88	AVMDL00082122	AVMDL00082127	7/31/2000	Draft Letter to Dr. Buse
89	AVMDL00082580	AVMDL00085580	6/19/2000	Excerpt from Rosiglitazone and Glyburide Combination Therapy study
90	AVMDL00088519	AVMDL00088520	11/29/1999	Email from J. Huang to M. Freed
91	AVMDL00095106	AVMDL00095108	11/20/2003	Email from Shapowal to Yuhas
92	AVMDL00097249	AVMDL00097279	01/??/1999	Global Clinic Safety & Pharmacovigilance, Pharmacovigilance Plan: Avandia
93	AVMDL00114205	AVMDL00114208	3/19/2001	Email from S. Shapowal to C. Blumhardt and D. Wheadon
94	AVMDL00133633-R	AVMDL00133634-R	7/1/1999	Email from S. Shapowal to D. Wheadon
95	AVMDL00133641	AVMDL00133645	06/??/1999	Letter from J. Buse to T. Yamada with enclosure
96	AVMDL00133666-R	AVMDL00133667-R	6/28/1999	Email from S. Shapowal to M. McCoy
97	AVMDL00134322	AVMDL00134323	5/10/1999	Letter from Kahn to Askin
98	AVMDL00140865	AVMDL00140867	11/21/2003	Email from Freed to Shapowal
99	AVMDL00141113	AVMDL00141114	11/14/2003	Email from Shapowal to Chen
100	AVMDL00141115	AVMDL00141120	4/12/2001	Analysis of Percent Change in Biomarkers from Baseline to Week 26
101	AVMDL00142021	AVMDL00142023	1/28/2004	Global Safety Board Minutes of Meeting held January 28, 2004
102	AVMDL00142068-R	AVMDL00142073-R	3/10/2003	Email from B. Cole to L. Porter
103	AVMDL00161518	AVMDL00161520	10/17/2002	Global Safety Board Meeting Minutes for meeting held October 17, 2002
104	AVMDL00173582	AVMDL00173587	8/22/2001	Cost Breakdown Spreadsheets
105	AVMDL00174676	AVMDL00174677	6/4/2001	Email from J. Balcarek to S. Shapowal
106	AVMDL00202397	AVMDL00202430	11/4/1996	Investigative Toxicology Programme for Rosiglitazone (BRL-49653-C)
107	AVMDL00202727	AVMDL00202728	10/14/1997	Email from S. Jones to J. Patel
108	AVMDL00203613	AVMDL00203616	03/??/1999	Handwritten notes: CV Panel
109	AVMDL00204549	AVMDL00204782	12/5/2003	General Correspondence: Submission of Briefing Document to Support Meeting with FDA
110	AVMDL00205260	AVMDL00205260	NA	Blue Print Meeting Follow-up: Avandia Core Claims
111	AVMDL00214623	AVMDL00214634	6/3/2003	GCS Review Bulletin - Record Study
112	AVMDL00215784	AVMDL00215792	5/7/2003	Prescribing Information Review Group Minutes for 'No' Decisions or Deferrals
113	AVMDL00217958	AVMDL00217972	??/??/02	"Progression of EBOS signal scores by year" Charts

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
114	AVMDL00223015	AVMDL00223015	3/29/2004	Email from K. Prodan to A. Zalewski et al.
115	AVMDL00223577	AVMDL00223577	11/19/2003	Additional Data for Rosiglitazone item
116	AVMDL00223648	AVMDL00223661	1/16/2004	Email from L. Hegg to A. Gianchetti, et. al.
117	AVMDL00249244	AVMDL00249249	1/28/2002	Email from M. Stewart to C. Shepherd et al.
118	AVMDL00253292	AVMDL00253293	11/20/2001	Email from F. Greenstein to A. Cobitz
119	AVMDL00259340-R	AVMDL00259348-R	8/24/2001	Avandia Clinical Matrix Team Meeting Minutes
120	AVMDL00260397	AVMDL00260418	9/16/2001	Email and attachments from B. Blakely to M. Freed
121	AVMDL00260408	AVMDL00260408	9/16/2001	Net Sales Upside/Downside
122	AVMDL00265180	AVMDL00265182	7/26/2001	Email from A. Cobitz to M. Freed
123	AVMDL00274378-R	AVMDL00274380-R	4/26/2001	Email from K. Batchelor to J. Balcarek et al.
124	AVMDL00277639	AVMDL00277639	3/15/2001	List of Pros and Cons for a Lipid Head-to-Head with Actos
125	AVMDL00283478	AVMDL00283480	10/30/2000	Email from J. Balcarek to M. Freed
126	AVMDL00283493	AVMDL00283494	10/28/2000	Email from R. Ruffolo to D. Brookset al.
127	AVMDL00288466	AVMDL00288468	3/14/2002	Email from M. Freed to F. Lee
128	AVMDL00288506	AVMDL00288508	3/11/2002	Email from M. Freed to W. Weston
129	AVMDL00295235	AVMDL00295235	4/27/2001	Email from M. Freed to B. Mansi
130	AVMDL00295244	AVMDL00295246	4/27/2001	GlaxoSmithKline Proposed Publication Policy
131	AVMDL00295388	AVMDL00295389	4/20/2001	Email from M. Freed to B. Mansi et al.
132	AVMDL00296565-R	AVMDL00296566-R	3/29/2001	Email from M. Freed to S. Dollow et al.
133	AVMDL00297244	AVMDL00297248	1/18/2001	Email from M. Freed to E. Lewis et al.
134	AVMDL00297822	AVMDL00297822	10/5/2000	Email from M. Freed to D. Krause et al.
135	AVMDL00297823-R	AVMDL00297825-R	10/5/2000	Response for ODB
136	AVMDL00305335	AVMDL00305337	11/15/1999	Email from S. Choi to M. Freed et al.
137	AVMDL00308992	AVMDL00308999	2/29/2000	Email string between R. Patwardhan, M. Freed, et al.
138	AVMDL00325635	AVMDL00325631	12/15/1998	"Avandia Lipid Advisory Board" slide set
139	AVMDL00337417	AVMDL00337607	7/24/1998	Rosiglitazone BRL 49653 Final Clinical Report
140	AVMDL00338892	AVMDL00339030	9/22/1998	Rosiglitazone BRL 49653 /020 Final Clinical Report
141	AVMDL00363933	AVMDL00371687	11/16/1998	SB Rosiglitazone BRL 49653 Integrated Summary of Safety
				Fax Sheet and letter from B. Chong, Department of Drug Marketing, Advertising and Communication, to
142	AVMDL00388196	AVMDL00388201	7/17/2001	J.P. Garnier
143	AVMDL00419965	AVMDL00419968	8/31/2000	Letter from M. Freed to Dr. Buse
144	AVMDL00422717	AVMDL00422808	4/12/2000	BRL 49653C/Rosiglitazone, Protocol 143, Final Protocol
145	AVMDL00428692	AVMDL00428697	8/10/1999	HPB's Request for the Addition of Cardiac Disease to the Avandia Product Monograph (Canada).
146	AVMDL00428719	AVMDL00428720	10/7/1999	Email from S. Shapowal to R. Cassidy
147	AVMDL00430169-R	AVMDL00430170-R	6/30/1999	Email from S. Shapowal to M. McCoy
148	AVMDL00430205	AVMDL00430206	6/24/1999	Email from S. Shapowal to M. Freed
149	AVMDL00445525	AVMDL00445526	9/6/2002	Email from C. Kahn to D. Wheadon
150	AVMDL00452456-R	AVMDL00452456-R	4/2/2004	Final minutes of Avandia Project Team Meeting Held Friday 2 April 2004

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
151	AVMDL00457119	AVMDL00457173	5/12/2003	"A 24-Week Randomized, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Avandia (8mg Once Daily) in Combination With Glyburide in African American and Hispanic Patients With Type 2 Diabetes Mellitus Who Are Inadequate Controlled on Glyburide Monotherapy" slide set
152	AVMDL00487101	AVMDL00487101	5/4/2007	Email from Krall to Slaoui
153	AVMDL00487219	AVMDL00487220	12/2/2004	Global Safety Board Minutes for Meeting held 12/2/2004
154	AVMDL00487221	AVMDL00487223	4/8/2005	Global Safety Board Minutes of Meeting held April 8, 2005
155	AVMDL00487224	AVMDL00487225	1/24/2006	Global Safety Board Minutes of Meeting held January 24, 2006
156	AVMDL00487226	AVMDL00487230	3/20/2006	Global Safety Board Minutes for Meeting held March 20, 2006
157	AVMDL00493195	AVMDL00493200	1/24/2007	Global Safety Board Minutes for Meeting held January 24, 2007
158	AVMDL00493263	AVMDL00493264	5/9/2007	Email from C. Dollery to M. Slaoui et al.
159	AVMDL00493269	AVMDL00493270	5/13/2007	Email from Ronald Krall to Steven Nissen
160	AVMDL00493291	AVMDL00493293	5/15/2007	Email from Ronald Krall to Moncef Slaoui
161	AVMDL00493789	AVMDL00493792	5/21/2007	Email from Nancy Pekarek to Chris Viehbacher et al
				Global Safety Board Briefing Document: Initial Results - Rosiglitazone Clinical Trials CV Event Modeling Analysis
162	AVMDL00494100	AVMDL00494121	09/??/05	
163	AVMDL00499387	AVMDL00499390	5/30/2007	Email from A. Thompson to William Collier
164	AVMDL00499707	AVMDL00499708	5/24/2007	"Avandia and the Risk of Heart Attack"
165	AVMDL00499779	AVMDL00499782	05/??/07	Internal Memorandum - Latest News on Avandia
	AVMDL00510146-AVMDL00510	AVMDL00487221-		
166	153 and	AVMDL00487223	4/8/2005	Briefing Document for 08-Apr-2005 Global Safety Board Meeting
167	AVMDL00510292	AVMDL00510324	4/8/2005	"Avandia CV Modelling Plan Evaluation" slide set
168	AVMDL00512249	AVMDL00512250	5/31/2007	Email from D. Cochetto to A. Metz et al.
169	AVMDL00512518	AVMDL00512519	6/3/2007	Email from C. Dollery to L. Macartney
170	AVMDL00513579	AVMDL00513580	7/15/2007	Email from Moncef Slaoui to Colin Dollery et al.
171	AVMDL00513584	AVMDL00513585	7/16/2007	Email from Colin Dollery to Lawson Macartney
172	AVMDL00523397	AVMDL00525401	06/??/1999	List of Items for Close Monitoring
				Clorets II Line Listing: Reports of Cardiovascular Events Received from August 01 to August 31, 2001
173	AVMDL00538908	AVMDL00538917	9/4/2001	
174	AVMDL00539585	AVMDL00539586	11/12/2001	List of Items for Close Monitoring for SB Products and Developmental Compounds
175	AVMDL00564084	AVMDL00564089	05/??/01 to 11/??/01	Body System Tabulation Adverse Experience Report
176	AVMDL00565739	AVMDL00564676	1/7/2000	Periodic Safety Update Report
177	AVMDL00571682	AVMDL00571686	7/5/2002	Email from J. Silvia to S. Hobbiger et al.
178	AVMDL00611866	AVMDL00612122	2/3/2004	Rosiglitazone Safety Update: Avandia, May 26, 2003 to November 25, 2003

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
179	AVMDL00628211	AVMDL00628215	5/24/2007	theheart.org: "The rosiglitazone aftermath: Legitimate concerns or hype?" By, S. Hughes
180	AVMDL0063435	AVMDL00635438	6/30/2004	Global Safety Board Minutes of Meeting held June 30, 2004
181	AVMDL00661064	AVMDL00661064	12/5/2000	Email from A. Nathwani to L. Caponi
182	AVMDL00667800	AVMDL00667805	4/5/2001	Email from J. Freid to R. Cassidy et al.
183	AVMDL00667818	AVMDL00667850	4/6/2001	SB Rosiglitazone Response to Canadian HPR
184	AVMDL00670374	AVMDL00670374	11/6/2001	Email from L. Caponi to A. Cobitz et al.
185	AVMDL00670375	AVMDL00670393	10/1/2001	Avandia and Myocardial Infraction
186	AVMDL00670394	AVMDL00670419	10/30/2001	Line Listing of Adverse Events: Reports of Myocardial Infraction Received as of 9/19/01
187	AVMDL00670420	AVMDL00670427	10/30/2001	Line Listing of Adverse Events: Reports of Myocardial Infraction with a Fatal Outcome Received as of September 19, 2001
188	AVMDL00738553	AVMDL00738581	12/21/2004	Worldwide Market Authorization Status
189	AVMDL00745304	AVMDL00745304	5/5/2005	Email from Sowell to Saltzman
190	AVMDL00755354	AVMDL00755356	1/30/2006	Request for Clarification Facsimile from HMC Heick, Health Canada, to P. Lam, GlaxoSmithKline
191	AVMDL00767906	AVMDL00767908	11/14/2007	Email from Osei to R. Saltzman et al.
192	AVMDL00768545	AVMDL00768549	3/1/2001	Line Listing of Adverse Events Avandia and Reports of Cardiac Arrest
193	AVMDL00773245	AVMDL00773262	10/30/2001	Worldwide Clinical Safety Marketed Products Group: Review/Approval Document
194	AVMDL00783678	AVMDL00783704	7/4/2006	Global Datasheet: Rosiglitazone (Version 22)
195	AVMDL00786005	AVMDL00786015	3/1/2007	Advisory Board Executive Summary Report
196	AVMDL00786445	AVMDL00786449	5/2/2007	Letter from Ronald Krall and Anne Phillips to Steven Nissen
197	AVMDL00786450	AVMDL00786450	5/3/2007	Email from Coccochetto to Reynolds
				Rosiglitazone and CV Events: Further Analysis of the Integrated Clinical Trial Dataset and Long-term Outcome Studies
198	AVMDL00796277	AVMDL00796353	5/31/2007	
199	AVMDL00799642	AVMDL00799643	6/7/2007	Email from Coccochetto to Moore
200	AVMDL00806102	AVMDL00806452	05/25/05 to 05/25/06	Rosi Safety Update
201	AVMDL00817987-R	AVMDL00817989-R	7/11/2007	"Rosiglitazone Pros Cons" slide set
202	AVMDL00819734	AVMDL00819736	11/13/2007	Dept. of Health & Human Services Inspection Notice
203	AVMDL00821244	AVMDL00821255	2/6/2007	Food and Drug Administration Memorandum: Thiazolidinediones and Cardiovascular Adverse Effects
204	AVMDL00834153	AVMDL00834190	5/18/2007	Letter to Mary Parks Re: NDA 021071/S-022
205	AVMDL00834652	AVMDL00834655	5/21/2007	Q&A Response to NISSEN Meta-Analysis
206	AVMDL00834814	AVMDL00834820	5/21/2007	Committee on Finance Memo to Reporters and Editors from Baucus and Grassley re Avandia

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
207	AVMDL00844704	AVMDL00844712	7/30/2007	Adcom Bulletin: GlaxoSmithKline's Avandia Recommended for Continued Marketing
208	AVMDL00845353	AVMDL00845445	8/4/2006	Statistical Review and Evaluation, Clinical Studies, Avandia
209	AVMDL00860279	AVMDL00860355	07/??/07	GlaxoSmithKline AdComm Presentation Slide Set
210	AVMDL00866317	AVMDL00866319	10/5/2004	Global Safety Board Minutes of Meeting held October 5, 2004
211	AVMDL00878593-R	AVMDL00878598-R	9/26/2007	Email from L. Caponi to L. Castagna et al.
212	AVMDL00879106	AVMDL00879109	9/10/2007	Email from S. Berry to T. Barker et al.
213	AVMDL00896823	AVMDL00896825	7/17/2006	Email from V. Strong to M. Sutaria et al.
214	AVMDL00896881	AVMDL00896911	7/4/2006	DRAFT Global Datasheet: Rosiglitazone (Version 22)
215	AVMDL00896908	AVMDL00896934	7/4/2006	Global Datasheet: Rosiglitazone (Version 22)
216	AVMDL00897043	AVMDL00897045	7/17/2006	Email from Pindoria to M. Sutaria et al.
217	AVMDL00897046	AVMDL00897062	7/13/2006	Data to Support Labeling Change - Myocardial Ischemia
218	AVMDL00910401-R	AVMDL00910401-R	10/31/2006	Email from Mignon to Osei
219	AVMDL00924082	AVMDL00924086	11/17/2006	Global Safety Board Minutes for Meeting held November 17, 2006
220	AVMDL00924089-R	AVMDL00924096-R	11/17/2006	Global Safety Board Minutes of Meeting held November 17, 2006
221	AVMDL00929183	AVMDL00929211	5/1/2006	Global Clinical Safety and Pharmacovigilance: Safety review team discussion document
222	AVMDL00966605	AVMDL00966607	1/19/2004	Email from S. Osei to D. Coccochetto
223	AVMDL00972115	AVMDL00972119	6/20/2007	Email from Suzette Osei to "Avandia Srt"
224	AVMDL00972125	AVMDL00972128	5/14/2007	Email from S. Smith-Dunston to Alexander Cobitz et al.
225	AVMDL00998540	AVMDL00998565	3/15/2006	Global Datasheet: Rosiglitazone (Version 21)
226	AVMDL01011949	AVMDL010011956	NA	Response to Senate Finance Committee Request No. 4
227	AVMDL01025565	AVMDL01025565	6/2/1998	SB letter from M. Whitman to Dr. S. Sobel
228	AVMDL0104581-R	AVMDL0104596-R	NA	Clinical Specialist Advisory Board Meeting Minutes
229	AVMDL0105937	AVMDL0106012	10/??/07	Commentary on Avandia (Rosiglitazone) and Myocardial Ischaemic Events D2007-6111
230	AVMDL01039843	AVMDL01039851	3/16/2007	Advisory Board Executive Summary Report
231	AVMDL01071702	AVMDL01071716	07/??/06	ADOPT US Plan Slide Set
232	AVMDL01086355	AVMDL01086362	5/1/2006	Avandia/T2D Ethnic Patient Potential Towers
				University of Texas Health Science Center at San Antonio, "Rosiglitazone Reduced Risk Factors for Coronary Heart Disease In People With Type 2 Diabetes"
233	AVMDL01130455	AVMDL01130457	11/12/2001	Clinical Study Report: BRL-049653
234	AVMDL01144623	AVMDL01144713	10/29/2003	Global Safety Board Minutes for Meeting held December 5, 2005
235	AVMDL01150096	AVMDL01150097	12/5/2005	GSB sub-group meeting/teleconference
236	AVMDL01150099	AVMDL01150100	4/25/2006	Email from M. Sowell to J. Byrne
237	AVMDL01150934	AVMDL01150934	6/26/2006	Email from J. Weber to M. Kreider
238	AVMDL01169115	AVMDL01169115	5/8/2007	Spontaneous Reports in GlaxoSmithKline OCEANS Database
239	AVMDL01169207	AVMDL01169213	05/??/07	Rosiglitazone BRL 49653, Report 01 Phase IIIA, Final Clinical Report
240	AVMDL01173099	AVMDL01173288	8/4/1998	Email from M. Freed to J. Huang et al.
241	AVMDL01192486	AVMDL01192487	3/3/2000	

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
242	AVMDL01196414	AVMDL01196415	9/25/2000	Email from S. Weill to W. Chow
243	AVMDL01197288	AVMDL01197291	10/9/2000	Email from J. Dole to J. Kreider
244	AVMDL01214359	AVMDL01214360	11/19/2003	Additional Data for Rosiglitazone item
245	AVMDL01224152-R	AVMDL01224153-R	2/8/2005	Email from Mark Heise to J. Hook et al.
246	AVMDL01371425	AVMDL01371490	5/16/2007	DRAFT "Review of Myocardial Ischemic Events During Treatment with Rosiglitazone" slide set
247	AVMDL01380042	AVMDL01380044	07/7/2006	Q. and A Preparation
248	AVMDL01427783	AVMDL01427796	7/22/1996	Memorandum to Marge
249	AVMDL01427797	AVMDL01427803	5/12/1994	Letter from R. Phillips to Dr. S. Sobel, with attachments
250	AVMDL01428993	AVMDL01428995	12/16/1998	Email from W. Nickerson to S. Weill et al.
251	AVMDL01434657	AVMDL01434659	4/11/1999	Email from M. Freed to S. Longman et al.
252	AVMDL01440069-R	AVMDL01440070-R	8/1/1999	Email from M. Freed to M. Kreider
253	AVMDL01440076	AVMDL01440076	8/1/1999	"Rosiglitazone is Effective and Well tolerated in Patients >65 years with Type 2 Diabetes" by M. Kreider
254	AVMDL01441112	AVMDL01441114	8/13/1999	Email from S. Longman to Sharon Shapowal et al.
255	AVMDL01443702	AVMDL01443718	9/15/1999	HPB Questions
256	AVMDL01444593	AVMDL01444598	10/5/1999	HPB's Request for the Addition of Cardiac Disease to the Avandia Product Monograph (Canada)
257	AVMDL01444599	AVMDL01444603	10/5/1999	Email from L. Porter to D. Everitt with attachment
258	AVMDL01444883	AVMDL01444884	10/13/1999	Email from N. Jones to M. Freed and J. Kreider
259	AVMDL01461877	AVMDL01461877	5/24/2000	Email from M. Kreider to M. Stewart
260	AVMDL01462016	AVMDL01462017	5/11/2000	Email from M. Stewart to M. Kreider et al.
261	AVMDL01465537	AVMDL01465537	8/18/2000	Email from L. Menci to M. Kreider
				"Efficacy and Safety of Rosiglitazone Combined with Glibenclamide in Type 2 Diabetes Patients Inadequately Controlled on Maximum-Dose Glibenclamide" by J. Rosenstock et al.
262	AVMDL01466924	AVMDL01466924	10/4/2000	Avandia Clinical Trial Matrix Team Minutes and Action Items for Meeting Held July 23, 2002
263	AVMDL01470467	AVMDL01470467	12/14/2000	Email from M. Freed to N. Biswas et al.
264	AVMDL01490392-R	AVMDL01490395-R	7/23/2002	Email from A. Werner to Margaret Kreider
265	AVMDL01495144	AVMDL01495146	11/25/2003	Email from David M Coccochetto to Mary Parks.
266	AVMDL01536732	AVMDL01536734	11/9/2007	Global Safety Board Minutes fro Meeting held September 30, 2005
267	AVMDL01546812	AVMDL01546814	9/30/2005	Email from J. Hook to Mark Heise et al.
268	AVMDL01550231	AVMDL01550231	12/16/2005	Email from D. Coccochetto to R. Kumar et al.
269	AVMDL01597641	AVMDL01597641	5/21/2007	Avandia Prescribing Information
270	AVMDL01597642	AVMDL01597675	5/21/2007	Remedial Review: NDA 21-071: Avandia (rosiglitazone maleate)Tablets Study 362-CTR
271	AVMDL01613327-R2	AVMDL01613504-R2	6/15/2008	3.3.5. RES11098
272	AVMDL01613364-R2	AVMDL01613366	3/10/2006	Marketing Slide Set
273	AVMDL01613378-R2	AVMDL01613381-R2	11/?/04	
274	AVMDL01616691	AVMDL01616801	10/6/2004	

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
275	AVMDL01620682	AVMDL01620684	3/15/2000	Letter from J. Buse to Dr. Henney
276	AVMDL01620781	AVMDL01620785	NA	"Primary Endpoint Excluding CHF" Charts
277	AVMDL01621115	AVMDL01621127	4/18/2007	Epidemiologic Assessment of the Population Impact of Ischemic Cardiovascular Injury Attributable to Rosiglitazone Use
278	AVMDL01622318	AVMDL01622319	10/7/2005	GlaxoSmithKline Memo re FDA Conversation Record
279	AVMDL01622595	AVMDL01622598	3/15/2007	WARNINGS Document
280	AVMDL01623261	AVMDL01623265	10/07/05 to 04/20/07	Chronology US Regulatory Affairs
281	AVMDL0162597	AVMDL01626600	11/7/2006	Global Safety Board Minutes of Meeting held November 7, 2006
282	AVMDL01643427	AVMDL01643441	11/5/2007	"HDI Decrease and RSG/Fibrate Use" slide set
283	AVMDL01671780	AVMDL01671780	4/22/2004	Adhoc Table 1220.2b
284	AVMDL01715686-R	AVMDL01715708-R	?/?/1999	Serious On-Therapy Adverse Events by Preferred Term within AE Group
285	AVMDL01718959-R	AVMDL01718967-R	10/22/2003	Avandia 1999 Publication Plan slide set
286	AVMDL01720697-R	AVMDL01720703-R	3/1/2004	GlaxoSmithKline Final Minutes of Avandia Project Team Meeting
287	AVMDL01821923	AVMDL01821923	11/19/2003	Final Minutes of Avandia Project Team Meeting Held Monday 1 March 2004
288	AVMDL01829677	AVMDL01829714	1/7/2004	Additional Data for Rosiglitazone item - GLC 19th November 2003
289	AVMDL01830528	AVMDL01830530	11/21/2003	Briefing Document for January 2004 FDA Meeting
290	AVMDL01853815	AVMDL01853817	1/8/1999	Email from Freed to Shapowal
291	AVMDL01855145	AVMDL01855146	9/24/1997	Email from C. Kahn to M. Whitman et al.
292	AVMDL01855148	AVMDL01855167	9/10/1997	Rosiglitazone and Cardiac Hypertrophy discussion
293	AVMDL01860309	AVMDL01860319	1/4/1999	R&D Avandia Update
294	AVMDL01861163	AVMDL01861164	8/19/1998	Email from I. Mitchell to C. Branch
295	AVMDL01861897	AVMDL01861955	3/31/1999	Avandia Global 3/1 Product Plan 2000-2002
296	AVMDL01863358	AVMDL01868367	6/23/1998	Notes from 12-Jun-1998 Discussion with John Lachin
297	AVMDL01869186	AVMDL01869189	3/17/1998	Additional Analysis for Monotherapy Studies in Light of New Developments
298	AVMDL01871122	AVMDL01871125	12/27/2000	SB fax from C. Kahn to B. Chong
299	AVMDL01890368	AVMDL01890374	11/14/2003	Email from Chen to Kahn
300	AVMDL01891551	AVMDL01891555	11/23/2003	Email from Chou to Yuhas
301	AVMDL01897279	AVMDL01897279	7/21/2004	Email from Shapowal to Kahn
302	AVMDL01903800	AVMDL01903801	4/4/2005	Email from Kahn to Wheardon
303	AVMDL01914948	AVMDL01914951	4/23/2007	Email from Nevine Zariffa to Joanna Balcarek et al.
304	AVMDL01916928	AVMDL01916931	2/9/2007	Email from S. Kahn to Anne Phillips and Nevine Zariffa
305	AVMDL01917502	AVMDL01917503	?/?/06	The Lancet, "The Dream Trial", by S. Nissen
306	AVMDL01922690	AVMDL01922798	9/2/2005	Diabetes Franchise Strategic Plan Slide Set
307	AVMDL01940358	AVMDL01940363	6/23/2006	Global Safety Board Minutes of Meeting held June 23, 2006
308	AVMDL01990173	AVMDL01990177	5/9/2007	Email from Lawson Macartney to D. Miller

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
309	AVMDL01990200	AVMDL01990210	NA	Summary of Events in Study 211
310	AVMDL02002294	AVMDL02002295	5/2/2007	Email from Nissen to Phillips
311	AVMDL02013490	AVMDL02013490	5/3/2007	Fax from University of Texas Health Science Center at San Antonio to Cobitz
312	AVMDL02014414	AVMDL02014418	4/13/2007	Handwritten notes dated April 13, 2007
313	AVMDL02014542	AVMDL02014546	NA	A. Phillips Handwritten Notes
314	AVMDL02027974	AVMDL02027990	11/26/2006	Media Q&A Document for ADOPT study results
315	AVMDL02042753-R	AVMDL02042795-R	NA	"Take Action, Make it Happen!" slide set
316	AVMDL02051460	AVMDL02051460	3/22/1999	Avandia Cardiovascular Review Panel agenda
317	AVMDL02088253	AVMDL02090715	11/??/03	Clinical Study Report for Study BRL-49653/143
318	AVMDL02938116	AVMDL02938119	5/16/2007	GlaxoSmithKline Memo from Cochetto and Kreider to Document Control Room
319	AVMDL03047799	AVMDL03047825	05/??/06	Global Clinical Safety and Pharmacovigilance Safety Review Team Discussion Document
320	AVMDL03183465	AVMDL03183468	2/28/2001	GlaxoSmithKline announces RECORD-A Benchmark Study to Determine Effects of Reducing Insulin Resistance on Cardiovascular Risk
321	AVMDL03200717	AVMDL03200718	11/21/2003	Email from Sharon Shapowal to Clare Kahn et al.
322	AVMDL03202171	AVMDL03202173	1/28/2004	Global Safety Board Minutes of Meeting held January 28, 2004
323	AVMDL03208530	AVMDL03208533	1/28/2002	Email from C. Shepherd to M. Stewart and M. Freed
324	AVMDL03236479	AVMDL03236485	4/11/2001	Physicians Online entry regarding SRB and Avandia - Anonymous
325	AVMDL03246768	AVMDL03246771	1/23/2002	Email from E. Gould to M. Freed and L. Porter
326	AVMDL03297056	AVMDL03297057	5/27/2004	Email from T. Rotterman to Eric Dube et al.
327	AVMDL03354527-R	AVMDL03354547-R	07/??/04	"Avandia Inc. 2005 Strategic Plan" slide set
328	AVMDL03386678	AVMDL03386680	2/17/2004	Commercial Analysis Executive Summary: Lipid War Games
329	AVMDL03438258	AVMDL03438645	03/??/1999	Avandia Launch Plan
330	AVMDL03440049	AVMDL03440129		Avandia POA 1 - Leader's Guide
331	AVMDL03457969	AVMDL03457981		Avandia: 2002 Cardiovascular Initiative Executive Summary
332	AVMDL03544519	AVMDL03544519	8/13/2001	Email from J. Eastgate to M. Stewart
333	AVMDL03544520	AVMDL03544568	8/13/2001	"Modifying Cardiovascular Risk in the Type 2 Diabetes Patient", By Steven M. Haffner, MD
334	AVMDL03628038	AVMDL03628040	5/9/2007	Email from Macartney to Atfring
335	AVMDL03629598	AVMDL03629600	5/29/2007	Email from M. Komajda to J. McMurray et al.
336	AVMDL03633322	AVMDL03638323	6/22/2007	Email from Dollery to Balcarek
337	AVMDL03644120-R	AVMDL03644145-R	6/16/2005	"Avandia CV Event Modeling GSB Follow Up" slide set
338	AVMDL03650266	AVMDL03650268	6/3/2007	Email from J. Jones to M. Stewart
339	AVMDL03650991	AVMDL03651004	8/20/2007	Email from R. Ishii to M. Stewart et al. attaching slide set
340	AVMDL03664936	AVMDL03664947	7/16/2007	Email from N. Jones to G. Wilson et al. attaching "Rosiglitazone Lipid Profile" slide set
341	AVMDL03668074	AVMDL03668078	5/22/2007	Email from Nielsen to Steward

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
342	AVMDL03722674	AVMDL03722676	11/2/1998	Status Report on Avandia Outcomes Study Discussion
343	AVMDL03746392	AVMDL03746399	4/8/2005	Briefing Document for 4-8-05 Global Safety Board Meeting
344	AVMDL03761746	AVMDL03761746	5/20/2007	Email from Buckingham to Balcarek
345	AVMDL03949043	AVMDL03949059	3/20/2001	Email from S. Dollow to J. Balcarek, cc: J. Patel, with Proposed Package Insert
346	AVMDL03953583	AVMDL03953587	10/11/2000	Email from Jensen to Nathwani
347	AVMDL03967481	AVMDL03967483	3/1/1999	Email from P. Johnson to D. Wheadon
348	AVMDL03970417	AVMDL03970418	10/14/1998	Email from E. Rappaport to R. Patwardhan et al.
349	AVMDL03972878	AVMDL03972881	8/6/1998	Email from M. Freed to H. Ross
350	AVMDL03973088	AVMDL03973090	8/3/1998	Email from E. Rappaport to M. Freed et al.
351	AVMDL03974745	AVMDL03974746	3/16/1998	Email from N. Jones to A. Salzman et al.
352	AVMDL03998194	AVMDL03998252	2/10/2000	"Consumerization" slide set
353	AVMDL04034945	AVMDL04034948	6/15/2007	E-mail from C. Dollery to J. Balcarek with attachment
354	AVMDL04048887	AVMDL04048888	5/8/2007	Email from L. Macartney to C. Dollery et al.
355	AVMDL04089075	AVMDL04089077	4/8/1998	Email from M. Freed to M. McCoy et al.
356	AVMDL04089091	AVMDL04089093	4/9/1998	Email from Martin Freed to J. Pennycook et. al
357	AVMDL04089532	AVMDL04089533	6/4/1998	Email from H. Ross to G. Champion, cc J. Balcarek
358	AVMDL04090061	AVMDL04090063	7/20/1998	Email from A. Rutt to J. Balcarek
359	AVMDL04090206	AVMDL04090206	7/30/1998	Email from R. Price to L. Mencic, M. Freed et al.
360	AVMDL04090236	AVMDL04090237	7/30/1998	Email from M. Freed to R. Price et al.
361	AVMDL04093545	AVMDL04093546	1/20/1999	Email from R. Price to H. Ross et al.
362	AVMDL04096034	AVMDL04096036	8/4/2003	Email from C. Depew to M. Freed et al.
363	AVMDL04130524-R	AVMDL04130528-R	5/23/2002	Email from J. Balcarek to L. Macartney
364	AVMDL04130540	AVMDL04130541	5/24/2002	Email from B. Mansi to L. Macartney et al.
365	AVMDL04130542	AVMDL04130548	5/22/2002	PublicCitizen.Org - "Statement at FDA Hearing on Risk Management of Prescription Drugs"
366	AVMDL04173813	AVMDL04173815		Avandia Media Alert For The Markets On RECORD Study
367	AVMDL04201445	AVMDL04201446	9/27/2004	Email from M. Freed to H. Chou et al.
368	AVMDL04214896	AVMDL04214904	3/1/2005	Strategy meeting Minutes
369	AVMDL04273432	AVMDL04273434	1/21/2003	Email from Martin Freed to Ameet Nathwani et al.
370	AVMDL04291094	AVMDL04291097	11/20/2003	Email from Freed to Gibbs
371	AVMDL04294642	AVMDL04294751	10/17/2003	Clinical Study Report: ERL-49653/143
372	AVMDL04322169	AVMDL0071828	6/16/2005	Global Safety Board Minutes for Meeting held June 16, 2005
373	AVMDL04380159	AVMDL04383890	9/5/2001	Rosiglitazone BRL 49653, Report 108 Phase IIIB, Clinical Report
374	AVMDL0439454	AVMDL04439488	1/27/1999	"Mind Map" "Begin with the end in mind" S. Covey
375	AVMDL04649673-R	AVMDL04649765-R	1/29/2001	"Overview of Clinical Program and Activities" slide set
376	AVMDL04677051	AVMDL04677069	5/1/2002	"CV Markers in Study 143" Slide Set
377	AVMDL05000687	AVMDL05000843	8/6/1999	Avandia SB/BMs Joint Marketing Committee document
378	AVMDL05003267-R	AVMDL05003267-R	NA	"Diabetes Market Experience: Regional Review" slide set
379	AVMDL05003268	AVMDL05003280	??/?/01	"Avandia Review" slide set

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
380	AVMDL05004429-R	AVMDL05004467-R	9/8/2000	Avandia Strategic Plan 2001-2003
381	AVMDL05005390	AVMDL05005390	10/26/2000	Email from P. Letendre to D. Brand
382	AVMDL05005452-R	AVMDL05005506-R	?/?/01	"Avandia: CV Strategy" slide set
383	AVMDL05019153-R	AVMDL05019217-R	01/?/05	Novo Nordisk Slide Set
384	AVMDL05049000	AVMDL05049000	4/17/2003	Email from N. Donahue to David Brand
385	AVMDL05067071	AVMDL05067071	12/13/2002	Invoice #474, "The Thiazolidinediones: Cardiovascular Benefits and Their Place in Management of Type 2 Diabetes" A Consensus Conference
386	AVMDL05067122	AVMDL05067122	9/18/2003	Invoice #5003A "The Thiazolidinediones: Cardiovascular Benefits and Their Place in Management of Type 2 Diabetes" A CME Journal Proceedings Publication
387	AVMDL05067124	AVMDL05067124	9/15/2003	Budget Reforecast "THE THIAZOLIDINEDIONES: PLACE IN TYPE 2 DIABETES AND BENEFICIAL CARDIOVASCULAR EFFECTS"
388	AVMDL05069127	AVMDL05069161		CME JOURNAL PROCEEDINGS PUBLICATION Manuscript: "Lessons Learned from Landmark Trials of Type 2 Diabetes Mellitus and Applications to Clinical Practice" By Andrew J. Drexler, MD
389	AVMDL05069235	AVMDL05069258		"Beneficial Effects Resulting from Thiazolidinediones for Treatment of Type 2 Diabetes Mellitus" by David S.H. Bell, MB, FACE, FACP
390	AVMDL05069912	AVMDL05069941	6/6/2003	"The Roles of Insulin Resistance, Hyperinsulinemia, and Thiazolidinediones in Cardiovascular Disease" By, G. Uwaifo, MD, and R. Rather, MD
391	AVMDL05070680	AVMDL05070721	1/31/2002	DRAFT "Effects of Plasminogen Activator Inhibitor-1 in Diabetes and Cardiovascular Disease" By C. Lyon, PhD and W. Hsueh, MD
392	AVMDL05070823	AVMDL05070843	12/6/2002	"The Patient with Diabetes and Heart Failure: At-Risk Issues" By, Thomas D. Giles, MD
393	AVMDL05071897	AVMDL05071900	4/19/2000	Fax From E. Kimbed to B. Blakey
				"Management of Diabetes Mellitus and Insulin Resistance in Patients with Cardiovascular Disease", By Vivian A. Fonseca
394	AVMDL05073600	AVMDL05073666	12/20/2002	SB100067-Avandia CASSPER Program Update Report
395	AVMDL05074043	AVMDL05074048	7/15/2002	Cardiovascular Executive Plan Summary
396	AVMDL05076273	AVMDL05076281		Memorandum from Dr. B. Foster to Departments and Medical Staff
397	AVMDL05076774	AVMDL05076774	3/26/2000	Circulation "Comments for Authors", Manuscript #01-04542
398	AVMDL05078576	AVMDL05078576	1/4/2002	Avandia Cardiovacular Initiative 2001 Public Relations Recommendations
399	AVMDL05087498	AVMDL05087507	4/12/2001	Email from P. Letendre to N. Abbed et al.
400	AVMDL05089054	AVMDL05089055	7/6/2001	Press Release - "AVANDIA® MAY REDUCE THE RISK OF CARDIOVASCULAR DISEASE IN PEOPLE WITH TYPE 2 DIABETES"
401	AVMDL05091369	AVMDL05091371	10/29/2001	

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
402	AVMDL05095238	AVMDL05095239	3/27/2002	Email from D. Harrison to R. James et al.
403	AVMDL05255198	AVMDL05255206	3/20/2006	"Avandia CV Modeling, GSB Discussion" slide set
404	AVMDL05255207	AVMDL05255266	3/20/2006	"Avandia CV Event Modeling: Results Updated Integrated Clinical Trials Data" slide set
405	AVMDL05255357	AVMDL05255386	6/23/2006	Avandia CV Modeling
406	AVMDL05284915	AVMDL05284915	4/16/1999	Email from N. Jones to M. Heise et al.
407	AVMDL05298611	AVMDL05298611	6/12/2001	Email from M. Heise to M. Stewart et al.
408	AVMDL05309148	AVMDL05309207	3/24/1999	Analysis of Lipids study
409	AVMDL05310600	AVMDL05310601	8/17/1999	Email from M. Heise to N. Jones
410	AVMDL05325041	AVMDL05325041	2/13/2001	Email from M. Heise to W. Nickerson et al.
411	AVMDL05331409	AVMDL05331413	8/28/2007	Email from Jane Hook to Nevine Zarifa
412	AVMDL05345345	AVMDL05349350	8/27/2002	Email from Jane Hook to Nevine Zarifa
413	AVMDL05350210	AVMDL05350216		Summary of Results for BRL 49653/243
414	AVMDL05416259	AVMDL05416262	11/19/2001	Email from G. Warsi to M. Heise
415	AVMDL05472348	AVMDL05472348	1/25/1999	Email from M. Heise to W. Nickerson et al.
416	AVMDL05548819	AVMDL05548819	5/24/2006	Letter from S. Lefebvre to Dr. R. Kumar
417	AVMDL05548820	AVMDL05548850	5/12/2006	Memo from Lefebvre to Rotter
418	AVMDL05628153	AVMDL05628155	6/16/2005	Global Safety Board Minutes of Meeting held June 16, 2005
419	AVMDL05641913	AVMDL05641916	5/16/2007	NDA 21-071-S-022; Avandia Tablets Meeting Minutes of May 16, 2007 with FDA
420	AVMDL05650699	AVMDL05650734	6/11/2005	GCSP Review Bulletin - RECORD Study
421	AVMDL05684649	AVMDL05684650	6/25/1999	Email from M. Freed to T. Leonard et al.
422	AVMDL05733210	AVMDL05733210	8/8/2003	THE STRATEGIC BRAND PLAN: (15) EVENT SCENARIO PLANNING
423	AVMDL05736721	AVMDL05736734	9/4/2002	Cardiovascular Initiative slide set
424	AVMDL05837686	AVMDL05837691		Email from Patwardhan to Crisp
425	AVMDL05896795	AVMDL05896797	12/5/2003	Global Safety Board Minutes of Meeting held December 5, 2003
426	AVMDL05927103	AVMDL05927111	5/7/2003	Prescribing Information Review Group Minutes for 'No' Decisions or Deferrals
427	AVMDL06124936	AVMDL06124938	1/3/2003	Email from Degnan to Weston
428	AVMDL06190203	AVMDL06190207	10/21/2002	Email from J. Rood to S. Weil
429	AVMDL06193818	AVMDL06193852	11/28/2005	"Addition of rosiglitazone is effective and well tolerated in African-American and Hispanic-American subjects with type 2 diabetes; inadequately controlled on sulfonylurea monotherapy: A randomized trial" by J.A. Davidson, et al.
430	AVMDL06233931	AVMDL06233931	5/22/2004	"Rosiglitazone Added to Sulfonylurea Improves Glycemic Control and Insulin Sensitivity in African American and Hispanic American Subjects with Type 2 Diabetes" By, J.C. Campbell, E. M. Gould, B.R. Waterhouse, and A.R. Cobitz
431	AVMDL06265593	AVMDL06265595	1/23/2006	Email from Krebs to Margaret Sowell
432	AVMDL06266134	AVMDL06266175	12/14/2005	Sales Rep Assistance Guide

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
433	AVMDL06413399	AVMDL06413405	10/11/2005	GlaxoSmithKline Clinical Trial Register - Rosiglitazone Studies
434	AVMDL06418561	AVMDL06418595	12/9/2004	GCS Review Bulletin - RECOI
435	AVMDL06506140	AVMDL06506191	12/12/2003	Email from M. Sowell to J. Krebs with attachments
436	AVMDL06620921	AVMDL06620923	11/6/2003	Email from M. Bennett to M. Sowell with attachments
437	AVMDL06670308	AVMDL06670308	7/2/1999	Email from T. Curry to J. Hill et al.
438	AVMDL06691125	AVMDL06691125	6/25/1999	Email from T. Yamada to Claypool, cc: Stout, J.P. Garnier,
439	AVMDL06691828	AVMDL06691828	8/5/1999	Email from D. Stout to D. Pernock, cc: T. Yamada
440	AVMDL06693762	AVMDL06693763	10/12/1999	E-mail from D. Strout to D. Wheadon
441	AVMDL06694101	AVMDL06694102	10/18/1999	SKB Memo from Garnier re 3/1 Plan Presentations for 2000 to 2002
442	AVMDL06709786	AVMDL06709800	?/?/1999	GlaxoSmithKline 1999 Annual Report
443	AVMDL06734668	AVMDL06734669	NA	List of Avandia Phase 1 studies not being included in the Clinical Trial Register
444	AVMDL06738708	AVMDL06738730	1/10/2001	E-mail from M. Geueke, T. Yamada to J. Palmer
445	AVMDL06742449	AVMDL06742451	4/21/2003	Email from Donahue to Brand
446	AVMDL06749178	AVMDL06749179	4/18/1999	Email from N. Jones to M. Heise
447	AVMDL06777177	AVMDL06777203	5/16/2007	"Review of Myocardial Ischemic Events During Treatment with Rosiglitazone" slide set
448	AVMDL06781216	AVMDL06781216	5/8/2007	Email from C. Viehbacher to J.P. Garnier
449	AVMDL06821313-R	AVMDL06821314-R	7/1/1999	Email from S. Shapowal to D. Wheadon, cc: C. Kahn
450	AVMDL06821315	AVMDL06821319	7/1/1999	Letter from Dr. J. Buse to T. Yamada with enclosure
451	AVMDL07178402	AVMDL07178441	2/28/2000	Product Monograph Avandia/ Canadian Label
452	AVMDL07479826	AVMDL07479828	4/24/2003	Email from Nigel Jones to Stacie Halbert et al.
453	AVMDL07496068	AVMDL07496073	3/13/2001	Email from M. Freed to J. Balcarek
454	AVMDL07505711	AVMDL07505711	12/13/2001	Email from J. Silvia to L. Caponi
455	AVMDL07633441	AVMDL07633445	11/20/2001	Email from M. Freed to S. Shapowal
456	AVMDL07636277	AVMDL07636279	9/4/2001	Email from S. Hobbiger to C. Rebel
457	AVMDL07646379	AVMDL07646380	5/12/1999	Email from I. Hudson to J. Scott et al.
458	AVMDL07646561	AVMDL07646562	3/15/2002	Email from J. Freid to R. Patwardhan
459	AVMDL07655558	AVMDL07655564	4/5/2001	Email from J. Freid to R. Cassidy
460	AVMDL07659235	AVMDL07659237	12/15/2000	Email from J. Fried to S. Yonren
461	AVMDL07667393	AVMDL07667393	5/12/2000	Email from J. Freid to E. Brubaker
462	AVMDL07668115	AVMDL07668116	5/1/2000	Email from J. Freid to D. Everitt
463	AVMDL07668117	AVMDL07668119	5/1/2000	Letter from D. Everitt to Dr. Lando
464	AVMDL07668120	AVMDL07668121	5/1/2000	Letter from Everitt to Shickmarter
465	AVMDL07673409	AVMDL07673410	3/17/1996	Email from J. Freid to A. Flagg
466	AVMDL07673907	AVMDL07673913	9/16/2001	Memo from Dr. Borer to Avandia
467	AVMDL07714294	AVMDL07714295	5/8/2007	Email from M. Slaoui to L. Macartney et al.
468	AVMDL07719829	AVMDL07719832	6/1/2007	New England Journal of Medicine letter to Professor Home
469	AVMDL07739822	AVMDL07739836		"Combine and Control" Avandia Marketing Materials
470	AVMDL07744693	AVMDL07744693	06/??/04	Avandia Marketing Poster - "A Favorable Lipid Profile"

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
471	AVMDL07771879	AVMDL07771884	1/12/2001	Email from T. Leonard to M. DiMatteo, cc: A. Cobitz, B. Wells, B. Mansi, E. Brubaker, M.Freed, M. Travaglini, P. Letendre
472	AVMDL07781624	AVMDL07781624	7/27/2006	CET Update on Rosiglitazone Cardiovascular Modeling
473	AVMDL07788063	AVMDL07788069	10/6/2006	E-mail and attachment from A. Cobitz to N. Clark
474	AVMDL07860847	AVMDL07860847	5/20/2007	Email from S. Osei to M. Kreider et al.
475	AVMDL07860848	AVMDL07860850	5/20/2007	DRAFT Letter to Health Care Providers re Important prescribing information
476	AVMDL08146749	AVMDL08146755	7/10/2006	Study 211-Review of Cardiac Events in Patients Receiving Avandia 8mg + SU Dual Therapy
477	AVMDL08234210	AVMDL08234254	2/24/2007	Global Position Paper on Avandia (Rosiglitazone Maleate) and Fluid-Related Events of CHF
478	AVMDL08474313	AVMDL08474315	3/28/2002	Global Safety Board Minutes of Meeting held March 28, 2002
479	AVMDL08484165	AVMDL08484250	1/26/2004	Email from M. Bennett to M. Sowell with attachments
480	AVMDL08972255	AVMDL08972255	4/19/2002	Email from S. Quinn-Robinson to N. Scott
481	AVMDL09019565	AVMDL09019571	4/14/2003	Email from S. Robinson to L. Macartney with attachment.
482	AVMDL09049683	AVMDL09049687	7/7/2004	Email from Mansi to D. Katzourakis et al.
483	AVMDL09104343	AVMDL09104343	6/14/2006	Email from M. Tomas to T. Reblin et al.
484	AVMDL09106767	AVMDL09106768	5/9/2007	Email from M. Shaoui to C. Dollery et al.
485	AVMDL09108252	AVMDL09108252	6/15/2007	Email from Robin Buckingham to Colin Dollery
486	AVMDL09108397	AVMDL09108397	6/21/2007	Email from Buckingham to Dollery
487	AVMDL09112959	AVMDL09112960	9/24/1999	Email from N. Jones to L. Porter et al.
488	AVMDL09116108	AVMDL09116109	11/4/2003	Email from Jones to Freed
489	AVMDL09130261	AVMDL09130289	5/29/2007	E-mail from J. McMurray to N. Jones with attachment
490	AVMDL09132207	AVMDL09132210	5/23/2007	FDA Information for Healthcare Professionals: Rosiglitazone maleate (marketed as Avandia)
491	AVMDL09132554	AVMDL09132558	4/24/2007	Email from S. Jammohamed to J. Donaldson et al. with attachment.
492	AVMDL09132556	AVMDL09132558	4/20/2007	Memorandum from D. Cocchetto and M. Kreider regarding FDA Teleconference
493	AVMDL09142076	AVMDL09142078	9/21/2007	Email from Jill Donaldson to Murray Stewart et al.
494	AVMDL09156472	AVMDL09156478	12/2/1998	Key Highlights from Meeting of Rosiglitazone Outcomes Study Advisory Group
495	AVMDL09160901	AVMDL09160906	07/??/03	Avandia for Athero in Non-diabetics: The Commercial Opportunity
496	AVMDL09161023	AVMDL09161075	7/3/2006	"Clinical Outcome Studies with a CV & Metabolism Spin" slide Set
497	AVMDL09190444	AVMDL09190448	12/9/1997	Form "49653 Investigator" letter
498	AVMDL09192237	AVMDL09192242	6/7/1999	Email from J. Knezevic to L. Castagna et al.
499	AVMDL09192243	AVMDL09192244	6/4/1999	Email from S. Yonren to J. Knezevic, cc. J. Freid
500	AVMDL09192245	AVMDL09192245	6/3/1999	Email from J Knezevic to J. Freid and S. Yonren
501	AVMDL09192795	AVMDL09192806	4/30/1999	Email from J. Knezevic to I. Hudson et al. attaching Avandia Action Plan
502	AVMDL09192808	AVMDL09192812	4/29/1999	Email from J. Knezevic to A. Micaleff, with attachment
503	AVMDL09196203	AVMDL09196205	6/24/1998	Email from A. Flagg to J. Scott et al.

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
504	AVMDL09196593	AVMDL09196593	3/9/1998	Email from A. Flagg to W. Castle
505	AVMDL09196597	AVMDL09196597	3/5/1998	Email from J. Bryne to R. Price
506	AVMDL09196611	AVMDL09196611	1/30/1998	Email from A. Flagg to A. Salzman et al.
507	AVMDL09196826	AVMDL09196826	12/5/1997	Email from J. Patel to J. Knezevic et al.
508	AVMDL09214328	AVMDL09214333	06/??/09	Summary of "An updated retrospective evaluation of myocardial ischemia, in addition to an evaluation of major adverse cardiovascular events, in 16 995 patients with type 2 diabetes mellitus enrolled in 52 double-blind, randomized clinical studies with rosiglitazone" by A. Cobitz et al.
509	AVMDL09230152	AVMDL09230186	??/?/08	Written Response Regarding Rosiglitazone for Therapeutic Goods Administration
510	AVMDL09291174-R	AVMDL09291175-R	12/11/1998	Email from M. Court to J. Balcarek et al.
511	AVMDL09370080	AVMDL09370089	10/??/06	"Summary of MACE Events" slide set
512	AVMDL09554058	AVMDL09554072	12/2/2004	"Avandia CV Modeling Analysis Plan" slide set
513	AVMDL09737196	AVMDL09737271	10/23/2009	Rapporteur Type 2 Variation Assessment Report
514	AVMDL09740721	AVMDL09740726	9/14/2009	"Discussions on request to remove boxed warning and review current PI"
515	AVMDL09760034	AVMDL09760036	5/17/2007	Email from D. Cocchetto to L. Macartney et al.
516	AVMDL09783725	AVMDL09783729	5/23/2002	Email from L. Macartney to G.M. Benson
517	AVMDL09828243	AVMDL09828244	1/5/2004	E-mail from L. Macartney to J. Balcarek
518	AVMDL09830876	AVMDL09830879	1/14/2004	E-mail from L. Macartney to N. Nishi
519	AVMDL09848422	AVMDL09848423	4/22/2004	E-mail from L. Macartney to M. Freed
520	AVMDL09875845	AVMDL09875870	1/19/2005	CTR Guidelines- CVM MDM
521	AVMDL09929729	AVMDL09929772	8/23/2001	Avandia Global Strategic Publication Plan
522	AVMDL09939140	AVMDL09939161	5/8/2007	DRAFT CV and non-ischemic events seen in Avandia clinical trials
523	AVMDL10110894	AVMDL10110906	04/??/07	Clinical Trial Publications and Presentations Audit
524	AVMDL10262853	AVMDL10262878	8/18/2005	"PROactive issues management update" slide set
525	AVMDL10405126	AVMDL10405127	5/15/2007	Myocardial Infarction SAEs
526	AVMDL10453919	AVMDL10453921	5/4/2007	Memorandum from D. Cocchetto to Document Control Room
527	AVMDL10454112	AVMDL10454114	6/1/2007	DRAFT "GlaxoSmithKline Updates Prescribing Information for Avandia" Press Release
528	AVMDL10454136	AVMDL10454137	5/7/2007	DRAFT Memorandum from D. Cocchetto and M. Kreider to Document Control Room
529	AVMDL10454214	AVMDL10454214	10/5/2007	E-mail from D. Cocchetto to M. Capone, cc: M. Kreider
530	AVMDL10455160	AVMDL10455161	9/6/2007	Draft Media Response
531	AVMDL10456044	AVMDL10456058	05/??/07	Black Box Labeling Analogs
532	AVMDL10458980	AVMDL10458984	3/19/2001	E-mail from M. Freed to J. Schell
533	AVMDL10459051	AVMDL10459052	3/5/2001	Email from M. Freed to E. Brubaker et al.
534	AVMDL10461628	AVMDL10461628	8/2/2000	Email from M. Freed to B. Jones et al.
535	AVMDL10461635-R	AVMDL10461640-R	4/17/2006	Draft Telecon Outline
536	AVMDL10504521	AVMDL10504543	6/6/2007	Potential Lines of Questioning for Mr. M. Slaoui

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
537	AVMDL10536889	AVMDL10536894	8/28/2007	Summary of Information from US Regulatory Affairs
538	AVMDL10536947	AVMDL10536950	5/23/2007	DRAFT Chronology: US Regulatory Affairs NDA 21-071/Supplement 022 for Avandia Tablets
539	AVMDL10608314	AVMDL10608320	6/8/1999	Patients with Myocardial Ischemia in Avandia Double-Blind Studies
540	AVMDL10616847	AVMDL10616847	6/24/2003	DRAFT "Dear Avandia Patient" Letter
541	AVMDL10618188	AVMDL10618189	6/30/1999	Email from M. Freed to J. Huang and S. Shapowal
542	AVMDL10645341	AVMDL10645341	5/25/2007	Email from Dallery to Tremery
543	AVMDL10645643	AVMDL10645644	5/16/2007	DRAFT: Myocardial Infarction SAEs table
544	AVMDL10666327	AVMDL10666338	8/20/2007	Email from Balcarek to Lepore
545	AVMDL10680006	AVMDL10680007	10/18/2007	Email from David Coccoetto to C. Reynders
546	AVMDL10681105	AVMDL10681106	8/2/2007	Email from David Coccoetto to Eric Duke
547	AVMDL10732582	AVMDL10732585	7/24/2007	Myocardial Ischemic Safety product brochure
548	AVMDL10735971	AVMDL10735971	NA	Rosiglitazone: DPA; FDA-AERS database
549	AVMDL10738485	AVMDL10738486	5/24/2007	E-mail from M. Slaoui to R. Krall et al.
550	AVMDL10738538	AVMDL10738538	5/24/2007	E-mail from P. Huckle to S. Greer
551	AVMDL10738553	AVMDL10738554	5/23/2007	E-mail from R. Rockhold to R. Krall
552	AVMDL10775664	AVMDL10775664	10/9/2001	"Rosiglitazone: Effects on the insulin Resistance Metabolic Syndrome" By A. Cobitz et al.
553	AVMDL10809888	AVMDL10809888	10/12/2000	"Rosiglitazone in Combination with Glipenclamide: Effect on PAI-1 Antigen, PA-1 Activity, and tPA in Patients with Type 2 Diabetes Mellitus" by, B.J. Goldstein, et al.
554	AVMDL10949023	AVMDL10949053	3/1/2006	Email from Heise to Stuart
555	AVMDL10959147	AVMDL10959150	6/6/2002	Email from A. Nathwani to M. Freed et al.
556	AVMDL10960141	AVMDL10960143	1/28/2004	Global Safety Board Minutes of Meeting held January 28, 04
557	AVMDL10996463	AVMDL10996468	9/22/2005	DRAFT Preliminary Summary of CV Modeling Results
558				
559	AVMDL11050678	AVMDL11050679	06/??/04	Summary of the feedback from the Advisory Board Meeting held on June 23, 2004
560	AVMDL11273090	AVMDL11273098	12/21/1999	Application to an Employment Tribunal
561	AVMDL11273101	AVMDL11273102	1/5/2000	Email from W. Claypool to J. Wright et al.
562	AVMDL11320816	AVMDL11320877	8/30/2001	Atherosclerosis/Dyslipidemia Disease Area Strategy CVU TAST
563	AVMDL11434052	AVMDL11434055	12/23/1999	Email from M. Tabona to W. Claypool, cc: J.P. Garnier
564	AVMDL11434059	AVMDL11434061	1/20/2000	Email from J. Boscia to JP Garnier et al.
565	AVMDL11452558	AVMDL11452561	5/27/1998	"Meeting with Prof M Taskinen, Helsinki University Hospital" outline
566	AVMDL11598883	AVMDL11598884	7/3/2008	Letter from D. Herd to Dr. Neil Mitchell
567	AVMDL11725350	AVMDL11725363	NA	"Team's GDS proposals for GSB input" draft slide set
568	AVMDL11726324	AVMDL11726352	3/12/2009	"Update on GSB Discussion, Rosiglitazone XR in Alzheimer's Disease" slide set
569	AVMDL11738888	AVMDL11738889	11/28/2007	Email from Nancy Pekarek to S. Sikora

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
570	AVMDL11741558	AVMDL11741562	3/25/2008	Letter from M. Wholeske, Department of Health and Human Services, to J.P. Garnier
571	AVMDL11741789	AVMDL11741818	4/23/2008	"Warning: Science + Media = Serious Damage to Company and Patient Health" Slide Set
572	AVMDL11789693	AVMDL11789694	9/12/2008	Update to Product Information for Avandia (Rosiglitazone) Avandamet (Rosiglitazone and Metformin)
573	AVMDL11790008	AVMDL11790010	5/14/2008	Email from J. Hook to B. Christopher et al.
574	AVMDL11801183	AVMDL11801184	7/1/2008	Email from J. Balcarek to A. Cobitz
575	AVMDL11801185	AVMDL11801198	7/1/2008	Rosiglitazone Expert Advisory Panel, Second Report
576	AVMDL11802714	AVMDL11802727	8/18/2008	Email from C. Eldred to C. Brough et.al. with attachments.
577	AVMDL11810400	AVMDL11810456	5/19/2009	"RECORD - Rosiglitazone Evaluated for Cardiac Outcome and Regulation of Glycaemia in Diabetes" Draft
578	AVMDL11868735	AVMDL11868737	6/5/2007	Dr. Slaoui Question and Answer Sheet
579	AVMDL11967326	AVMDL11967326	11/16/2005	Email from M. Sowell to R. Saltzman
580	AVMDL11967328	AVMDL11967328	11/16/2005	Email from J. Hook to J. Balcarek
581	AVMDL11967950	AVMDL11967955	11/12/2005	Email from A. Cobitz to H. Chou
582	AVMDL11968147	AVMDL11968148	10/26/2005	Email from A. Cobitz to A. Zambanini
583	AVMDL12021550	AVMDL12021557	6/2/2007	Key Medical Issues and Sub-Bullets
584	AVMDL12022238	AVMDL12022238	6/1/2007	Email from Colin Doherty to Lawson Macartney, CC: Joanna Balcarek
585	AVMDL12051213	AVMDL12051215	9/6/2001	Avandia Growth Opportunities slide set
586	AVMDL12246502	AVMDL12246504	3/2/1998	Email from S. Patterson to N. Zariffa
587	AVMDL12513682	AVMDL12513684	4/18/2008	Email from M. Stewart to C. Russo et al.
588	AVMDL12523366	AVMDL12523377	06/??/08	Cardiovascular Outcome Studies: Summary of rosiglitazone related data ADA 2008
			02/??/06 to 06/??/06	Handwritten notes of Moncef Slaoui
589	AVMDL12565009	AVMDL12565340	06/??/06	
590	AVMDL13262237	AVMDL13262239	6/27/2008	Letter to Mary H. Parks
591	AVMDL14038792	AVMDL14038794		GDS changes Table
592	AVMDLN00047031	AVMDLN00047105	10/31/2000	Rosiglitazone Final Safety Update 2000
593	AVMDLN00068949	AVMDLN00068970	??/??/1999	Avandia Promotional Material
594	AVMDLN00072767	AVMDLN00072818	8/30/2001	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use."The Future of Type 2 Diabetes" promotional materials
595	AVMDLN00078177	AVMDLN00078234	11/14/2002	Transmittal of Advertisements and Promotional Labelling for Drugs and Biologics for Human Use
596	AVMDLN00078224	AVMDLN00078225	11/17/2002	GlaxoSmithKline Marketing Materials
597	AVMDLN00157222	AVMDLN00157224	11/11/1994	Letter from R. Phillips to Dr. Sobel
598	AVMDLN00165664	AVMDLN00166021	8/29/1996	Letter from M. Whiteman to Dr. Sobel

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
599	AVMDLN00196043	AVMDLN00196228	11/4/1998	IND 43,468 Serial NO. 176 Avandia (Rosiglitazone - BRL49653) Volume 131 - Report 024 Phase IIIA Final Clinical Report
600	AVMDLN00289837	AVMDLN00289992	11/24/1998	NDA 21-071 Avandia (rosiglitazone maleate) Tablets Volume 1.8.051
601	AVMDLN00640801	AVMDLN00640963	?/?/?/04	Summary of Clinical Efficacy
602	AVMDLN00662334	AVMDLN00662398	5/9/2006	Letter to Parks from Kreider and submission.
603	AVMDLN00664382	AVMDLN00664409	10/7/2005	AV.L15 PRESCRIBING INFORMATION
604	AVMDLN00665350	AVMDLN00667802	8/4/2006	"Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use" Letter from M. Kreider, GlaxoSmithKline, to M. Parks, Division of Metabolic and Endocrine Drug Products
605	AVMDLN00665352	AVMDLN00665354	8/4/2006	Letter to Parks from Kreider
606	AVMDLN00667968	AVMDLN00667972	9/8/2006	Letter to Parks from Kreider
607	AVMDLN00681297	AVMDLN00681314	10/29/2003	Issues in the Effective Management of Type 2 Diabetes in Diverse Populations
608	AVMDLN00698278	AVMDLN00698284	4/30/2007	Letter from D. Cocchetto and M. Kreider to M. Parks, FDA
609	AVMDLN00698336	AVMDLN00698337	5/14/2007	Fax from D. Cocchetto to J. Weber
610	AVMDLN00698369	AVMDLN00698373	5/18/2007	Letter from D. Cocchetto to M. Parks, FDA
611	AVMDLN00698935	AVMDLN00698941	5/21/2007	Letter from D. Cocchetto to M. Parks, FDA
612	AVMDLN00699882	AVMDLN00699883	5/23/2007	Facsimile from D. Cocchetto to J. Weber, FDA
613	AVMDLN00711911	AVMDLN00711912	6/4/2007	Memo from Cocchetto re: teleconference
614	AVMDLN00712042	AVMDLN00712046	5/16/2007	GlaxoSmithKline Memo, Trip Report by D. Cocchetto
615	AVMDLN00716786	AVMDLN00716901	11/13/2007	S-031 Submission Letter to the FDA
616	AVMDLN00923640	AVMDLN00926183	12/10/2001	Study 097 - Final Clinical Report
617	AVMDLN00926733	AVMDLN00928982	02/?/?/02	Periodic Safety Update Report
618	AVMDLN05515156	AVMDLN05515160	2/26/2002	Email from Hongi Chen to Williamsk
619	BMS0000748	BMS0000782	10/?/?/01	Avandia: Grow the Class Leader's guide
620	BMS0001287	BMS0001289	7/21/1999	FIT Team Results
621	BMS0001425	BMS0001452	12/1/1999	Millenium Message Meeting Leader's Guide
622	BMS0001659	BMS0001662	7/23/1999	Memo from Avandia Product Management to SBP Consultants et al.
623	BMS0002681	BMS0002703	?/?/?/01	Brand Review Summary slide set
624	BMS0003008	BMS0003008	8/18/1999	One-page excerpt from "C:\My Documents\Avandia ADVANTAGE.doc"
625	CHF030477	CHF030481	NA	Avandia Marketing Materials with Handwritten Notes
626	FDAACDER0000132	FDAACDER0000207	2/22/2006	Memo from Green to Parks
627	GSK101_000000275	GSK101_000000287	12/28/2003	Letter from J. Borer to M. Sowell
628	GSK101_000000402	GSK101_000000405	6/30/1999	Email from M. Freed to M. McCoy
629	GSK101_000000468	GSK101_000000471	10/21/2002	Email from S. Weill to M. Freed, cc E. Miller
630	GSK101_000054430	GSK101_000054435	5/10/1999	Telifax from J. Weber, FDA, to C. Kahn
631	GSK101_000081076	GSK101_000081090	3/27/2006	Letter from M. Kreider to Dr. M. Parks, Center for Drug Evaluation and Research, FDA

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
632	GSK101_000081705	GSK101_000081891	10/13/2005	Letter from M. Kreider to Dr. G. Orloff, FDA, attaching Investigational New Drug Application and analysis plan
633	GSK101_000138897	GSK101_000138914	5/14/2007	"Ad Hoc Avandia GSR" Slide Set
634	GSK101_000139061	GSK101_000139063		New Data: HRS for Cardio Events
635	GSK101_00030021	GSK101_00030022	5/8/2007	Email from L. Macarthy to N. Zariffa
636	GSK101_000300113	GSK101_000300120	5/4/2007	Report on the article by SE Nissen & K Wolski "Effect of rosiglitazone on the risk of myocardial infarction and cardiovascular death" By, P. W. Lane
637	GSK102_000000001	GSK102_000000004	7/1/1999	Letter from Dr. J. Buse to T. Yamada
638	GSK102_000000178	GSK102_000000178	6/3/2004	Avandia 211 CHF study-Review of Study Results
639	GSK102_00000085	GSK102_00000086	5/16/2007	Email from A. Phillips to S. Kahn et al.
640	GSK102_00000515	GSK102_00000516	7/1/1999	Email from S. Shapowal to T. Leonard, cc: D. Brand, J. Huang, M. McCoy and R. Williams
641	GSK102_00000752	GSK102_00000757	7/13/2000	Email from P. Letendre to D. Brand
642	MONEY0050	MONEY0053	5/25/2000	Letter from J. Freid to Dr. Salvatore DiMerricu
643	AVMDL07040248	AVMDL07040249	6/29/1999	Letter from M. Askine, Division of Drug Marketing, Advertising and Communication, to S. Shapowal
644	AVMDL0001270	AVMDL0001274	4/1/1998	Email from I. Faiferman to H. Ross
645	AVMDL0001643	AVMDL0001644	4/22/1994	U.S. Regulatory Affairs, FDA Conversation Record
646	AVMDL0003034	AVMDL0003041	4/29/1999	Summary Results for BRL 49653/243
647	AVMDL0003067	AVMDL0003073	4/21/2000	Study Proposal (Freezer Study Proposal)
648	AVMDL0003085	AVMDL0003087	8/28/2000	Analysis Plan for Study 243
649	AVMDL0004256	AVMDL0004256	7/18/2000	Email from H. Gerstein to M. Freed
650	AVMDL0005029	AVMDL0005033	08/??/02	Actos Head-to-Head Study Defence: Diabetes as an Inflammatory Disease
651	AVMDL0005238	AVMDL0005240	2/21/1999	Letter from Dr. J. Buse to FDA
652	AVMDL0005538	AVMDL0005614	2/26/1999	"Lipids-- Stuff to Chew On"
653	AVMDL0007266	AVMDL0007276	4/4/1997	FDA Correspondence from M. Whitman to Dr. Sobel, Center for Drug Evaluation and Research
654	AVMDL0065139	AVMDL0065139	12/13/2000	Email from R. Cox to L. Porter et al.
655	AVMDL13362699	AVMDL13362705	3/26/2009	Letter to C. Clark from M. Sauers, DDMAC
656	AVMDL00217364	AVMDL00217373	N/A	DRAFT Comparison of Reporting Frequency between Adults and Elderly Patients Using Disproportionality Methods
657	AVMDL0422565	AVMDL06422626	2/9/2004	"Routine Monitoring for Unlabelled Events" chart
658	AVMDL00634851	AVMDL00635064	7/20/2004	Rosiglitazone Safety Update, 26 November 2003 to 25 May 2004
659	Public Document	Public Document	6/6/2007	Transcript of 6/6/07 Hearing on FDA's Role in the Evaluation of Avandia's Safety
660	AVMDL01902410	AVMDL01902411	2/16/2005	Email from L. Horgan to CVM
661	AVMDL0897882	AVMDL0897883	8/21/2002	Email from S. Robinson to A. Gianchetti et al.
662	AVMDL05049378	AVMDL05049379	4/21/2003	Email from N. Donahue to D. Brand
663	AVMDL09809070	AVMDL09809077	5/15/2002	Avandia Global Strategic Brand Plan: PMB Summary

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
664	AVMDL0007411	AVMDL0007416	5/12/1994	SmithKline Beecham-TDA Meeting File Note
665	AVMDL01853723	AVMDL01853725	8/19/1999	Email from c. Kahn to D. Wheadon et al.
666	AVMDL01859179	AVMDL01859183	8/18/1998	Letter from D. Wheadon to Dr. A. Fleming
667	AVMDL01859178	AVMDL01859178	9/14/1998	Letter from C. Kahn to Dr. A. Fleming
668	AVMDL03769799	AVMDL03769801	6/30/1999	Email from M. Freed to M. McCoy et al
				Summary: Rosiglitazone is Effective and Well Tolerated in Combination with Sulfonylureas in Japanese Type 2 Diabetic Patients
669	AVMDL00297249	AVMDL00297249	1/8/2001	
670	AVMDL0066038	AVMDL0066043	11/21/2000	Email from P. Leitendre to M. Freed
671	AVMDL00471372	AVMDL00471389	12/00/2001	Avandia Lipid Publication Strategy
672	AVMDL01003511	AVMDL01003552	11//?/07	Avandia Highlights of Prescribing Information
673	AVMDL00849468	AVMDL00849473	10/4/2007	Email from D. Cocchetto to S. Hinnisdaels et al.
674	AVMDL00833368	AVMDL00833369	5/15/2007	Email from L. Macartney to A. Zambanini et al.
675	AVMDL00833891	AVMDL00833892	5/15/2007	Email from D. Cocchetto to P. Huckle, cc: L. Macartney
676	AVMDL01621757	AVMDL01621766	10/9/2007	Question and Answer spreadsheet
677	AVMDL00539783	AVMDL00539795	9/10/2001	Avandia Package Insert
678	AVMDL006669916	AVMDL006669983	6/00/2001	Rosiglitazone and Diuretic Response
679	AVMDL00539367	AVMDL00539397	04/00/2001	Rosiglitazone and Cardiac Arrhythmias
680	AVMDLN00061182	AVMDLN00061192	7/25/2003	Rosiglitazone (Avandia) One Year Summary Bridging Report
681	AVMDL0590880	AVMDL0590880	3/3/2003	Email from J. Silvia to L. Caponi et al.
682	AVMDL00539894	AVMDL00539937	5/00/05	Rosiglitazone: Evaluation of Fatal Events in Rosiglitazone Clinical Trials
683	AVMDL00631799	AVMDL00631801	6/1/2004	Email from J. Osborne to L. Caponi et al.
684	AVMDL01616458	AVMDL01616473	6/14/2006	"Avandia Franchise Sales Leadership Town Hall" slide set
685	AVMDL01616254	AVMDL01616263	6/4/2007	"Commercial Analysis: Avandia Physician In-Depth Interviews" slide set
686	AVMDL12056240	AVMDL12056247	8/8/2002	"Avandia - cardiovascular quick wins Pre-Clinical strategy" slide set!
687	Regulatory Materials	Regulatory Materials	4/26/1999	021071 Pharmacology Review(s)
688	Regulatory Materials	Regulatory Materials	5/11/1999	021071 Statistical Review(s)
689	Regulatory Materials	Regulatory Materials	5/7/1999	021071 Clinical Pharmacology and Biopharmaceutics Review(s)
690	Regulatory Materials	Regulatory Materials	Various	021071 Administrative/Correspondence Documents
691	Public Document	Public Document	9/22/2008	21 CFR § 314.70 - Supplements and other changes to an approved application
692	AVMDL01144779	AVMDL01144895	12/22/2005	Clinical Study Report - Avandia Cardiovascular Event Modeling Project
693	AVMDLN00418119	AVMDLN00418305	10/13/2005	
694	AVMDLN00667974	AVMDLN00668188	10/23/2006	S-023 Supplemental New Drug Application Submission
				Commission of the EU Communities - Commission Decision amending the marketing authorisation for Avandia.
695	AVMDL00785389	AVMDL00785442	12/22/2006	
696	Public Document	Public Document	1999	Avandia Label - AV:L1
697	AVMDLN00025110	AVMDLN00025130	1999	Avandia Label - AV:L2

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
698	AVMDL07181766	AVMDL07181788	2000	Avandia Label - AV:I:13
699	AVMDL00316773	AVMDL00316796	2001	Avandia Label - AV:I:16
700	AVMDL00405219	AVMDL00405238	2001	Avandia Label - AV:I:17
701	AVMDLN00776363	AVMDLN00776384	2003	Avandia Label - AV:I:9
702	AVMDLN00648752	AVMDLN00648774	2004	Avandia Label - AV:I:10
703	AVMDLN00654126	AVMDLN00654126	2004	Avandia Label - AV:I:11
704	AVMDLN00655531	AVMDLN00655553	2005	Avandia Label - AV:I:12
705	AVRMDLN00054040	AVRMDLN00054067	2005	Avandia Label - AV:I:14
706	AVMDLN00664382	AVMDLN006664409	2005	Avandia Label - AV:I:15
707	AVMDLN00662419	AVMDLN00662447	2006	Avandia Label - AV:I:16
708	AVMDLN00664959	AVMDLN00664987	2006	Avandia Label - AV:I:17
709	AVMDLN00695845	AVMDLN00695873	2006	Avandia Label - AV:I:18
710	AVMDLN00703293	AVMDLN00703325	2007	Avandia Label - AV:I:19
711	AVMDL03379023	AVMDL03379028	2007	Avandia Label - AVD:20PI
712	AVMDLN00690860	AVMDLN00690865	2007	Avandia Label - AVD:21PI
713	AVMDL07765674	AVMDL07765715	2007	Avandia Label - AVD:23PI
714	AVMDL00514737	AVMDL00514778	2007	Avandia Label - AVD:22PI
715	AVMDL11597052	AVMDL11597094	2009	Avandia Label - AVD:28PI
716			2/00/2011	Avandia Label - Attachment: Labeling revision for Avandia (rosiglitazone maleate) Tablets, 2 mg, 4mg and 8 mg NDA 021071S-038 AVD: XMG
717			5/00/2011	Avandia Label - Highlights of Prescribing Information AVD:XXPI
718	AVMDL07742662	AVMDL07742673	8/31/2007	Sales Aid - The Myocardial Ischemia Profile of Avandia (rosiglitazone maleate)
719	AVMDL0934253	AVMDL0934276	7/30/1999	Sales Aid - Introducing for type 2 diabetes Avandia rosiglitazone maleate
720	AVMDL11501282	AVMDL11501290	November, 2001	Sales Aid - Focus on Their Future
721	AVMDL07746309	AVMDL07746309	2003	Sales Aid - Avandia Has an Impressive Long-Term Effect on HDL
722	AVMDL07738610	AVMDL07738625	December, 2003	Sales Aid - Get To Goal and Durable Control
723	AVMDL07739380	AVMDL07739399	March, 2004	Sales Aid - Insulin Resistance Beta Cell Impairment Get To Goal and Durable Control
724	AVMDL07740616	AVMDL07740619	June, 2005	Sales Aid - Avandia Effect on Lipids
725	AVMDL07741528	AVMDL07741548	May, 2006	Sales Aid - For patients challenged with type 2 diabetes not at A1C goal, Help Move Them in the Right Direction
726	AVMDL07742139	AVMDL07742156	March, 2007	Sales Aid - Type 2 diabetes Despite your best efforts, patients drift out of control
727	AVMDL07743223	AVMDL07743238	November, 2007	Sales Aid - Type 2 diabetes Despite your best efforts, patients drift out of control
728	Avandia sales aide	Avandia sales aide		Avandia sales aide - Avandia rosiglitazone maleate Access for Healthcare Professionals AVANDIAAccess.com - 1-877-AVA-0322

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
729	AVMDL10680018	AVMDL10680019	10/19/2007	Email to Metz, et al., from Cocchetto, dated 10/19/2007 re: Avandia: Revised Labeling from FDA
730	AVMDL10680020	AVMDL10680060		AVD-XXPI "N.B.: Although this is the first PLR version of the Avandia label, this labeling change concentrates on myocardial ischemia. Further revisions related to PLR issues may occur in future label changes."
731	AVMDL0850320	AVMDL0850320	10/21/2007	Email to Slaoui et al., from Huckle dated 10/21/2007 re: Avandia: Revised labeling from FDA
732	AVMDL0850321	AVMDL0850322	10/21/2007	Email to Huckle et al., from Cocchetto, dated 10/21/2007 re: Avandia: Revised draft labeling from FDA
733	AVMDL04069091	AVMDL04069093	10/24/2007	Letter to Mary Parks, MD from GSK, dated 10/24/2007 re: NDA 21-071/S022; Avandia (rosiglitazone maleate) Tablets; Amendment to pending supplemental application; revised draft labeling and request for a meeting
734	AVMDL04069094	AVMDL04069143		Draft - Highlights of Prescribing Information - Label editing
735	AVMDL10787512	AVMDL10787545	11/3/2007	Email and attachments to Metz et al., from Cocchetto, dated 11/3/2007 re: Avandia: Revised Draft Labeling
736	AVMDL10818817	AVMDL10818821	11/3/2007	Email to Krall from Huckle dated 11/3/2007 re: Avandia: Revised Draft Labeling
737	AVMDL10786947	AVMDL10786947	11/3/2007	Email to Cocchetto et al., from Viehbacher dated 11/3/2007 re: Avandia: Revised Draft Labeling
738	AVMDL01536151	AVMDL01536151	11/4/2007	Email to Mahoney from Cocchetto dated 11/4/2007 re: n21071 updated label draft
739	AVMDL07412670	AVMDL07412671	11/5/2007	Email to Netz et al., from Cocchetto, dated 11/5/2007, re: Avandia: Areas for Discussion with FDA
740	AVMDL07412672	AVMDL07412674	11/5/2007	Memo to Mary Parks, MD from GSK, dated 11/5/2007 re: NDA 21-071/S-022; Avandia (rosiglitazone maleate) Tablet; Follow Up to Teleconference of November 5; Areas for Discussion Regarding Draft Labeling
741	AVMDL07072558	AVMDL07072559	11/6/2007	Email to Netz et al., from Cocchetto dated 11/6/2007 re: Feedback from FDA
742	AVMDL10638994	AVMDL10638996	11/8/2007	Email to Metz, et al., from Cocchetto, dated 11/8/2007 re: FDA feedback on draft labeling for Avandia
743	AVMDL10638997	AVMDL10639055		Draft - Highlights of Prescribing Information - Label editing
744	AVMDL01536902	AVMDL01536902	11/9/2007	Email to parks et al., from Kreider, dated 11/9/2007 re: Avandia NDA 21-071/S-022, revised draft labeling
745	AVMDL01536903	AVMDL01536938		Draft - Highlights of Prescribing Information - Label editing
746	AVMDL0852463	AVMDL0852465	11/13/2007	Letter to Mary Parks, MD from GSK dated 11/13/2007 re: NDA 21-071/S-022; Avandia (rosiglitazone maleate) Tablet; New Supplemental Application for Prior Approval by FDA; Labeling Supplement
747	AVMDL0852462	AVMDL0852489	11/13/2007	Email and attachment re Draft - Highlights of Prescribing Information - Label editing

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
748	AVMDL09293518	AVMDL09293565	11/14/2007	Email an attachments to Metz et al., from Kreider dated 11/14/2007 re: APPROVAL Avandia US Label
749	GSK101_000054390	GSK101_000054429	5/5/1999	Fax to J. Weber from C. Kahn re: NDA 271-071 Request for revised Annotate Labelling Phase IV Commitments
750	AVMDL10619940	AVMDL10619941	5/31/2007	Email chain Shapowal, Schaffzin, Freed, Garnier, Karpinski re: Avandie
751	AVMDL10619942	AVMDL10619945	6/25/1999	Memo: to J. Garnier, Yamada from Freed Re: Avandia Queries for Analyst Email Shapowal, Kahn, Gianchetti, Brand, Huang, McCoy, Pein, Garnier, Allison, Bains, Stout, Rapaport, Freed re: Complaint Re: Buse
752	AVMDL06898987-R	AVMDL06898988-R	6/28/1999	Email from Curry to Hill Re: SG Cowen Report & Buse's ADA Presentation
753	AVMDL06691270	AVMDL06691270	7/2/1999	Committee Staff Report to the Chairman and Ranking Member, Committee on Finance, United States Senate, November 2007. The Intimidation of Dr. John Buse and the Diabetes Drug Avandia
754	AVMDL12589268	AVMDL12589279	2007	Email from Littman to Adrian et al Re: REVISED & URGENT -IP Garnier Response to Employee Question Re: Avandia
755	AVMDL10617945	AVMDL10617948	8/29/2002	Email chain Slaoui, Garnier, Learmouth, Stout, Krall, Macarthy, Phillips, Baxter, Greer Re: call with Dr. Nissen
756	AVMDL10750137	AVMDL10750138	5/4/2007	Email chain Viebacher, Garnier, Stout Re: Nouveau President
757	AVMDL06781095	AVMDL06781095	5/6/2007	Email chain Kinney, Garnier Re: June 6
758	AVMDL06781543	AVMDL06781544	5/22/2007	Email chain Slaoui, Garnier, Learmouth RE: Linda Robinson
759	AVMDL06781678	AVMDL06781679	5/26/2007	Email chain Slaoui, Pekarek, Viehbacher et al RE: DRAFT FOR REVIEW: Possible Epi Study Release
760	AVMDL10635530	AVMDL10635535	7/24/2007	Letter to Garnier from Dept of Health and Human Services GSK WARNING LETTER
761	AVMDL10683640-R	AVMDL10683641-R	9/25/2007	(08-ATL-05)
762	AVMDL11684236	AVMDL11684239	3/25/2008	Email chain Colaprete, Stout, Garnier, Viehbacher, Lilley Subject: US Pharma News Releases
763	AVMDL06778562	AVMDL06778563	2/24/2004	Article - New Data from RECORD Study Show No Increase in Cardiovascular Risk with Avandia
764	AVMDL10506357	AVMDL10506359		Email Chain Freed, Dollow, Balcarek, Nathwani, Bellin, Malone, Blumhardt w/attachments Study 175 Headline Results Summary
765	AVMDL00296565	AVMDL00296571	3/29/2001	Organizational chart
766	AVMDLMKT0000000001	AVMDLMKT0000000001		Organizational chart. GSK - US Marketing Metabolic/Endocrine
767	AVMDLMKT0000000005	AVMDLMKT0000000005		PowerPoint Presentation
768	AVMDL03710730-R	AVMDL03710748-R		Email chain Letendre, Janicki, Wells et al, RE: ACTION REQUIRED: RECORD MEDIA ALERT w/attachment "Avandia Press Alert on Record Study"
769	AVMDL00278344	AVMDL00278352		

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
770	AVMDL04000374	AVMDL04000444		PowerPoint Presentation - Avandia Marketing Plan 2001-2003
771	AVMDL050004429-R	AVMDL050004467-R		Strategic Plan 2001-2003; September 8, 2000
772	AV EXPERT 000000000220	AV EXPERT 000000000223	10/25/2000	Email chain Letendre, Balcarek, Brand, Schnackenberg, Brooks, Laping, Ruffolo, Buckingham, Wade-Whittaker RE: Pio abstract
773	AVMDL028113 AVMDL0281519-R AVMDL0281124 AVMDL 0281113 AVMDL03239584	AVMDL0281123 AVMDL00281522-R AVMDL0281124 AVMDL02811123 AVMDL03239584	1/4/2001	Email chain consisting of multiple chains RE: Japanese RSG abstract for ADA
774	AVMDL0295388 AVMDL00295235	AVMDL00295389 AVMDL00295238	4/20/2001 4/27/2001	Email chain Freed, Mansi RE: Action-GSK Publication Policy; email chain Freed, Mansi STP-GSK Proposed Publication Policy
775	AVMDL07508671	AVMDL07508674	1/1/2002	Email chain Letendre, Freed, Short, Mansi, Shapowal SUBJECT: publication of 570 data
776	BMS00000039	BMS00000067		Powerpoint Presentation - Avandia Product Management Team
777	AVMDL11931378	AVMDL11931418		Powerpoint Presentation - Avandia Spring SSM Workshop
778	AVMDL00072054	AVMDL00072073	6/4/2001	Sales Aid - Avandia NDA-21071
779	AVMDL07223855	AVMDL07223855	6/5/2001	Email chain Letendre, Weil RE: Avandia and Atrovastatin
780	AVMDL00280994	AVMDL00280995	1/8/2001	Email chain Letendre, Balcarek RE: Avandia combos
781	AVMDL00176758	AVMDL00176758	5/9/2001	Email from Lowry to Shapowal, Weil SUBJECT: Draft 3 of Avandia 108 report for your review
782	AVMDL00260397 AVMDL00260414-R	AVMDL00260413 AVMDL00260418-R	9/16/2001	Email chain Blakey, Freed, Tucker, Chung RE: Avandia Strategic Plan Templates w/attachment "The Strategic Brand Plan: Key Issues and Brand Strategies"
783	AVMDL05091021	AVMDL05091023	10/12/2001	Email chain Letendre, Dimatteo, Freed, Juliana, Weber RE: Avandia Advantage
784	AVMDL05091024	AVMDL05091024	10/9/2001	Letter to Stout from Weber
785	AVMDL00254044	AVMDL00254046	11/8/2001	Email chain Letendre, Freed, Brand, Whitehead RE: Avandia & Avandia vs Actos Trials
786	AVMDL00409083	AVMDL00409084	11/16/2001	Email chain Shapowal, Phyll, Letendre, Stevens, Brand, Johnson, Bush, Sexton, Windrem, Maia, Murray RE: Avandia Diagnostic Presentation
787	AVMDL00409085	AVMDL00409134		Powerpoint Presentation - Avandia Diagnostics Meeting - November 2001
788	AVMDL00078224	AVMDL00078225		Slide presentation - CV Risk Management
789	AVMDL04677051 AVMDL04677068	AVMDL04677066 AVMDL04677069		Powerpoint presentation- CV Markers in Study 143
790	AVMDL0067819	AVMDL0067819		Lp Pla2 - Results of Assay of Frozen Samples from Avandia study 011
791	AVMDL04380159	AVMDL04380273		Report 108 Phase IIIB

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
792	AVMDL05289116	AVMDL05289116	2/24/1998	Email string Rita Patwardhan, Frank Rockhold, Mark Heise1 Bob Schriver, Wendy Nickerson; Re: BRL 49653c 024 Modifications lipid efficacy parameter
793	AVMDL0548384	AVMDL05548386	3/30/1999	Email String Hamish Ross, Douglas Greene, Martin Freed, Frank Rockhold, Bob Schriver, Wendy Nickerson Re:Thoughts from Doug Greene
794	AVMDL05413588	AVMDL05413588	5/5/1999	Email String Frank W. Rockhold, Wendy Nickerson, Mark Heise1, Maureen Sautter, Rita Patwardhan, Susan Longman1, Anthony Rebuck, Bob Schriver Re: Franks comments Avandia Pink slip review of agency working document
795	AVMDL05352392	AVMDL05352392	6/7/1999	Email string John Ilgenfritz, Rita Patwardhan, Weihang Bao1 Nandita Biswas1 Ying Yan1 Mark Heise1 Re: % change of lipids
796	AVMDL00429278	AVMDL00429280	9/22/1999	Email string Sharon Shapowa, Andres Brueil1, James Z. Huang, Trish Goodwin; Re: URGENT re: 080 Oral Pres - Lipids
797	AVMDL05335630	AVMDL05335630	11/30/1999	Email string Mark Heise1, Susan Longman1, Caroline Boulton1; Re substantive Draft Avandia Appeal document
798	AVMDL05339565	AVMDL05358496	8/16/2000	Email from Wendy Nickerson to Nandita Biswas1, Mark Heise; Re: freezer study update and rationale
799	AVMDL05358496	AVMDL05358496	3/13/2001	Email from Zhiyuan 2 Liu to Murray W. Stewart; Re: CV Risk Table
800	AVMDL05136198	AVMDL05136205	3/13/2003	Email E Lewis, M Heise, J Balcarek, F Rockhold Re: EdemasidcuSSION and word from Frank
801	AVMDL05442205	AVMDL05442211	2/8/2004	Email N Zariffa, R Patwardhan, M Heise; Re: Another analysis going down the drain- IR identification
802	AVMDL0526111	AVMDL0526114	11/9/2004	Email A Zampanini, M Heise, L Porter, F Rockhold
803	GSK101_000100021	GSK101_000100022	5/8/2007	Email L Macartney to N Zariffa
804	AVMDL05380236	AVMDL05380236	2/7/2005	Email M Heise to R. Thwaites
805	AVMDL00817988	AVMDL00817989	6/3/2007	Rosiglitazone Pros and Cons
806	AVMDL03650266	AVMDL03650267	11/2/2004	Email N Jones, M. Stewart, F Rockhold, S Pocock, J McMurray Study No. 49653/136
807	NONE (9 page doc)			ATTACHMENT 2 - RESPONSE TO SENATE FINANCE COMMITTEE REQUEST NO.4
808	AVMDL001001949	AVMDL001001956	6/11/2004	Email M Heise to N Zariffa, J Roberts
809	AVMDL05309865	AVMDL05309865		Avandia Launch Plan
810	AVMDL03438259	AVMDL03438645		Email G. Smith to D. Pernock Re:
811	AVMDL05020161	AVMDL05020162	1/9/2001	Email D. Pernock to Tachi, etc. Re: Update from RADEX Presentation
812	AVMDL06729952	AVMDL06729952	11/23/2003	Email Vienbacher to Pernock Re: Fw: Update from RADEX Presentation
813	AVMDL07676052	AVMDL07676052	1/25/2004	All General Pharma Sales Forces
814	AVMDL07543521	AVMDL07543521		Study No. BRL-049653/311; A 12 week, randomized, double blind study to evaluate the effects of rosiglitazone 4 mg and rosiglitazone 4 mg QD on lipids in Type 2 diabetes mellitus subjects taking statins
815	11255	11255		

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
816	AVMDL07682591	AVMDL07682592	8/6/2004	Email Joynes to DeMarco Re: Embracing Women's Health/Oprah Tour recap memo
817	AVMDL07682593	AVMDL07682593		Interoffice Memo from Pernock and Hull to Lortie, etc. Re: Internal Press Release
818	AVMDL0391481	AVMDL0391484	8/17/2004	Giordano to Peter, etc. Re: Action Required- Pernock's Upcoming Investors Roundtable
819	AVMDL0391485	AVMDL0391537	9/11/2004	Investor Roundtable Presentation- David Pernock, Senior VP, General Pharma
820	AVMDL07693837	AVMDL07693840	9/11/2004	Email Pernock to Barton, etc. Re: 05 Plan Summary
821	AVMDL07697490	AVMDL07697490	11/26/2006	Email Duke to David, etc. Re: Fort Monday Copy Approval: Adopt Flashcarc
822	AVMDL07697491	AVMDL07697526		Document entitled 'Agenda, GSK Capabilities, Brand Plan, Schering-Plough Overview, Bates Overview
823	AVMDL04268708	AVMDL04268710	8/6/2003	Email Freed to O'Neill Re: USP Presentation to Pernock
824	AVMDL04268711	AVMDL04268783	7/31/2003	Document entitled "US Pharmaceuticals Philadelphia, CDMA NA 2004 Study Budget Presentation
825	AVMDL07687065	AVMDL07687067	1/9/2004	Email Douglas to Rossello, etc. Re: Final 2004 Spring POA
826	AVMDL07682633	AVMDL07682633	1/14/2004	Email Pernock to Collier Re: Final 2004 Spring POA
827	AVMDL07685676	AVMDL07685678	3/5/2004	Email Lammers to Pernock Re: MEA
828	GSK102_000000134	GSK102_000000135	4/21/2007	Email Pernock to Metz Re: Avandia
829	AVMDL00823095	AVMDL00823096	4/20/2007	Document re: FDA and GSK teleconference
830	AVMDL07675918	AVMDL07675918	5/8/2007	Email Viehbacher to Pernock RE: Avandia Meeting with JF
831	AVMDL0711113	AVMDL07711114	6/13/2007	Email Viehbacher to Pernock Re: Three Items
832	AVMDL07698573	AVMDL07698576	7/9/2007	Email Viehbacher to Pernock, etc. Re: Request for update on..
833	AVMDL02010521	AVMDL02010522		Document entitled "W-Avandia prescribing patterns
834	AVMDL0709723-R	AVMDL0709725-R	8/2/2007	Email Joynes to Pernock Re: Speaker Cap Exceptions
835	AVMDL07699861-R	AVMDL07699862-R	8/8/2007	Email Viehbacher to Pernock Re: Avandia RX Early Read (Week Ending 8/3/07)
836	AVMDL09380033	AVMDL09380034		Email and attachment Willard to Litteras, etc. Re: Diabetes Franchise Label Updates: Approved Resources
837	AVMDL09380059	AVMDL09380071	8/16/2007	Document entitled "2007 Town Hall Meeting"
838	AVMDL07700045	AVMDL07700134	8/13/2007	Document entitled "Investor Roundtable Presentation"
839	AVMDL11745607	AVMDL11745658		Document entitled "Retiree Luncheon"
840	AVMDL0708471	AVMDL07708496	10/5/2007	Campbell to Curry, etc. Re: Updated David Pernock Slide Deck
841	AVMDL0708470	AVMDL07708470	9/14/2007	Email Campbell to Pernock Re: Revised Retiree Presentation
842	AVMDL11745318	AVMDL11745318	9/27/2007	Email Campbell to Francoise, etc. Re: Pernock Budget Review Slides
843	AVMDL11745400	AVMDL11745401	10/3/2007	Email Foley to Willard, etc. Re: ATTN: Final Materials & Information for Diabetes 'Live' Webcast
844	AVMDL11745402	AVMDL11745402		Document entitled "Gain Control Sustain Control, Webcast Event"
845	AVMDL11745403	AVMDL11745443		Document entitled "Update on Avandia, Fall 2007 Webcast"

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
846	AVMDL11745319	AVMDL11745362		Document entitled "David Pernock, Senior VP, General Pharma/Vaccines"
847	AVMDL0743253	AVMDL07743258		Sales ad entitled "A1c Type 2 Diabetes: Despite your best efforts, patients drift out of control"
848	AVMDL13948247	AVMDL13948247	2/16/2008	Pernock to Rossello Re: 2QPOA
849	AVMDL13901929	AVMDL13901929	7/6/2008	Email Carlo 2 Russo to Pernock, etc. Re: Diabetes
850	AVMDL08259160	AVMDL08259193	6/6/2007	Email Mansi to Aftring, etc. Re: Oversight Committee Documents
851	none	none		Transcript of testimony before Congress
852	none	none		Clinical Trial Registry posting for study 011
853	none	none	6/14/2007	Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
854	none	none		Clinical Trial Registry posting for study 024
855	AVMDLN00196046, 047, 158	AVMDLN00196046, 047, 158		Final Clinical Report for study 024
856	none	none	9/23/2006	Effect of Rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial
857	4778	4782		GSK Public Disclosure of Clinical Research
858	4783	4785	3/14/2011	PharmaVoice.com Podcast
859	AVMDL00066245	AVMDL00066247	11/17/2000	Email Mansi to Porter & Freed Re: Meeting Confirmation: Introductory meeting w/CMC set f or Nov 20
860	AVMDL08085897	AVMDL08085921	9/13/2001	Email DiMatteo to Cobitz Re: Would you please send me an electronic copy of all he CSS forms and the START Forms- I need to put together a presentation for Stout
861	AVMDL08967579	AVMDL08967579	9/23/2001	Email Giandotti to Robinson Re: Avandia Global Strategic Publication Plan
862	AVMDL08966616	AVMDL08966620	10/17/2001	Email Mansi to Robinson Re: European Avandia Key Messages- Please share your thoughts
863	AVMDL08966622	AVMDL08966622		Avandia European Key Messages
864	AVMDL08966623	AVMDL08966629		Avandia CV Promise Strategy
				Email Mansi to CDPS-Avandia Country Marketing CDPS-Avandia Country Medical Re: ADA Abstract Submissions
865	AVMDL00249765	AVMDL00249765	1/19/2002	ADA 2002 Avandia Abstracts
866	AVMDL00249766-R	AVMDL00249770-R		Email Letendre to Freed, etc. Re: Publication Of '570' date
867	AVMDL07508671	AVMDL07508674	1/1/2002	Meeting Report
868	AVMDL06116244	AVMDL06116248	6/6/2002	Q&A Document: ADA Meeting
869	AVMDL10493329	AVMDL10493339		Email Mansi to Cobitz, etc. Re: Study 108 Concept Sheet
870	AVMDL0058132 - 134;	AVMDL0058132 - 134;	4/16/2001	Effects of Rosiglitazone Alone, Article
871	AVMDL03295049	AVMDL03295054		Email Mansi to Robinson Re: Draft Actos + Atorva STP: Opportunity to effectively address a lipid issue
872	AVMDL09035666	AVMDL09035666	1/29/2004	

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
873	AVMDL09035667	AVMDL09035668		Actos + Atorvastatin Drug Interaction
874	AVMDL04252633	AVMDL04252637	10/31/2001	Avandia Position Paper Meeting Minutes
875	AVMDL05774867	AVMDL05774898		Avandia Position Paper Edema and Cardiac Failure
876	AVMDL04321735	AVMDL04321739		ADA/AHA Consensus Conference Issues Management Plan
877	AVMDL03736649	AVMDL03736657	11/19/2003	ADA/AHA Consensus Document
878	AVMDL0987039	AVMDL0987044	11/19/2003	Email Mansito Hicks Re: For Review: Draft Global Recommendations for the AHA/ADA Consensus statement
879	AVMDL0986323-R	AVMDL09986324-R	11/28/2003	Email Mansito Zambanini Re: AHA/ADA TZD Consensus Publication Clarification
880	AVMDL10460705	AVMDL10460719		Global Communications Standby Statement ADA/AHA Consensus Paper
881	AVMDL01953022	AVMDL01953023		AHA/ADA Issue Statement on Diabetes Drug Linked to Heart Failure
882	AVMDL09025680	AVMDL09025681		AHA/ADA Issue Statement Guiding Doctors on Use of TZDs
883	AVMDL09025666	AVMDL09025659	12/9/2003	Email Mansito Dybka, etc. Re: ADA/AHA TZD Consensus Publication Response Materials
884	AVMDL09025699	AVMDL09025699		Dear Colleagues Letter From Nesto
885	AVMDL03438392	AVMDL03438402		Clinical Plan
886	AVMDL04439454	AVMDL04439488		Mind Map
887	AVMDL0938270	AVMDL09938272		Agenda Avandia PST Meeting
888	AVMDL04090206	AVMDL04090206	7/30/1998	Email Price to Menci, etc. Re: Avandia 127 SPS
889	None	None	5/1/2007	Email from Nissen to G. Cuffman cc K. Wolski Re: Rosiglitazone Manuscript
890	None	None	1/10/2011	ENDORSEMENT OF PROTECTIVE ORDER
891	None	None	5/21/2007	Email string Nissen, Wolski, Peto
892	Public-Literature	Public-Literature	9/28/2010	"Rosiglitazone Revisited: An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality"
893	None	None	?????	Slide presentation given by Nissen "Rosiglitazone: A Critical Overview"
894	CCFe 000015967	CCFe 000015967	5/4/2010	Email from Nissen to K. Wolski Re: NNH calculations
895	None	None	5/21/2007	Letter sent out by the Cleveland Clinic regarding Nissen article advising patients to speak to their treating doctor regarding their use of Avandia
896	CCFe 000003178	CCFe 000003178	2/18/2007	Email Nissen to Cha, Nelson Re: Rosiglitazone Analysis
897	CCF 002320 - 21, 39-43	CCF 002320 - 21, 39-43		"the SAS System" printouts of a pooled analysis of stroke from DREAM and ADOPT combined
898	Public-Literature	Public-Literature	Fall 2007	CCEB Newsletter Vol. 2 No. 4 "Q&A: Dispelling the Myths about Avandia"
899	Public-Literature	Public-Literature	Dec-07	Nature Clinical Practice, Editorial, "Meta-analysis of small trials: Proceed with caution"
900	FDA Website	FDA Website	8-Dec	Guidance for Industry Diabetes Mellitus- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
901	CCFe 000003171	CCFe 000003171	4/25/2007	Email string Nissen, Wolski Re: Urgent Next Steps
902	CCFe 00003154	CCFe 00003154	4/26/2007	Email string Nissen, Wolski Re: P values
903	CCFe 000003528	CCFe 000003528	1/5/2007	Email string Nissen, Wolski et al. Subject: Eureka I Found it

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
904	AVMDL12431695	AVMDL12431698	May-07	Phillips letter to Nissen Re: request for data on Rosiglitizone
905	AVMDL11871702	AVMDL11871726	5/22/2007	Email from Glenn Gornley to Alan Breier talking about Nissen flaws in statistical practice
906	CCFe 000015973	CCFe 000015974	2/26/2010	Email string Nissen, Wolski Re: Updated Analysis (Draft)
907	AVMDL06217252	AVMDL06217277	1/1/2003	Avandia Publication Status Report
908	STI 0010466	STI 0010472	11/29/2004	Email from G. Johnson to J. Scott, K. Colquitt et al. Re:Invitation: Publication Transition Meeting
909	AVMDL11754757	AVMDL11754779	1/30/2008	Slide presentation Scenario Planning: VICTORY, PERISCOPE & APPROACH
910	AVMDL10061761	AVMDL10061769	8/22/2005	Email string DeCastro, Swartz, Robinson et al. Re: Acute Cardiac Care 2006
911	AVMDL0994314	AVMDL0994315	3/19/2004	Email string Mansi, Rave Re: 771 Positioning Research
912	AVMDL10942729	AVMDL10942736	7/28/2004	Email from Porter to Tuttle cc Cobitz et al. Re: Summaries of studies 234 and 133
913	6159	6161	11/2/2004	Study 49653/133
914	AVMDL0410324	AVMDL04105324	8/3/2001	Email from Freed to Harrison Re: PST Meeting 8/7/2001
915	6049	6052	9/22/2004	Study 49653/127
916	AVMDLN00214277	AVMDLN00214381	10/12/2000	Avandia Volume 222
917	AVMDL04090236	AVMDL04090237	7/30/1998	Email string Freed, Price, Balcarek Re: Study 127
918	AVMDLMK10000001	AVMDLMK10000010		Organizational chart
919	AVMDL0427037	AVMDL0427260	2002	Avandia 2002 Operating Plan dated 12/5/2001
920	AVMDL03247605	AVMDL03247610	2/22/2002	Agenda for the Avandia Commercial Advisory Board, Bacara Resort and Spa
921	AVMDL03247601	AVMDL03247602	2/7/2002	Typed communication to Martin Freed from Alexander Cobitz, 2/7/2002
922	AVMDL03457982	AVMDL03457989	2002	Avandia 2002 Ethnic Initiative Plan
923	AVMDL05084057	AVMDL05084057	8/30/2000	Chain Emails
924	AVMDL05084058	AVMDL05084060	9/5/2000	GSB SmithKline Beecham Pharmaceuticals dated 9/5/2000
925	AVMDL05085675	AVMDL05085676	1/30/2001	Email from C. Bennett to S. Tenuto dated 1/30/2001, with an attachment
926	AVMDL05085678	AVMDL05085679	1/30/2001	Email from C. Bennett to S. Tenuto dated 1/30/2001, with an attachment
927	AVMDL05087056	AVMDL05087056	3/19/2001	Email from C. Bennett to W. Tucker dated 3/19/2001
928	AVMDL05087057	AVMDL05087058		List of key opinion leaders
929	AVMDL05087059	AVMDL05087060		List of key opinion leaders
930	AVMDL05086663	AVMDL05086667	1/14/2002	Avandia memo entitled "ENDOFORCE" dated 1/14/2002
931	AVMDL00272803	AVMDL00272804	5/18/2001	Advisory Board Proposal Form
932	AVMDL00272805	AVMDL00272810	2001	Email from N. Neal to a serious of people dated 5/18/2001
933	AVMDL04256829	AVMDL04256834	2/19/2001	"Insulin Resistance Advisory Summit"
934	STI0002702	STI0002715	12/6/2001	Email from M. Maura to C. Bennett dated 2/19/2001
935	AVMDL03431601	AVMDL03431603	4/2/2004	Fax to S. Kennedy from U. Kistner dated 12/6/2001, with attachments
936	AVMDL0260397	AVMDL0260418-R	9/16/2001	Document, P. Lammers from C. Bennett dated 4/2/2004
937	AVMDL05087495	AVMDL05087507	4/12/2001	Email from B. Blakey to M. Freed dated 9/16/2001, with attachments
938	AVMDL03349349	AVMDL03349367	2/17/2004	Email from C. Bennett to M. Chung dated 4/12/2001, with attachments
939	AVMDL03457996	AVMDL03458005	2002	Email from R. Stevens to P. Lammers dated 2/17/2004, with attachments
				Avandia 2002 DTC Plant

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
940	GSK notes	GSK notes		Handwritten diagram
941	STI 0011132	STI 0011132	1/29/2004	Email to Grace Johnson from Merry Sada, dated 1/29/2004 re: LaSalle
942	STI 0026376	STI 0026391	12/18/2001	Email to Grace Johnson from Una Kistner, dated 12/18/2001 re: FW: 2002 planning and action with attachments
943	STI 0004210	STI 0004227	2/15/2002	Letter to Janet McGill from Grace Johnson, dated 2/15/2002, re: Invitation to author manuscript entitled "Durability of Glycemic Control: A Feature of the Thiazolidinediones" and attachments
944	AVMDL05100656	AVMDL05100672		Avandia Publication Status Report
945	email		10/10/2001	Email to Marion et al., from Una Kistner, dated 10/10/2001, re: Avandia supplements
946	STI 0008919	STI 0008919	1/9/2003	Email to Johnson et al., from Romankiewicz, dated 1/9/2003, re: 1919 or the Supplement to 1919
947	AVMDL05074195	AVMDL05074195	10/17/2002	Confidential 10/17/2002 letter from Judy Fallon
948	STI 0017051	STI 0017051	11/1/2002	Confidential Nov 1, 2002 email from Judy Fallon
949	STI 0002524	STI 0002621	11/16/2002	Confidential 11/16/2002 email from Michael DiMatteo and attachment
950	STI 0005070	STI 0005070	5/13/2002	Confidential 5/13/2002 email from Grace Johnson
951	STI 0004314	STI 0004314	9/10/2002	Confidential 9/10/2002 email from Grace Johnson
952	STI 0004757	STI 0004787	9/3/2002	Confidential 9/3/2002 email from Grace Johnson
				Article - Freed MD, M. et al., The American Journal of Cardiology Vol. 90, Nov. 1, 2002 "Effect of Rosiglitazone Alone and in Combination with Atorvastatin on the Metabolic Abnormalities in Type 2 Diabetes Mellitus"
953	STI 0002560	STI 0002565	11/1/2002	Confidential 9/8/03 email from Jessica Leber re: FW: Lipid Manuscript Windheuser re-write 8 Sept 03
954	STI 0012243	STI 0012298	9/8/2003	
955	STI 0012238	STI 0012239	1/14/2004	Confidential 1/14/04 email from Jennifer Scott re: Avandia 2004 Publication Brief
956	Public - Literature	Public - Literature	8/18/2003	The American Journal of Cardiology Vol 92(4A) August 18, 2003 "Management of Diabetes Mellitus and Insulin Resistance in Patients with Cardiovascular Disease", By Vivian A. Fonseca
957	Public - Literature	Public - Literature	11/30/2010	Article - Wilson, The New York Times Business, Tuesday, November 30, 2010 "Drug Maker Wrote Book Under 2 Doctors' Names, Documents Say"
958	Public - Literature	Public - Literature	4/16/2008	Editorial - DeAngelis MD, C and Fontanarosa MD, P, JAMA, April 16, 2008 Vol. 299, No. 15 "Impugning the Integrity of Medical Science"
959	Public - Literature	Public - Literature	4/15/2008	Editorial - Ross MS, J., et al., JAMA, April 16, 2008 - Vol 299, No. 15 "Guest Authorship and Ghostwriting in Publications Related to Rofecoxib"
960	STI 004884	STI 004885	5/14/2002	Email to Braunstein from Johnson, dated 5/14/2002 re: Manuscript Outline
961	STI 003010	STI 003010	9/30/2002	Email to Braunstein from Johnson, dated 9/30/2002 re: Manuscripts

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
962	Public Document	Public Document	2008/2009	Medical Education Services, Skin Disease Education Foundation
963	Public Document	Public Document		website information for Medcalliance
964	AVMDL00060103	AVMDL00060105	3/30/2001	GSK document entitled Insulin Resistance Advisory Summit
965	AVMDL03447438	AVMDL03447438		GSK document entitled Evidence with Rosiglitazone: What Does It Mean?
966	AVMDL05087674	AVMDL05087676	4/24/2001	Meeting Summary, Avandia CV Team
967	AVMDL10454544	AVMDL10454549		Meeting Profile Form
968	AVMDL05098554	AVMDL05098556	8/2/2002	Email to DiMatteo from Lean, dated 8/2/2002 re: CD ROM Rep Memo
969	AVMDL10454528	AVMDL10454531		Advisory Board Proposal Form
970	AVMDL04687482	AVMDL04687485		Advisory Board Proposal Form
971	AVMDL05087108	AVMDL05087109	3/27/2001	Email to Bennett et al., from Chung, dated 3/27/2001 re: CV tactical plan from Medcalliance to review at our Thursday mtg
972	Public - Literature	Public - Literature		website information for Medcalliance
973	AVMDL05088266	AVMDL05088267	5/24/2001	Email to chung et al., from Fishman, dated 5/24/2001 re: American Heart Association Survey
974	AVMDL00238197	AVMDL00238221	10/1/2002	Avandia Publication Status Report 01 October 2002, Avandia Primary Publication
975	AVMDL05268832	AVMDL05268839	November, 2001	Harrison, D., "Process for Developing and Approving Avandia Abstracts, Conference Presentations, and Manuscripts
976	AVMDL05036021	AVMDL05036024	3/22/2002	Email to Blakey et al., from DiMatteo, dated 3/22/2002, re: Evident Study
977	AVMDL0406558	AVMDL0406560	5/6/2002	Email to Letendre et al., from Shapowal, dated 5/6/2002, re: FW: 3568 Letter to the editor
978	AVMDL0406561	AVMDL0406567	5/1/2002	Letter to the Editor - Barry Goldstein, MD, dated 5/1/2002
979	Public - Literature	Public - Literature	2002	Clinical Therapeutics/Vol. 24, No. 8, 2002, Letter to the Editor
980	AVMDL05361927	AVMDL05361927	11/16/2001	Email to Biswas from Heise, dated 11/16/2001, re: Confidential Discussion re: PPA20015 (rsg v 5/70 v Pio v Pac)
981	AVMDL05088077	AVMDL05088077	5/17/2001	Email to Chung et al., from Fishman, dated 5/17/2001, re: Goldstein Outline - revised
982	AVMDL05088149	AVMDL05088149	5/21/2001	Email to Fishman et al., from Chung, dated 5/21/2001 re: Commented Goldstein paper with attachments
983	AVMDL05088150	AVMDL05088157		Goldstein Manuscript Outline
984			5/23/2001	Email to Fishman et al., from Chung dated 5/23/2001 re: Draft Goldstein Outline: Final feedback
985	AVMDL05088407	AVMDL05088407	5/30/2001	Email to Goldstein et al., from Fishman, dated 5/30/2001 re: Manuscript Outline
986	Deposition Exhibit	Deposition Exhibit	7/27/2011	Avandia, Avandamet, Avandaryl Projects as of 7/27/2011
987	STI 0013154	STI 0013157	7/21/2003	Email to Una Kishner from Grace Johnson, dated 7/21/2003 re: Invitation to Author a Manuscript
988	STI 001315	STI 0013147	10/10/2003	Email to file from Rita Chandra, dated 10/10/2003, no subject

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
989	STI 0013377	STI 0013409	10/29/2003	Letter from Chandra, dated 10/29/2003 re: "Current Management of Type 2 Diabetes: Why TZDs Should be the Cornerstone of Therapy"
990	STI 0013113	STI 0013113	12/17/2003	Email to GSK from Johnson, dated 12/17/2003 re: FW: Manuscript
991	STI 0013342	STI 0013373	12/18/2003	Email to Ismail et al., from Johnson, dated 12/18/2003 re: Invitation to Author a Manuscript (Ismail)
992	Public - Literature	Public - Literature	2004	Firhad Ismail, MD, The Journal of Applied Research, Vol 4, No. 3, 2004 "Current Management of Type 2 Diabetes: Why Thiazolidinediones Should Be the Cornerstone of Therapy" Email to Colquitt-Hall et al., from Johnson, dated 6/2/2006, re: Avandia Publications Status Report
993	STI 0013366	STI 0013372	6/2/2006	Avandia Key Messages
994	AVMDL10914452	AVMDL10914466	November, 2003	Avandia Publication Status Report
995	AVMDL05102560	AVMDL05102567	1/10/2003	Memo from Huang, dated 6/3/1998 re: Avandia Publication Plan
996	AVMDL03996348	AVMDL03996349	6/3/1998	
997	STI 0007876	STI 0007882	3/27/2003	Email to Krauss from Johnson, dated 3/27/2003 re: Ms for Diabetes Care (Krauss)
998	Public - Literature	Public - Literature	June, 2004	Krauss, Diabetes Care, "Lipids and Lipoproteins in Patients With Type 2 Diabetes"
999	STI 0006629	STI 0006681	10/9/2002	Letter from Johnson dated 10/9/2002 re: Manuscript for GSK
1000	STI 0004210	STI 0004227	2/15/2002	Letter to McGill from Johnson dated, 2/15/2002 re: Invitation to Author Manuscript Entitled "Durability of Glycemic Control: A Feature of the Thiazolidinediones"
1001	STI 0005070	STI 0005070	5/13/2002	Email from Johnson dated 5/13/2002, re: 1870 Braunstein MS
1002	STI 0004757	STI 0004787	9/3/2002	Email to Kistner from Johnson dated 9/3/2002 re: Braunstein publication
1003	STI 0004314	STI 0004314	9/10/2002	Email to Kistner from Johnson dated 9/10/2002 re: Braunstein Manuscript
1004	STI 0003223	STI 0003223	1/9/2003	Email to Dodge et al., from Kistner, dated 1/9/2003, re: Wyne supplements 1639 & 1738
1005	STI 0003496	STI 0003496	1/13/2003	Email to Kistner et al., from Dodge, dated 9/13/2003, re: 1633 supplement
1006	Public - Literature	Public - Literature	May, 2003	A Special Report, Reappraisal of Type 2 Diabetes Mellitus Management in Primary Care
1007	STI 0022632	STI 0022663	12/4/2001	Letter to Dimatteo dated 12/4/2001 re: Reusch Manuscript For American Journal of Cardiology
1008	Public - Literature	Public - Literature	2002	Article - Reusch MD, J. Am J Cardiol 2002, 90(suppl): 19G-26G "Current Concepts in Insulin Resistance, Type 2 Diabetes Mellitus, and the Metabolic Syndrome"
1009	STI 0011132	STI 0011132	1/29/2004	Email to Johnson from Saba, dated 1/29/2004, re: LaSalle
1010	STI 0003470	STI 0003471	4/29/2003	Email from Monica Dodges, dated 4/29/2003 re: Overrun copies of The Endocrinologist
1011	STI 0003521	STI 0003521	6/25/2003	Invoice - Lippincott, Williams & Wilkins

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1012	STI 0016805	STI 0016807	3/19/2004	Email to Bivins et al., from Johnson dated 3/19/2004, re: FW: AIM Supplement to 6600 AIC readers
1013	STI 022523	STI 022523	2/28/2002	STI Release Form
1014	AVMDL08138203	AVMDL08138215		GlaxoSmithKline CIP Publication Approval Policy - Introduction
1015	AVMDL09348669	AVMDL09348674		Specific Protocol Summary study no. 49653/311
1016	AVMDL00248762	AVMDL00248762	11/29/2001	Diabetes CST Minutes November 29, 2001
1017	AVMDL01732744	AVMDL01732747		311: Design
1018	AVMDL0297697	AVMDL0297697	10/25/2000	Email to Freed fr: Brooke re: abstract objective:
1019	AVMDL04105036	AVMDL04105039	7/23/2001	Memo re the company is considering a head to head trial of Avandia vs. Actos.
1020	AVMDL04105032	AVMDL04105035	7/23/2001	Email re:H2H Lipid effects
1021	AVMDL0030370	AVMDL0030374	10/23/2001	Email fr: Freed to Balcarek
1022	AVMDL04317155	AVMDL04317161	12/7/2002	correspondence to Eric Lewis fr: Ryutaro Ishi
1023	AVMDL03173331	AVMDL03173331		Differences in Lipid profile
1024	AVMDL00255935	AVMDL00255936		Possible items/Studies for Scientific Advisory Board Meeting (Tempe Arizona, Nov 16-18)
1025	AVMDL03252982	AVMDL03252984	4/17/2001	email to Murphy and Freed - presentation 311
1026	AVMDL10137253	AVMDL10137348	2007	Pioglitazone for type 2 diabetes mellitus (review)
1027	AVMDL03253023	AVMDL03253028	2002	Avandia vs. Actos Lipid Study 49653/311 Abstract 441: Rosiglitazone Monotherapy Significantly Lowers HbA1c Levels in Treatment - Naïve Type 2 Diabetic Patients
1028	AVMDL03261686	AVMDL03261686		Response to Major Objections
1029	AVMDL01441125	AVMDL01441167	9/12/1996	Briefing Notes - Meeting with FDA
1030	AVMDL0007281	AVMDL0007286	4/17/1998	Rosiglitazone Maleate (BRL 49653C) Tablets - Meeting with FDA
1031	AVMDL01420097	AVMDL01420103		Notes from 23-Jun-1998 Discussion with John Lachin
1032	AVMDL01422297	AVMDL01422306	7/1/1998	Avandia Proposed NIH Pilot Study - Evaluation and Recommendation
1033	AVMDL04090684	AVMDL04090688	8/31/1998	Efficacy Analysis Plan
1034	AVMDL01429145	AVMDL01429148	1/7/1999	Draft Lebovitz Efficacy Paper
1035	AVMDL04094793	AVMDL04094808	4/20/1999	Responses to Efficacy Questions
1036	AVMDL07148619	AVMDL07148636	4/21/1999	Email to Balcarek fr: Freed re: Avandia Study 020
1037	AVMDL10404515	AVMDL10404518	5/20/1999	correspondence to Gould and Calmels fr: Cobitz
1038	AVMDL06251570	AVMDL06251571	2/5/2002	
1039	AVMDL00434404	AVMDL00434404	1/16/2003	correspondence to PM-METABOLIC - Avandamet fr: Greg Wilson/PharmRD/GSK
1040	AVMDL00434405	AVMDL00434447	1/16/2003	Avandamet First Line Update - power point slides
1041	AVMDL11725642	AVMDL11725861	November, 2009	Confidential UVM 2009/00290/00 EU Risk-Mgmt. Plan Version 4 Updated November 2009
1042	AVMDL01443662	AVMDL01443662	9/5/1999	email fr: Cassidy re: label negotiation
1043	AVMDL00570706	AVMDL00570717	5/30/2002	EMEA telefax message re: conclusions of April 2002 CPMF

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1044	AVMDL12289627	AVMDL12289629	5/22/2003	correspondence fr: Diane M. Miller - Re: Never mind for now -- Avandia full combination initiating meeting
1045	AVMDL11380740	AVMDL11380741	5/10/2007	email from Anne Phillip re: Dr. Nissen notes from a conversation by Ron Krall
1046	AVMDL11375334	AVMDL11375337	5/8/2007	CV and non-ischemic events seen in Avandia clinical trials
1047	AVMDL11365442 - R	AVMDL11365446 - R	5/11/2007	FDA's Pre-decisional language on myocardial ischemia for inclusion in a boxed warning EMEA Opinion of the committee for proprietary medicinal products on the granting of a marketing authorization
1048	AVMDL0932779	AVMDL0932785	1999	Appendix 2 - Response to HPB Questions 9 (i), 10 (i), and 11 Email from N. Jones to M. Kreider/ M. Freed
1049	AVMDL01442576	AVMDL01442598	10/13/1999	SINDA 21-071/S-004
1050	AVMDL0116017	AVMDL0116018	2/7/2000	Memo from S. Malozowski to D. Orloff
1051			11/29/2000	FDA Teleconference Record between FDA Team & GSK Team
1052	AVMDL11739721	AVMDL11739725	12/7/2000	Memo from D. Orloff titled "NDA Review Issues & Recommended Action"
1053	AVMDL01470236	AVMDL01470240	2/26/2003	Medical Review of NDA 21071/ NDA 21071-S004/ NDA 21071- S006 by Joanna Zawadzki
1054	AVMDL00012955	AVMDL00012957	2/7/2003	Email from J. Weber (FDA) to S. Shapowal (GSK) with Proposed Label
1055			2/26/2003	Email from S. Shapowal to J. Weber with Label Edits
1056	AVMDL00097654	AVMDL00097678	2/27/2003	Fax from S. Shapowal to J. Weber with Label Edits
1057	AVMDL00097361	AVMDL00097361	2/27/2003	Email from A. Gianchetti to J. Balcarek, et al.
1058	AVMDLN00058859	AVMDLN00058864	2/27/2003	Email from S. Ball to C. Kahn/F. DiMarco with attachment entitled "Additional Data for Rosiglitazone Item"
1059	AVMDL0027440	AVMDL0027441	2/28/2003	Email from S. Ball to C. Kahn/F. DiMarco with attachment entitled "Additional Data for Rosiglitazone Item"
1060	AVMDL01821923	AVMDL01821923	11/19/2003	Rosiglitazone Combination Therapy with Insulin (Studies 082, 095, and 114)
1061	AVMDL01182922	AVMDL01182940	8/7/1999	Email from T. Williams to Avandia Team
1062	AVMDL07071052	AVMDL07071053	9/25/2001	Rosiglitazone Lipid Advisory Board Meeting
1063	AVMDL0005615	AVMDL00005637	12/15/1998	
1064	AVMDL00068189	AVMDL00068207	10/18/2000	Metabolism & Pulmonary Agenda: 18 October 2000 TU/TT/BDS Teleconference
1065	AVMDL01224136	AVMDL01224142	2/4/2005	Slideshow Presentation: CV Modeling Scenario Planning
1066				Study No. 082
1067				Study No. 085
1068				Study No. 095
1069				Study No. 49653/127
1070				Study No. 49653/133
1071			11/19/2003	Additional Data for Rosiglitazone item- GLC 19th November 2003
1072			9/25/2001	Minutes for ACT Meeting 25 September 2001
1073				GSK Document: Net Sales Upside v. Net Sales Downside
1074	AVMDL7164255	AVMDL7164299	10/7/1999	Safety Board Briefing Document: Rosiglitazone and Insulin Combination Product Monograph Avandia
1075	AVMDL1444592	AVMDL1444592	9/28/1999	Email from Sharon Shapowal re: PM - Canada - Ischemic Heart

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1077	AVMDL1442599	AVMDL1442625	8/7/1999	HPB comments - PM - Canada Discussion
1078	AVMDL01182725	AVMDL01182741		Response to HPB Request for Clarification
1079	AVMDL01182724	AVMDL01182724	8/13/1999	Email fr: Jo Dole re: 1st draft of HPB response re: cardiovascular disease
1080	AVMDL04090772	AVMDL04090772	9/4/1998	Email to Clare Kahn from Martin Freed dated 9/4/1998 re: Avandia proposal
1081	AVMDL04092611	AVMDL04092612	10/28/1998	Email to Mark McCoy, et al., from Martin Freed dated 10/28/1998 re: Avandia 108 SPS
1082	AVMDL0097654	AVMDL0097654	2/26/2003	Email from Shapowal to Werner re: Confidential.
1083	AVMDL0097384, 94, 405	AVMDL0097384, 94, 405	2/26/2003	Portions of March 2003 Avandia label.
1084	AVMDL0097394	AVMDL0097394		Portions of March 2003 Avandia label.
1085	AVMDL04154588	AVMDL04154588	2/28/2003	Email to Balcarek, et al., from Gianchetti re: Avandia/Insulin
1086	AVMDL0027440	AVMDL0027441	3/3/2003	Email to Gianchetti et. Al., from Shapowal re: Avandia/insulin
1087	AVMDL04097162-R	AVMDL04097164-R	9/21/1999	Email to Goodwin et al., from Bruell dated 9/21/1999 re: URGENT Re: 080 Oral Pres-Lipids
1088	AVMDL10682602	AVMDL10682603	10/16/2007	Summary of meeting minutes held on 10/16/2007
1089	AVMDL10690543	AVMDL10690545	10/17/2007	Email to Aftring et al., from Cocchetto re: Draft /summary of meeting on Avandia dated 10/17/2007
1090	AVMDL10680006	AVMDL10680007	10/18/2007	Email to Reynders et al., from Cocchetto re: Item for CARDs dated 10/18/2007
1091	AVMDL10699495	AVMDL10699496	10/19/2007	Email to Metz et al., from Cocchetto re: Avandia: Revised draft labeling from FDA dated 10/19/2007
1092	AVMDL10699497	AVMDL10699508		FDA Label Black Box
1093	AVMDL10680244	AVMDL10680246	10/30/2007	Email to Cobitz et al., from Zariffa re: FDA request for info on new study dated 10/30/2007
1094	AVMDL10680528	AVMDL10680533	11/5/2007	Email to Krall et al., from Slaoui re: Avandia: Revised Draft Labeling dated 11/5/2007
1095	AVMDL0438607	AVMDL00438609	11/3/2003	correspondence re: CV FDA briefing document, Draft two dated 11/4/2003
1096	AVMDL00897138	AVMDL00897151	7/4/2006	Global Datasheet- Rosiglitazone - Glimepiride
1097	AVMDL00897125	AVMDL00897137		Global Datasheet- Rosiglitazone - Glimepiride
1098	AVMDL00897046	AVMDL00897062		Data to support labeling change, Rosiglitazone/Glimepiride
1099	AVMDL05091025	AVMDL05091026	10/12/2001	2001-10-12 Email re: process for ADA abstracts pages 1-2
1100	AVMDL04505090	AVMDL04505223		Investigator Brochure
1101	AVMDL039996348	AVMDL039996349	6/3/1998	Memo to James Huang from Erin Snyder re: Avandia Publication Plan, dated 6/3/1998
1102	AVMDL04001440	AVMDL04001441	7/14/1998	Memo to James Huang from Erin Snyder re: Avandia Publication Plan, dated 7/14/1998
1103	AVMDL0309492	AVMDL0309499	8/18/1998	Avandia Target Authors revised 8/18/1998
1104	AVMDL03996350	AVMDL03996350	9/9/1998	Memo to James Huang from Erin Snyder re: Publication Strategy, dated 9/9/1998
1105	AVMDL0308374	AVMDL0308391	1998-1999	Avandia Publication Plan 1998-1999 presented by Andrea P. Bruell
1106	AVMDL03967481 - R	AVMDL03967483 - R	3/1/1999	Email from P. Johnson to D. Wheaddon

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1107	AVMDL04260192	AVMDL04260195	7/28/1999	Avandia Publication Strategy Team
1108	AVMDL07541094	AVMDL07541094	9/13/2000	Internal memo to Avandia Consultants re: CASPPER dated 9/13/2000
1109	AVMDL00066964	AVMDL00066964	11/2/2000	Email to Becky Ambron from Maria Maura re: URGENT: RESPONSE REQUESTED: Meeting Availability Avandia Pub Strat/CMC, dated 11/2/2000 A proposal for SmithKline Beecham Pharmaceuticals - Avandia Case Study Publication
1110	AVMDL03435561	AVMDL03435570	9/18/2001	A proposal for Peer Review 2000-2001 Plan
1111	AVMDL04116411	AVMDL04116453	8/7/2001	Avandia Global Strategic Publication Plan Meeting Report for meeting held on 8/7/2001 re: Avandia Core PST meeting/teleconference
1112	AVMDL03254955	AVMDL03254958	8/7/2001	Field Communications dated 3/28/2001
1113	AVMDL07541905	AVMDL07541908	3/8/2001	A proposal for GlaxoSmithKline - Avandia ONE in Diabetes
1114	CHC0000001	CHC0000009	5/4/2001	Correspondence to Freed from Harrison re: Letter on 082 Manuscrip
1115	AVMDL00048434	AVMDL00048434	8/10/2001	Email to Agrawal et al., from David Harrison re: Process for ADA abstracts, dated 10/12/2001
1116	AVMDL05091025	AVMDL05091026	10/12/2001	Type 2 Diabetes Mellitus and Avandia Publications Program, Proposed to Michael DiMatteo, RPh, PhD, GlaxoSmithKline
1117	AVMDL05076416	AVMDL05076431	10/31/2001	"Evolution of Management For Type 2 Diabetes Mellitus" Grant Request Proposed to Michael DiMatteo, RPh, PhD dated 11/2/2001
1118	AVMDL05076433	AVMDL05076445	11/2/2001	Top Line News - Avandia wows the Long Island Diabetic Expo dated 12/19/2001
1119	AVMDL07543634	AVMDL07543637	12/19/2001	Avandia Publication Plan 2002 prepared by David Harrison
1120	AVMDL03428213	AVMDL03428232	2002	Meeting Report for meeting held on 2/5/2002 re: PST Teleconference
1121	AVMDL03932310-R	AVMDL03932314-R	2/5/2002	A Proposal for GlaxoSmithKline - Avandia Literature Search and Analyses
1122	CHC0000015	CHC0000021	3/21/2002	Rosiglitazone and Fluid Retention an Overview
1123	AVMDL10790389	AVMDL10790454		Email to Maria Maura from Martin Freed re: ADA/AHA Talk - Version 10 - please print color notes version- thanks, dated 6/20/2002
1124	AVMDL10459728	AVMDL10459728	6/20/2002	Rosiglitazone and Fluid Retention an Overview, final version
1125	AVMDL10459729	AVMDL10459779		Email to Mansi et al., from Harrison re: Development of manuscript based on Vinik Study, dated 8/5/2002
1126	AVMDL08979826	AVMDL08979826	8/5/2002	Invoice Number 16521211, project description: Avandia CASPER Renewal for 2002-2003, dated 12/11/2002
1127	CHC0000145	CHC0000155	12/11/2002	A Renewal Proposal for GlaxoSmithKline Avandia CASPPER renewal for 2002-2003, dated 10/21/2002
1128	CHC0000022	CHC0000033	10/21/2002	A Renewal Proposal for GlaxoSmithKline Avandia CASPPER renewal for 2002-2003, dated 8/29/2002
1129	AVMDL05078450	AVMDL05078458	8/29/2002	

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1130	AVMDL03993621-R	AVMDL03993642-R	2003	Avandia Publication Plan 2003 prepared by David Harrison dated December 2002
1131	CHC0000060	CHC0000073	2/12/2003	A proposal for GlaxoSmithKline - Diabetes Medicis Director-Employer Regional Forums dated 2/12/2003
1132	CHC0000043	CHC0000051	4/23/2003	A proposal for GlaxoSmithKline - Avandia and Avandamet Therapeutic Specialist rep (TSR) Concepts dated 4/23/2003
1133	CHC0000052	CHC0000059	5/1/2003	A proposal for GlaxoSmithKline - Avandia and Avandamet Key Congress Abstract Compendium dated 5/1/2003
1134	CHC0000074	CHC0000087	9/9/2003	A revised proposal for GlaxoSmithKline - Diabetes Medical Director-Employer Regional Forums dated 9/9/2003
1135	CHC0000088	CHC0000112	9/25/2003	A proposal for GlaxoSmithKline - Avandia and Avandamet Experts Program dated 9/25/2003
1136	CHC0000113	CHC0000125	10/31/2003	A revised proposal for GlaxoSmithKline - 2003 Avandia and Avandamet Experts Program: Activities and Planning dated 10/31/2003
1137	CHC000133	CHC000142	1/8/2004	A proposal for GlaxoSmithKline - 2004 Diabetes Employer Regional Forums dated 1/8/2004
1138	AVMDL09058283-R	AVMDL09058287-R	7/13/2004	Email to Farrow from Robinson dated 7/13/2004 re: PROactive preparation- publications
1139	AVMDL03441057	AVMDL03441115	8/19/2004	Avandia Summer 2004 Scientific Advisory Board Meeting held on July 29-30, 2004 Editorial - Fontanarosa, P.B., et al., JAMA, July 6, 2005 - Vol. 294, No 1 (reprinted)
1140	AVMDL05393712	AVMDL05393713	7/6/2005	"Reporting Conflicts of Interest, Financial Aspects of Research and Role of Sponsors in Funded Studies
1141	AVMDL07854252	AVMDL07854255	9/23/2005	Email to Bernadette Mansi from Alexander Cobitz re: Further to my message...please forward to Bernadette King and Bernadette Mansi..., dated 9/23/2005
1142	AVMDL01541185	AVMDL01541185	9/23/2005	Email to MDC-Avandia ClinMT from Dana Miller re: Media responses from Avandia team dated 9/23/2005
1143	AVMDL01075649	AVMDL01075712	October, 2006	Avandia US Diabetes Franchise Update dated October, 2006
1144	AVMDL05455427	AVMDL05455428	11/9/2005	Email to Charles Miller from Jon Dixon re: New MS development process to be discussed at Nov. 8 Avandia PST meeting, dated 11/6/2005
1145	AVMDL04041767	AVMDL04041767	10/10/2007	Email to Balcarek from Ishii re: Publication of the Japan Avandia Study, dated 10/10/2007

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1146	AVMDL11741170	AVMDL11741177	3/25/2008	Letter to Jean-Pierre Garnier, PhD from FDA re: Warning Letter (08-ATL-05) dated 3/25/2008
1147	CHC0000126	CHC0000132	7/26/2004	A revised proposal for GlaxoSmithKline - Avandia National Employer Advisory Board Meeting dated 7/26/2004
1148	AVMDL09111168	AVMDL09111168		Meta Analysis
1149	AVMDL00275587	AVMDL00275590	4/12/2001	Email to Mansi, et al., from Carmels dated 4/12/2001 re: subject unknown
1150	AVMDL09111166	AVMDL09111166		Meta Analysis
1151	AVMDL05393714	AVMDL05393719		JAMA policy of industry - sponsored studies
1152	AVMDL05393707	AVMDL05393711	1/20/2006	Fontanarosa and DeAngelis, JAMA, BMJ 2006;332:177-doi:10.1136/bmj.332.7534.177 JAMA policy of industry - sponsored studies
1153	AVMDLN00410105	AVMDLN00410108		Confidential completed studies Protocol No./ BRL49653c/143
1154	AVMDLN00569350	AVMDLN00569350		Study Procedures Chart 49653/143
				Confidential - The GlaxoSmithKline group companies CM2003/00004/00 BRL-049653/143 - A 24-Week Randomized, Double-blind study to evaluate the efficacy safety and tolerability of Avandia (8mg once daily) in combination with Glyburide in African American and Hispanic Patients with Type 2 Diabetes Mellitus who are Inadequately Controlled on Glyburide Monotherapy
1155	AVMDLN00768986	AVMDLN00769129		Avandia Sales Aide - "Control For The Duration"
1156	AVMDLN00078223	AVMDLN00078225		Avandia sales aide - Avandia A Favorable Lipid Profile
1157	AVMDL01225477	AVMDL01225477		Avandia sales aide - Avandia A Favorable Lipid Profile
1158	AVMDL07739833	AVMDL07739833		Glitazone Market Research Telephone Conference Discussion Materials- January - February, 2000 888-567-7959
1159	AVMDL00015081	AVMDL00015090		GSK - Important Correction Of Drug Information dated 9/6/2001 addressed to Dear Healthcare Provider signed by David M. Stout, President, US Pharmaceuticals GlaxoSmithKline
1160	GSK letter	GSK letter	9/6/2001	FDA/SB Meeting Record
1161	AVMDL10636064	AVMDL10636070	11/15/2001	
1162	AVMDL00252825	AVMDL00252842	December, 2001	Avandia Lipid Publication Strategy, Prepared by David Harrison - December 2001
1163	CHF028705	CHF028708		Avandia S.W.O.T.
1164	AVMDL01570414	AVMDL01570417		Sales Aid - Focus on the Guidelines
1165	AVMDL07740557	AVMDL07740558		Avandia Sales Aide - Effect On Lipids
1166	Letter	Letter	10/17/2009	Letter to Patients from City Drug Store
1167	AVMDL07188798-R	AVMDL07188800-R	7/3/2002	Email to Gould from Shapoval re: DOF for Sales Aid dated 7/3/2002
1168	AVMDL04090357	AVMDL04090358	7/15/1998	Minutes of Avandia Clinical Submission Team Meeting #3, 15 July 1998
1169	AVMDL00078994	AVMDL00078995		Avandia Sales Aid - Effect of Avandia on LDL and LDL Particle Density

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1170	AVMDL00301226-R	AVMDL00301257-R		SmithKline Beecham Pharmaceuticals - Product Development Strategy - Metabolism Pulmonary - Disease Area Strategies/Priorities - First Draft
1171	AVMDL03966938	AVMDL03966947	4/1/1999	Email to Salzman et al., from Clare Kahn re: Avandia Ethics in Monotherapy
1172	AVMDL08582017	AVMDL08582021	5/14/2007	Email to Barker et al., from Shurneva Berry re: Global Safety Board Minutes: 14 May 2007
1173	AVMDL0296565-R	AVMDL0029656-R	3/29/2001	Email to Dollow from Freed re: Avandia in Japan - Actos data
1174	AVMDL0097656	AVMDL0097678		Draft label - SB Avandia BRL-049653 Item 3A Annotated Labeling
1175	AVMDL07599727	AVMDL07599727		Obesity, T2DM and CVD
1176	AVMDL11951419	AVMDL11951420	1/31/2003	Email re: Portfolio review mtg Avandia in Alzheimers TC, UMR 2160, dated 1/31/2003
1177	AVMDL01470236	AVMDL01470240	12/7/2000	Memo from Shapowal - FDA teleconference record dated 12/7/2000
1178	AVMDL0060095	AVMDL0060097	3/22/2001	Email from Steven Kahn re: ADOPT Methodology Manuscript - Please Review, dated 3/22/2001
1179	AVMDL0066284	AVMDL0066296		Freezer Study
1180	AVMDL10840032	AVMDL10840084	8/7/2001	Modifying Cardiovascular Risk in the Type 2 Diabetes Patient, Draft- by Steven M. Haffner, MD
1181	AVMDL10840031	AVMDL10840031	8/7/2001	Email from David Harrison dated 8/7/2001 re: Haffner manuscript for review
1182	AVMDL05090074	AVMDL05090104	8/30/2001	Draft - Modifying Cardiovascular Risk in the Type 2 Diabetes Patient, by Steven M. Haffner, MD
1183	AVMDL05090072	AVMDL05090073	8/30/2001	Email from Chung dated 8/30/2001 re: Haffner manuscript
1184	AVMDL0938530	AVMDL0938530	9/1/2001	[Abstract] The American Diabetes Association 61st Scientific Session:
1185	Public - Literature	Public - Literature	December, 1999	Haffner, et al., Arch Intern Med/Vol 159, Dec 13/27, 1999 www.archinternmed.com "Reduced Coronary Events in Simvastatin-Treated Patients With Coronary Heart Disease and Diabetes or Impaired Fasting Glucose Levels"
1186	AVMDL03927152	AVMDL03927157	2/5/2002	Meeting Report for PST Teleconference
1187	AVMDL00308798	AVMDL00308798	11/17/2000	Avandia Publication Timeline as of 11/17/00
1188	AVMDL00295236	AVMDL00295238	4/27/2001	GSK Proposed Publication Policy, Situation-Target-Proposal
1189	AVMDL00172581	AVMDL00172582	10/1/2001	Email from Whealon to Kidgell re: Diabetes Presentation dated 10/1/2001
1190	AVMDL03435571	AVMDL03435575	9/5/2001	A Proposal for GlaxoSmithKline - Avandia Casper 2001-2002
1191	AVMDL03922373	AVMDL03922378	6/6/2002	Meeting Report regarding 6/6/2002 PST Teleconference
1192	AVMDL00140467	AVMDL00140468	7/30/2002	Email to Shapowal from McManus re: 483 findings and response to inspection of Avandamet Bioanalysis data, dated 7/30/2002
1193	AVMDL11396025	AVMDL11396042	6/19/2007	Greer, Draft Pioglitazone-Meta-Analysis Defense6.doc, Draft in Progress: GSK reactive statement and question & answer document

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1194	AVMDL11823516	AVMDL11823517	8/8/2007	Email to Miller from Siobhan re: For comment: Epidemiologic study of CHF and MI in elderly Canadians (Rosi and Rio vs other OAD's), dated 8/8/2007
1195	AVMDL11823518	AVMDL11823518	8/8/2007	Email to Crisp from Chou re: CV studies as discussed, dated 8/8/2007
1196	AVMDL11618838	AVMDL11618835	12/5/2007	GlaxoSmithKline Reputation Management 2007 Update - Corporate Responsibility Committee 5 December 2007
1197	AVMDL11618836	AVMDL11618837	11/23/2007	Email to Curry et al., from: Balmer re: Opportunity to Comment: Reputation report for the Corporate Responsibility Committee, December 2007, dated 11/23/2007
1198	AVMDL07512403	AVMDL07512410	3/13/2001	Email to Bray et al., from Elliott, re: Avandia and HIV lipodystrophy dated 3/13/2001
1199	AVMDL0982068	AVMDL09982072	2003	Product Public Relations Director/Manager, Pre-Interview Assignment
1200	AVMDL07734289	AVMDL07734307	2/11/2005	New York Journalist Interviews, Results Day, February 11, 2005, Introductory Comments
1201	AVMDL10960536	AVMDL10960540	6/9/2005	Minutes of the 18th Meeting (VTC) of the Risk Oversight and Compliance Council ("ROCC") dated 6/9/2005
1202	AVMDL06707564	AVMDL06707566	March, 2005	CET Report - March 2005
1203	AVMDL06711459	AVMDL06711462	April, 2005	CET Report - April 2005
1204	AVMDL09165871	AVMDL09165874	July, 2005	CET Report - July 2005
1205	AVMDL09889636	AVMDL09889641	June, 2005	CET Report - June 2005
1206	AVMDL06704263	AVMDL06704263	2/1/2006	Email to Tamada et al., from Ray re: For Review -- Corp Resp Report (2nd draft) dated 2/1/2006
1207	GSK102_000050035	GSK102_000050135	3/23/2007	Public Relations Guidelines 10 Most Common Practices dated 3/23/2007
1208	AVMDL06781848	AVMDL06781849	6/4/2007	Email to Garnier et al., from king re: GLAXO Big Pharma's Mother Theresa dated 6/4/2007
1209	AVMDL10484110	AVMDL10484111	9/20/2007	Letter from GSK to Mark Booth dated 9/20/2007
1210	AVMDL11742780	AVMDL11742783	3/6/2008	2008 Corporate Issues Management draft dated 3/6/2008
1211	AVMDL11561339	AVMDL11561390	2009	GSK Corporate Responsibility Report 2009 - request for information, research practices Confidential to corporate communications & Community Partnerships, Corporate Communications
1212	AVMDL11743077	AVMDL11743083	7/6/2009	Weekly Heads Up Meeting Monday 6th July 2009
1213	BBDO0000000007908	BBDO0000000007964	March, 2006	Avandia Communications Assessment March 2006
1214	AVMDL0734744	AVMDL07734760		Final Avandamet, Cidra Consent Decree Q&A, Background (to be used to provide context to responses)
1215	AVMDL11741308	AVMDL11741324	3/20/2008	Appendix 2: Learnings From Avandia Crisis Management - Avandia Lessons Learned

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1216	AVMDL11823907	AVMDL11823934	2007	TZDs and Cardiac Outcomes - Lipscombe et al. 2007 - Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
1217	AVMDL06704264	AVMDL06704277		Research and Development
1218	REGAN001442	REGAN001454		The Avandia Controversy
1219	AVMDL09809078	AVMDL09809078	1/14/2002	Memo to Distribution List re: Avandia Global Strategic Plan
1220	AVMDL03501367	AVMDL03501367	6/21/2002	Avandia IMT Study (334) - Protocol/Amendment No 2 submitted to PRG for review
1221	AVMDL10628930	AVMDL10628964		Stewart, M., Rosiglitazone - Effects on Atheroma in non-diabetes
1222	AVMDL03559251	AVMDL03559425	9/1/2005	BRL-049653/334 - Final Clinical Study Report, 9/1/2005
1223	Study	Study		BRL-049653/334 - Study
1224	AVMDL0070011	AVMDL0070020	8/11/2000	11 August 2000 Draft Steering Committee Meeting Minutes - Avandia - CV Outcome Study (231)
				Email to Fricke et al., from Stewart, re: minutes steering committee meeting 231 in Paris, dated
1225	AVMDL0071354	AVMDL0071355	8/17/2000	8/17/2000
1226	AVMDL09116444	AVMDL09116449	2/21/2003	Draft minutes 7th Steering Committee Meeting - 21 February 2003
1227	AVMDL12314884	AVMDL12314891	2/11/2004	Draft minutes 9th Steering Committee Meeting - February 2004
				Email to gomis et al., from Dargie re: ESC congress abstract of sMI data !!!, dated
1228	AVMDL09114760	AVMDL09114761	2/14/2006	2/14/2006
				Email to michaelrossmacdonald from Jones re: Occurrence of silent MI in diabetic patients in the RECORD study, dated 4/24/2008
1229	AVMDL09230933	AVMDL09230933	4/24/2008	Email to Jones from michaelrossmacdonald re: Occurrence of silent MI in diabetic patients in the RECORD study, dated 5/8/2008
1230	AVMDL09230341	AVMDL09230342	5/8/2008	
1231	AVMDL09741133	AVMDL09741135	9/9/2009	Email to Komajda Michael from Philip Home re: RECORD & silent MI , dated 9/9/2009
1232	AVMDL09741171	AVMDL09741171	9/9/2009	Email to ON=Drusilla from Jones, dated 9/9/2009 re: RECORD
				Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD) study: Interim findings concerning Cardiovascular Hospitalisations and Deaths
1233	AVMDL03675060	AVMDL03675088		Email from McMurray, to McMurray et al., dated 6/2/2007 re: reviewers comments RECORD
1234	AVMDL09129997	AVMDL09130000	6/2/2007	
1235	AVMDL07813896	AVMDL07813903	11/23/2006	Draft minutes 14th steering committee meeting - November 2006
				Email to gomis et al., from Donaldson, dated 2/20/2006 re: ESC congress abstract on s MI data !!!
1236	AVMDL09114716	AVMDL09114717	2/20/2006	Email to gomis et al., from Hanefeld, dated 2/20/2006 re: ESC congress abstract on s MI data !!!
1237	AVMDL09114710	AVMDL09114712	2/20/2006	Email to Hanefeld et al., from Komajda, dated 2/20/2006 re: ESC congress abstract on s MI data !!!
1238	AVMDL09114713	AVMDL09114715	2/20/2006	

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1239	AVMDL09114752	AVMDL09114753	2/15/2006	Email to Home from Komajda dated 2/15/2006 re: Comments on the sMII abstract for ESC
1240	AVMDL09114737	AVMDL09114741	2/15/2006	Email to Donaldson from Komajda, dated 2/15/2006 re: Comments on the sMII abstract for ESC
1241	AVMDL09114726	AVMDL09114731	2/15/2006	additional Email to Donaldson from Komajda, dated 2/15/2006 re: Comments on the sMII abstract for ESC
1242	AVMDL09114716	AVMDL09114717	2/20/2006	Email to gomis et al., from Donaldson, dated 2/20/2006 re: ESC congress abstract on sMII data !!!
1243	AVMDL09114762	AVMDL09114763		Prevalence and incidence of silent myocardial infarction in type 2 diabetic patients: the RECORD study
1244	AVMDL09240547	AVMDL09240550	10/7/2008	Email to Curtis et al., from Jones, dated 10/7/2008 re: RECORD: sMII
1245	AVMDL09240308	AVMDL09240311	11/17/2008	Email to MacDonald from Curtis dated 11/17/2008 re: RECORD: sMII
1246	AVMDL09230360	AVMDL09230363		Overview of ECG analysis for study BR 04965321 (pilot study).
1247	AVMDL05642956	AVMDL05642957	5/9/2007	Email to Aftring et al., re: Fw: Avandia, dated 09-May-2007 06:13
1248	AVMDL0719546	AVMDL07719546	5/25/2007	Email to Balcarek et al., from Dollery dated 5/25/2007 re: Fw: Privileged and confidential; Avandia brief Printed
1249	AVMDL07719547	AVMDL07719543	5/25/2007	Cardiovascular and related issues with rosiglitazone and other thiazolidinedione's. Version 3: 20:33 BST 25/May/07 [paper]
1250	AVMDL07719710	AVMDL07719712	5/31/2007	Email to McCartney et al., from Balcarek dated 5/31/2007, re: Next Steps PRINTED
1251	AVMDL07719713	AVMDL07719721		Private and Confidential - Draft, What is the impact of Rosiglitazone and lipids and could a detrimental effect be seen within 6 months?
1252	AVMDL09106817	AVMDL09106818	6/1/2007	Email to Dollery from Buckingham, dated 6/1/2007, re: Privileged and confidential attorney client communication your review
1253	AVMDL09110695	AVMDL09110696	6/1/2007	Email to Dollery dated 6/1/2007 re: Privileged and confidential attorney client communication
1254	AVMDL09110638	AVMDL09110638	6/15/2007	Email to Balcarek, dated 6/15/2007 re: Privileged and confidential attorney client communication fluid overload and cardiac ischemia
1255	AVMDL10681550	AVMDL10681551	6/19/2007	Email to Dollery et al., from McCartney dated 6/19/2007 re: Privileged and confidential attorney client communication; calculations
1256	AVMDL10504493	AVMDL10504493	6/22/2007	Email to Balcarek et al., from Dollery dated 6/22/2007 re: Privileged and confidential attorney client communication; Avandia briefing
1257	AVMDL10681588	AVMDL10681589	6/22/2007	Email to Dollery et al., from McCartney dated 6/22/2007 re: Privileged and confidential attorney client communication; Avandia briefing
1258	AVMDL10740735	AVMDL10740735	6/23/2007	Email to McCartney et al., from Dollery dated 6/23/2007 re: Privileged and confidential attorney client communication; Avandia briefing and follow up

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1259	AVMDL10579319	AVMDL10579332	8/10/2007	Email to Chou et al., dated 8/10/2007 re: Privileged and confidential- seeking legal counsel
1260	AVMDL09108456	AVMDL09108465		Report 3 Dr. R.E. Buckingham, King's College & Guy's Hospital, London, U.K., Rosiglitazone and the J-Curve: a formula for cardiac ischemia and acute myocardial infarction?
1261	AVMDL10537193	AVMDL10537194	6/3/2007	Email to Krall et al., dated 6/3/2007 re: Privileged and confidential attorney client communication
1262	AVMDL09109180	AVMDL09109181	5/31/2007	Email to Slaoui et al., from Dallery dated 5/31/2007 re: Effect of fluid overload
1263	AVMDL05942089	AVMDL05942095	July, 2007	Bhatt MD, D.L., Chew, D.P., et al., American Heart Journal, Volume 154, Number 1 "Peroxisome proliferator-activated receptor γ agonists for the prevention of adverse events following percutaneous coronary revascularization results of the PPAR study"
1264	AVMDL04127364	AVMDL04127366	4/5/2002	Email to Shapowal et al., from Brown dated 4/5/2002 re: FW: Vascular actions of PPAR
1265	Study No.: BRL - 049653/342	Study No.: BRL - 049653/342	5/7/2007	Study No.: BRL-049653/342
1266	AVMDL00487083	AVMDL00487092	5/22/2007	Email to Urquhart et al., from Krall dated 5/22/2007 re: Diabetes drug Avandia linked to heart risks; Vioxx parallels cited- CNN.com.htm
1267	AVMDL05701148	AVMDL05701150	5/4/2007	Memo to Document Control Room from Cocchetto re: NDA 21-071/S-022; Avandia (rosiglitazone maleate) Tablets; Notes from Teleconference with FDA on May 4, 2007
1268	AVMDL05908451	AVMDL05908452	5/4/2007	Memo to Document Control Room from Cocchetto re: NDA 21-071/S-022; Avandia (rosiglitazone maleate) Tablets; Notes from Teleconference with FDA on May 4, 2007
1269	AVMDL10456092	AVMDL10456094	1/2/2007	Letter to Healthcare Professional from GSK re: boxed warning
1270	AVMDL0844608	AVMDL0844608	7/30/2007	Email to Cocchetto from Phillips dated 7/30/2007 re: Congratulations...
1271	AVMDL01595966	AVMDL01595966	5/13/2007	Email to Phillips et al., from Freider dated 5/13/2007 re: Slides on US Labeling for GSB
1272	AVMDL01595967	AVMDL01595970		US Labeling Options - 1, slides
1273	AVMDL10483690	AVMDL10483692	5/10/2007	Press Release - "GlaxoSmithKline updates advice for physicians prescribing Avandia, prescribing information to reinforce existing CHF risk for TZD class; information added on risk of [myocardial ischemic events]."
1274	Public Document	Public Document	8/8/2010	Letter from J. Woodcock, Center for Drug Evaluation and Research to Margaret Kreider dated 8/8/2010 re: Data on Rosiglitazone
1275	Public Document	Public Document	8/19/2010	Letter to Curtis Rosebraugh, MD from Mary Parks, MD re: Recommendations on marketing status of Avandia (rosiglitazone maleate) and the required postmarketing trial, Thiazolidinedione Intervention and Vitamin D Evaluation (TIDE) following the July 13 and 14, 2010 public advisory committee meeting

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1276	Public Document	Public Document	8/23/2010	Letter to John Jenkins, MD from Curtis Rosebraugh, MD dated 8/23/2010 re: Avandia AC memo
1277	Public Document	Public Document	9/1/2010	Letter to Gerald Dal Pan, MD from David Graham, MD dated 9/1/2010, re: Analysis of Medicare thiazolidinedione study by date of birth
1278	Public Document	Public Document	9/2/2010	Letter to Gerald Dal Pan, MD from David Graham, MD dated 9/2/2010, re: Comments on the study by Wertz et al. published in Circulation 2010
1279	Public Document	Public Document	9/2/2010	Letter to Janet Woodcock, MD from John Jenkins, MD dated 9/2/2010 re: Recommendation for regulatory actions- rosiglitazone
1280	Public Document	Public Document	9/10/2010	Secondary Statistical Review and Evaluation NDA 21-073, dated 9/10/2010, subject: Secondary review of pioglitazone meta-analysis statistical review by Qian Li
1281	Public Document	Public Document	December, 2009	Statistical Review and Evaluation, Pioglitazone Meta-Analyses, NDA/IND: 21-073/33, 729, dated, December, 2009
				Memo to Janet Woodcock, MD, from Gerald Dal Pan, MD, dated 9/12/2010 re: Recommendation for Regulatory Action for Rosiglitazone and Rosiglitazone-containing Products (NDA 21-071, supplement 035, incoming submission dated August 25, 2009)
1282	Public Document	Public Document	9/12/2010	Memo to NDA 021071 from Janet Woodcock, MD re: Decision on continued marketing of rosiglitazone (Avandia, Avandamet, Avandaryl)
1283	Public Document	Public Document	9/22/2010	Letter to GSK from FDA, dated 9/23/2010 re: Safety Labeling Change, REMS, and PMR Notification
1284	Public Document	Public Document	9/23/2010	
1285	Public - Literature	Public - Literature	6/18/2007	Gottlieb, S., The Wall Street Journal online, Commentary Uncle Sam, MD, June 18, 2007
				Letter to Mary Parks, MD from GSK, dated 7/26/2007, re: NDA 021071/0022; Avandia (rosiglitazone maleate) Tablets Amendment to Pending Application: Safety Independent Cardiology Review of Adverse Events in the ICT Analysis and ADOPT Study
1286	AVMDLN00709309	AVMDLN00709350	7/26/2007	Letter to Mary Parks, MD from GSK, dated 8/23/2007, re: NDA 021-071/S-022; Avandia (rosiglitazone maleate) Tablets; Response to Not Approvable Letter: Complete response
1287	AVMDLN00710078	AVMDLN00710082	8/23/2007	Summary of Avandia Cardiovascular Events Based on Independent, Blinded, External Cardiology Review of 42 Integrated Clinical Trials (ICT) and ADOPT plus, The Combination of External Cardiology Review of ICT and ADOPT with Prospectively Adjudicated Events from DREAM and RECORD (May 2007 Interim Analysis)
1288	AVMDLN00711101	AVMDLN007111224	9/13/2007	Draft Q&A re RECORD "Whay didn't you tell the FDA about the RECORD Study"
1289	AVMDL10454071	AVMDL10454074	6/3/2007	

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1290	AVMDL06555218	AVMDL06555218	6/9/2004	Email to Robin 2 Saltzman from Margaret 2 Sowell dated 6/9/2004 re: Avandia RECORD bulletin, release 6
1291	AVMDL00730359	AVMDL00730359	9/10/2004	Email to Caponi et al., from Sowell dated 9/10/2004 re: Avandia RECORD bulletin, release #7 June 2004
1292	AVMDL0715448	AVMDL0715488	May, 2007	RECORD safety interim analysis, May 2007
1293	AVMDL0715447	AVMDL0715447	5/15/2007	Email to Gibbs, et al., from MacCarthy dated 5/15/2007 re: slides
1294	AVMDL04039499	AVMDL04039505	6/15/2007	Email to Zariffa et al., dated 6/15/2007 re: List of RECORD firewall individuals
1295	AVMDL09197613	AVMDL09197618		GCSP safety bulletin - RECORD study Release 2
1296	AVMDL00523065	AVMDL00523077	October, 2003	GCSP review bulletin - RECORD study Release 3-oct 2003
1297	AVMDL0619734	AVMDL06619751	October, 2003	GCSP review bulletin - RECORD study Release 4, October 2003
1298	AVMDL00522507	AVMDL00522525	January, 2004	GCSP review bulletin - RECORD study Release 5, January 2004
1299	AVMDL06555219	AVMDL06555242	April, 2004	GCSP review bulletin - RECORD study Release 6, April 2004
1300	AVMDL00522014	AVMDL00522059	April, 2004	GCSP review bulletin - RECORD study Release 6 a, April 2004
1301	AVMDL00636046	AVMDL00636070	June, 2004	GCSP review bulletin - RECORD study Release 7, June 2004
1302	AVMDL06418561	AVMDL06418595	December, 2004	GCSP review bulletin - RECORD study Release 9, June 2004
1303	AVMDL05627228	AVMDL05627263	March, 2005	GCSP review bulletin - RECORD study Release 10, March 2005
1304	AVMDL05630144	AVMDL05630178	June, 2005	GCSP review bulletin - RECORD study Release 11, June 2005
1305	AVMDL00511118	AVMDL00511120	5/18/2007	Email to Cocchetto et al., from Zariffa, dated 5/18/2007, re: Request from FDA
1306	AVMDL10673958	AVMDL10673961	6/19/2007	Email to Huckle et al., from Shaoui, dated 6/19/2007 re: Fw: Privileged and Confidential-Avandia items requiring discussion
1307	AVMDL12187634	AVMDL12187636	9/8/2009	"Large, long-term study shows Avandia (rosiglitazone maleate) has no increased overall cardiovascular (CV) risk compared to other commonly used diabetes medicines"
1308	AVMDL10971275	AVMDL10971284		"Briefing Document for 08-Apr-2005 Global Safety Board Meeting Avandia Cardiovascular Modeling Plan Evaluation"
1309	NPD000000000125	NPD000000000126	10/29/2007	Email to Andrus at el., from Overholtz, dated 10/29/2007 re: FW: Senator asks FDA about internal Avandia vote
1310	AVMDL00514536	AVMDL00514537	10/29/2007	Email to Krall et al., from Huckle, dated 10/29/2007, re: Grassley release, fyi
1311	AVMDL10690667	AVMDL10690668	11/1/2007	Email to Metz et al., from Coccoitto, dated 11/1/2007, re: Revised Draft Labeling for Avandia Sent to FDA
1312	AVMDL10555974	AVMDL10555976	11/1/2007	Email to Krall et al., from Russo, dated 11/1/2007 re: For REVIEW - draft commitment to FDA

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1313	AVMDL10680436	AVMDL10680440	11/3/2007	Email to Kreider from Cocchetto, dated 11/3/2007 re: FYI: Avandia: Revised Draft Labeling
1314	AVMDL10680549	AVMDL10680555	11/5/2007	Email to Krall et al., from Cocchetto, dated 11/5/2007 re: Avandia: Revised Draft Labeling
1315	AVMDL10681066	AVMDL10681068	11/5/2007	Memo to Mary Parks, MD from GSK, dated 11/5/2007 re: NDA 21-071/S-022; Avandia (rosiglitazone maleate) Tablet; Follow Up to Teleconference of November 5; Areas for Discussion Regarding Draft Labeling
1316	AVMDL10680617	AVMDL10680622	11/6/2007	Memo to Document Control Room from Cocchetto re: NDA 21-071/S-022; Avandia (rosiglitazone maleate) Tablets; Notes from Teleconference with FDA on November 6, 2007
1317	AVMDL10579935	AVMDL10579936	11/7/2007	Email to Jammoahmed from Osei, dated 11/7/2007, re: FW: Feedback from FDA
1318	AVMDL07138873	AVMDL07718873	5/18/2007	Email to Slaoui from Huckle dated 5/18/2007 re: FW: Enquiry
1319	AVMDL10693227	AVMDL10693228	10/21/2007	Email to Cocchetto et al., from Slaoui, dated 10/21/2007, re: Avandia: Revised draft labeling from FDA
1320	AVMDL10692441	AVMDL10692443	10/30/2007	Email to Cocchetto et al., from Slaoui, dated 10/30/2007, re: Avandia: Feedback from FDA
1321	AVMDL10670263	AVMDL10670265	10/31/2007	Email to Krall et al., from Viehbacher, dated 10/31/2007 Re: Privileged and Confidential: Draft Press Release for Review
1322	AVMDL05873946	AVMDL05873947	11/14/2007	Email to Cocchetto et al., from Slaoui, dated 11/14/2007, re: Avandia 10 pm update
1323	Public Document	Public Document	7/20/2010	Drug Safety and availability - FDA Statement on Avandia TIDE Trial
1324	Public Document	Public Document	7/21/2010	Perrone, M., Johnson, LA, the Associated Press: "FDA issues hold on much-debated Avandia study"
1325	AVMDL03427014	AVMDL03427015	7/18/2001	Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults
1326	GSK102000000438	GSK102000000438	4/22/2007	Email between Krall and Anne Phillips Re: Nisser
1327	AVMDL10465296	AVMDL10465300	5/18/2007	Krall letter describing his contact with Nissen in May of 2007
1328	AVMDL10731664	AVMDL10731665	5/3/2007	E-mail from Krall to Lawson Re: Conversation with Nissen
1329	GSK101000300021	GSK101000300022	5/8/2007	E-mail string Lawson to Zariffa cc: Krall
1330	AVMDL12001241	AVMDL12001242	5/8/2007	Email string between Krall and Lawson requesting Avandia issue be designated a corporate crisis
1331	AVMDL10465043	AVMDL10465047	5/9/2007	E-mail from Pekarek to Krall et al Re: Avandia Key Messages based on Nissen findings
1332	AVMDL10454585	AVMDL10454586	5/14/2007	Global Safety Board Minutes of Meeting held May 14, 2007
1333	AVMDL10464721	AVMDL10464722	5/16/2007	Myocardial Ischaemia Adverse Events Chart

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1334	AVMDL10405121	AVMDL110405127	5/16/2007	Email string between Bernadette Mansi, Balcarek, Cobitz regarding Charts requested by Investor Relations regarding CV Deaths and other Adverse events seen with Avandia
1335	AVMDL00487093	AVMDL00487094	5/13/2007	E-mail string Nissen and Krall
1336	AVMDL10683214	AVMDL10683216	5/20/2007	Email from Krall Re: NEJM Press release
1337	AVMDL10683217	AVMDL10683217	5/18/2007	GlaxoSmithKline Updates Advice for Physicians Prescribing Avandia
1338	AVMDL10683218	AVMDL10683219	5/18/2007	GlaxoSmithKline Responds to NEJM Article on Avandia
1339	AVMDL10464935	AVMDL10464938	May-07	Q&A Response to NISSEN meta-analysis
1340	AVMDL10552274	AVMDL10552282	5/23/2007	Email string Siaoui, Krall, Macartney, Christopher
1341	AVMDL10738553	AVMDL10738554	5/23/2007	Email string Siaoui, Krall, Macartney
1342	AVMDL10738555	AVMDL10738559	5/23/2007	Draft of response letter to NEJM Re: Nissen Article
1343	AVMDL10683919	AVMDL10683922	5/24/2007	Email string Gibbs, Krall, Siaoui, Macartney
1344	AVMDL09145910	AVMDL09145912-R	5/25/2007	Email string Gibbs, Krall, Siaoui, Macartney
1345	AVMDL11869774	AVMDL11869775	5/30/2007	"Cardiovascular Safety of Rosiglitazone" Letter to Lancet Editor from Kral
1346	AVMDL09348669	AVMDL09348674	4/21/2001	Specific Protocol Summary 49653/311
1347	AVMDL00248762	AVMDL00248762	11/29/2001	Diabetes CSM Minutes
1348	AVMDL01732744	AVMDL01732747	11/29/2001	Study 311 Design
1349	AVMDL00297697	AVMDL00297697	10/25/2000	Email Freed to David Brooks Re: Abstract Objections
1350	AVMDL04105032	AVMDL04105035	7/23/2001	Email String Lewis, Heise, Freed, et al Re: H2H lipid effects
1351	AVMDL04105036	AVMDL04105039	7/23/2001	Situation paper created to outline lipid issue and possible studies to identify Actos & Avandia effects on lipids (Balcarek)
1352	AVMDL00030370	AVMDL00030374	10/23/2001	Email from Freed to Balcarek re data in Japan
1353	AVMDL04317155	AVMDL04317161	12/17/2002	Email string Lewis, Ishii, Freed, Porter, Heise Re: Study 570 Avandia v. Actos, Japan Regulatory
1354	AVMDL03173331	AVMDL03173331	3/25/2001	Slide from presentation created by Freed Re: Actos will win in H2H on TG and LDL
1355	AVMDL00255935	AVMDL00255936	10/17/2001	Possible items/Studies for Scientific Advisory Board Meeting (Tempe Az 11/16/18/2001)
1356	AVMDL03252982	AVMDL03252984	4/17/2001	"Pioglitazone for type 2 diabetes mellitus" article published in the Cochran Database of Systematic Reviews
1357	AVMDL10137253	AVMDL10137348	10/18/2006	Presentation slides Re: Actos v. Avandia Study 311
1358	AVMDL03253023	AVMDL03253028	4/7/2001	Presentation slides Re: Actos v. Avandia Study 311
1359	AVMDL12271988	AVMDL12271989	10/18/2002	Email from Berry Re: Canadian study
1360	AVMDL03768212	AVMDL03768212	7/30/1998	Email from Price to Menci Re: Big number for commercial
1361	AVMDL10404450	AVMDL10404452	5/20/1999	Email string Freed, Blacarek, Leonard Re: Avandia study 020 Manuscript for PST Review
1362	AVMDL00265186	AVMDL00265188	7/26/2001	Email string Cobitz, Freed, Letendre Re: Bari 2D subanalysis

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1363	AVMDL06251570	AVMDL06251571	2/5/2002	Email string Cobitz, Gould, O'Neill, Letendre Re: Canadian pause IV study-mirror to 326
1364	AVMDL00140467	AVMDL00140468	7/30/2002	Email string Green, McManus, Shapowal Re: 483 findings and response to inspection of Avandamet Bioanalysis data
1365	AVMDL00434404	AVMDL00434448	1/16/2003	Email and attachments re: presentation created by Shapowal for Avandamet First Line Update
1366	AVMDL0007378	AVMDL0007382	?????	Document produced by Clare Kahn
1367	AVMDL00308798	AVMDL00308798	11/17/2000	Chart: "Avandia Publication Timeline As of 11/17/2000"
1368	AVMDL00338974	AVMDL00338979	2/3/1999	Pages 83 to 88 of Lipids Clinical Report
1369	AVMDL00337495	AVMDL00337498	2/3/1999	Pages 79 to 82 of Lipids Clinical Report
1370	AVMDL01116217	AVMDL01116224	4/9/1999	Lipid - Apo B assessment
1371	AVMDL03964777	AVMDL03964777	5/5/1999	Email from Patwardhan to Balcarek
1372	AVMDL01436715	AVMDL01436715	5/5/1999	Email from Patwardhan to Balcarek, Shapowal, Freed, Kreider, Kahn
1373	AVMDL03446106	AVMDL03446108	8/23/1999	Email string Williams, Hung, Brand et al
1374	AVMDL040971162-R	AVMDL040971164-R	9/21/1999	Email string Brueil, Goodwin, Balcarek, Huang et al
1375	AVMDL01459042	AVMDL01459043	3/3/2000	Email string Freed, Huang, Shapowal
1376	AVMDL04105032	AVMDL04105035	7/23/2001	Email string Lewis, Balcarek, Heise et al Re: H2H Trial
1377	AVMDL03260388	AVMDL03260389	11/2/2001	Email from Freed to Porter, Stewart, Nathwani Re: Study 175 Lipids by Gender
1378	AVNDL00074584	AVNDL00074585	11/6/2001	Email from Freed to Brand re: Avandia vs. Actos Trials
1379	AVMDL04251702	AVMDL04251705	4/8/2002	Email string Porter, Freed, Hobbiger, Stewart et al Re: GSK "official" veiw on TC:HDL Ratio
1380	AVMDL03388499	AVMDL03388500	4/21/2004	Email string Lammers, Carr Re: Phoenix and Memphis PCRM Feedback
1381	AVMDL09809078	AVMDL09809078	1/14/2002	Macartney memo Re: Avandia Global Strategic Plan
1382	AVMDL8085900	AVMDL8085921		Nama Budget
1383	AVMDL006254081	AVMDL006254095	2002	Avandia US Publication Plan 2002-2003
1384	AVMDL06245857	AVMDL06245857	9/26/2002	E-mail String Cobitz, Stewart, et al
1385	AVMDL06244951	AVMDL06244952	12/11/2002	E-mail String Cobitz, Phyll, Heise
				E-mail String Cobitz, Freed, Kreider, Balcarek, Shapowal Re: Avandia re-investment/metformin combo 1st line
1386	AVMDL1475151	AVMDL1475153	4/30/2001	
1387	GSK101_000050245	GSK101_000050284		Avandia 211 CHF study - Senior Review of Additional Analysis
1388	AVMDL0155321	AVMDL01554347	4/10/2006	AVi-LXX Prescribing Information
1389	AVMDL01554319	AVMDL01554320	4/7/2006	Email string Kreider, Ebel, Parks, Mahoney, Weber Re: NDA 21-071 (016) SE8 Labeling Review
1390	AVMDL10504493	AVMDL10504493	6/22/2007	Email from Dillery to Balcarek Re: Privileged and Confidential Attorney Client Communication Avandia briefing

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1391	AVMDL10740735	AVMDL10740735	6/23/2007	Email from Dollery to Macartney, Re: Privileged and Confidential Attorney Client Communication Avandia briefing and follow up
1392	AVMDL14057156	AVMDL14057157	3/4/2009	Memo: Frank Rockhold PhD, Ellen Strahlman MD, MHSc Thru: REFLECT IDMC From: Gary Cutler PhD Re: Information Requested on CPK Changes, Troponin and Aldolase Email from Strahlman to Shaoui, Baxter Re: Update: IDMC Query to the Rosi-AD Team
1393	AVMDL14057172	AVMDL14057172	3/5/2009	Email string Witty, Strahlman, Shaoui, Christopher, Benbow, Gold, Cobitz, Liddle Subject: PRVILEGED AND CONFIDENTIAL and attachment
1394	AVMDL14057158	AVMDL14057162	3/7/2009	Email string Shaoui, Dollery, Strahlman Subject: REFLECT IDMC
1395	AVMDL14057105	AVMDL14057107	3/9/2009	Email string Shaoui, Dollery, Strahlman Subject: REFLECT IDMC
1396	AVMDL14038734	AVMDL14038743	3/20/2009	FOR REACTIVE USE ONLY - Termination of Alzheimer's trial with rosiglitazone XR
1397	AVMDL14038522	AVMDL14038522	3/31/2009	Table 2196.2 - Rate of Subjects with Lab Value at Study End >= F3
				Analyses of Creatine Kinase and Troponin for Study REFLECT-2 (Rosiglitazone Efficacy in alzheimer's disease Clinical Trial- Study AVA102672)
1398	AVMDL14038573	AVMDL14038639	4/1/2009	Powerpoint Presentation - Analysis of Troponin I, Total CPK, and CPK-MB fraction in Study SB-712753/007
1399	AVMDL14038490	AVMDL14038506	4/14/2009	
1400	AVMDL0072551	AVMDL0072555	2/25/2002	The Pink Sheet February 25, 2002 - "Avandia/Metformin Combo To Launch By End of 2002, GSK Says" THE-PINK-SHEET, February 25, 2005, Page 12
				Email and attachment re: memorandum to J.P. Garnier, Yamada; From: M. Freed Subject: Avandia Queries for Analysts
1401	AVMDL05684649	AVMDL05684654	6/25/2009	
1402	AVMDL01181366	AVMDL01181850	8/10/1999	Email and attachment re: Avandia - Request for Clarification - August 10, 1999
1403	AVMDL01441112	AVMDL01441912		Email and attachment re: response to Major Objections
1404	AVMDL00312842	AVMDL00312843	6/24/1999	Email from K. Karpinski to M. Freed Subject: Avandia
1405	AVMDL07164254	AVMDL07164299	10/19/1999	Email and attachment re: Product Monograph - Canada
				Email from S. Sharpowal to N. Jones Subject: comments on 085
1406	AVMDL0012087	AVMDL00012088	1/18/2000	
1407	AVMDL09724109	AVMDL09724110	2/3/2000	Email from J. Mastrocoda to N.S. Haran re: Avandia CPMP (Sent for Tachi Yamada)
1408	AVMDL00080664	AVMDL00080667	9/29/2000	Email string Nathwani, Buckingham, Bril, Khandoudi, Ohlstein, Yue, Schwartz, Shusterman Re: Outside interest in rosiglitazone and the heart
1409	AVMDL07657305	AVMDL07657366	12/6/2000	Email and attachment re: DRAFT: SES Response to MHW Query

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1410	AVMDL01200042	AVMDL01200045	1/22/2001	Email from J. Dole to M. Kreider Subject: time to onset for cardiovascular events in insulin studies - draft 1
1411	AVMDL07674416	AVMDL07674421	7/12/2001	Email and attachment re: Memo from P. Watkins, MD re: Avandia (Medwatch) Email from CAPONILM@phv124.um.us.sphrd.com Subject: Avandia and Myocardial Infarction: Hitlist Successfully Created
1412	AVMDL00539113	AVMDL00539114	9/19/2001	Email from R. Buckingham to Balcarek, Dole, Berry, Freed, Mather, Jones, Biswas, Shapowal, Patwardhan, Kreider, Cole, Pearce Subject: Further thoughts following yesterday's ACT meeting
1413	AVMDL01205831	AVMDL01205832	9/26/2001	Email from Shapowal to Freed, Cobitz, Nathwani, Balcarek, Brown, Porter subject: 082 and 095 BP change from baseline and Survival Curve for ICH Chart - Beta Blockers
1414	AVMDL03209730	AVMDL03209739	10/31/2001	Email and attachment from Porter Subject: LP's beta blocker table from 085 and 136
1415	AVMDL09111639	AVMDL09111639	12/19/2001	Email from Mansi to Jones re: GOOD (Avandia study 344) CV outcome study unlikely to proceed
1416	AVMDL09111638	AVMDL09111638	12/19/2001	Email and attachment re: Communications Standby Statement Re: Health Canada Report on Glitazones and Heart Failure/Liver-Related Risks
1417	AVMDL00030132	AVMDL00030134	5/28/2002	Email and attachment from Macartney to Frick subject: Here is the poster ... TZD's Cut Myocardial Infarction Risk in Type 2s - WORTH THE READ!!
1418	AVMDL10406555	AVMDL10406577	7/1/2002	Email and attachment re: Supplementary Data on Mortality During the Rosiglitazone in Heart Failure Rat Study
1419	AVMDL09785174	AVMDL09785178	12/6/2002	Complete Response to FDA's Not Approvable Letter for NDA 21-071/S-022 for AVANDIA (rosiglitazone maleate) Tablets
1420	AVMDL00442640	AVMDL00442680	9/30/2002	Chart - Additional Data for Rosiglitazone item - GLC 19th November 2003
1421	AVMDLN07010252	AVMDLN0710325	1/27/2004	Email and attachment re: Thiazolidinediones and cardiac disease, Article: New strategy for detection of signals in the WHO Database, and The BCPNN - What it is, what it does and how to interpret the numbers it generates,
1422	AVMDL00223574	AVMDL00223579	5/5/2005	Email and attachment re: Chart - Mortality Rate for RSG vs. Control DRAFT Summary of CV Modelling Results
1423	AVMDL08478906	AVMDL08478915	1/20/2004	Email and attachment re: DRAFT - 5. Avandia (rosiglitazone); review CV modeling results
1424	AVMDL00653046	AVMDL00653047	10/20/2005	Email and attachment re: DRAFT - Rosiglitazone - Further Interim Results from Analysis of Cardiovascular Events in Clinical Trials
1425	AVMDL10408382	AVMDL10408385	10/20/2005	
1426	AVMDL10461081	AVMDL10461083	12/19/2005	
1427	AVMDL11966329	AVMDL11966368	12/19/2005	

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1428	AVMDL11489856	AVMDL11489882		Global Datasheet - Rosiglitazone
1429	AVMDL08143979	AVMDL08144016	6/30/2006	European Union Risk Management Plan for Rosiglitazone CV Modeling Data
1430	AVMDL0716854	AVMDL07716855	8/22/2006	Email from Macartney to Siaoui Re: Avandia CV modelling; CET brief
1431	AVMDL05703324	AVMDL05703595	11/1/2006	Email and attachment re: Strategy plans 2002-2006 - Chart
1432	AVMDL10454277	AVMDL10454277	5/3/2007	Handwritten Notes re Nissen request for data and concerns re CV Aex:
1433	GSK101_000300111	GSK101_000300112	5/4/2007	Fax Cover sheet to Bob Schwin
1434	GSK101_00030077	GSK101_00030077	5/4/2007	Fax Cover sheet to Bob Schwin re: RSU Assessment of Avandia Metc-analysis
1435	AVMDL10638299	AVMDL10638303	5/8/2007	Email and attachment re: DRAFT CV and non-ischemic events seen in Avandia clinical trials
1436	GSK101_000300019	GSK101_000300020	5/8/2007	Follow-up to report on the article by SE Nissen & K Wolski "Effect of rosiglitazone on the risk of myocardial infarction and cardiovascular death"
1437	AVMDL11380740	AVMDL11380741	5/10/2007	Email string Pekarek, Macartney, Phillips, Baxter, Siaoui, Greet
				Email and attachment re: ICT + ADOPT CV Event Table 1.1 - Myocardial Ischemia Aex: Results from Proportional Hazards Regression Analysts
1438	AVMDL05399694	AVMDL05399711	5/10/2007	Email and attachment re: Clinical Review of SAEs of Myocardial Infarction
1439	AVMDL10405121	AVMDL10405127	5/12/2007	GlaxoSmithKline Updates Advice For Physicians Prescribing Avandie
1440	AVMDL10504551	AVMDL10504551	5/18/2007	Email from Huckle to Siaoui re: Enquiry
1441	AVMDL07718873	AVMDL07718873	5/18/2007	GlaxoSmithKline Responds to NEJM Article on Avandia - press release
1442	Public Document	Public Document	5/21/2007	Email and attachment from McMurray to Jones Re: Urgent. RECORD MS REQUIRING REVIEW WITHIN 24 Hours
1443	AVMDL09131091	AVMDL09131119	5/28/2007	Email from Kolatkar to Phillips, Cobitz Re: Case Review
1444	AVMDL08263095	AVMDL08263096	6/15/2007	Email Heise to Phillips, Saltzman, Laws
1445	AVMDL03656483	AVMDL03656485	6/15/2007	Email from Dillery to Siaoui Re: Fluid overload and cardiac ischemie
1446	AVMDL07720526	AVMDL07720526	6/16/2007	Email from Zariffa to Heise et al
1447	AVMDL03656486	AVMDL03656490	6/17/2007	Email from Patterson to Zariffa et al
1448	AVMDL10749506	AVMDL10749509	6/27/2007	Email Dillery to Siaoui re: Avandia Advisory Committee Briefing Document
1449	AVMDL11504297	AVMDL11504297	6/28/2007	E-mail String Cobitz, Lyles Re: Avandate Slides for Cigna Meeting
1450	AVMDL06246213	AVMDL06246214	8/23/2003	E-mail Cobitz to Mencz Re: insulin plus Avandia efficacy slide:
1451	AVMDL06230857	AVMDL06230858	8/16/2001	
1452	AVMDL06033727	AVMDL06033729	12/13/2005	E-mail Waterhouse to McMorn, Cobitz Re: McMorn's comments on study 143
1453	AVMDL08065100	AVMDL08065101	2/8/2005	E-mail String Zambanini, Blacarek, Cobitz, Hook et al Re: CV modeling outcomes scenarios
1454	AVMDL01244136	AVMDL01244142	2/4/2005	Draft: CV Modeling Scenario Planning Authors, Blacarek, Heise, Cobitz, Zambanini
1455	AVMDL08115953	AVMDL08115954	Jan-06	E-mail String Cobitz, Rall, Lammers, Phillips Re: Avandia Franchise Strategy Meeting
1456	AVMDL10671304	AVMDL10671312	9/1/2006	Global Communications Stand-By Statement
1457	AVMDL13204240	AVMDL13204242	6/10/2008	E-mail String Heise, Cobitz, Miller, Kreider, Re: Cardivascular Modeling

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1458	AVMDL09131091	AVMDL09131092	5/28/2007	E-mail String McMurray, Cobitz, Jones, Re: NEJM Article Submission
1459	AVMDL010131705	AVMDL010131706	6/20/2007	E-mail String DeCastro to Mansi Re: Key Message Document
1460	AVMDL03397076	AVMDL03397078	11/8/2005	E-mail string Macartney, Lammers, Sotirhos Re: AHA press release PROactive
1461	AVMDL03458280	AVMDL03458345	2003	ASAP Selling Model
1462	AVMDL0692973	AVMDL0692978	8/28/2002	E-mail string Anaokar, Chow, Schwarz
1463	AVMDL00203570	AVMDL00203636	4/13/1999	Email and attachment from Freed to Kahn Re: Misbin Review and Post Marketing Studies
1464	AVMDL00203606	AVMDL00203612	4/9/1999	Mock Advisory Committee Agenda
1465	AVMDL10632623	AVMDL10632626	7/25/2007	Email from Macartney to Krall Re: slides for Ad Com Presentation
1466	AVMDL04334813	AVMDL04334851	5/12/2002	Email and attachment re: Regulatory question from the Swedish MPA in regard to the DREAM clinical trial application.
1467	AVMDL10674189	AVMDL10674224	6/22/2007	Email and attachment re: Follow Up meeting on Preparations for the Avandia Ad Com Meeting (30Jul07)
1468	AVMDL07668300	AVMDL07668335	4/18/2000	Email and attachment re: BMS CV138-055 STUDY OVERVIEW
1469	AVMDL04253003	AVMDL04253118	5/11/2000	Email and attachment re: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ROSIGLITAZONE ADDED ON TO A BACKGROUND OF METFORMIN/GLYBURIDE TABLETS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE INADEQUATE GLYCEMIC CONTROL ON METFORMIN/GLYBURIDE THERAPY
1470	AVMDL10406734	AVMDL10406746	6/5/2000	Email and attachment string re: Mesrobian, Ashe, Wagner Re: Clinical Supply Agreement (Bristol Myers Squibb)
1471	AVMDL10800453	AVMDL10800484	6/20/2000	Email and attachment re: Draft Agreement to Supply Meds
1472	AVMDL07097529	AVMDL07097927	2/24/2003	Email and attachment string re: Rood, Shapowal, Cobitz Re: Glucovance + Avandia data
1473	AVMDL10495594	AVMDL10498616	4/20/2004	Email and attachment string re: Freed, Rebar Re: Clinical supply agreement
1474	AVMDL09369574	AVMDL09369576	8/11/2004	Email to Fuell, from Biswas re: Clinical Trials Register Summaries
1475	AVMDL10942859	AVMDL10942864	7/30/2004	Email to Berry from Fuell, re: Avandia CTR Summaries 127, 133, 134 and 234 - Approval Forms
1476	AVMDLN00214277	AVMDLN00214381	10/12/2000	Report 127 Phase IIIB: A 26-week Randomized, Double-blind Study to Compare the Efficacy, Safety and Tolerability of Rosiglitazone (BRL 49653C) 8mg/day (4ngbd) Versus Placebo in Combination with Glyburide in Patients with Type 2 Diabetes Mellitus Who Are Inadequately Controlled on Maximum Dose Glyburide
1477				Study No: 49653/127 - pages 1-4
1478	AVMDL10842743	AVMDL10842748	6/26/2001	New Sales Aid Audiocape Script- Copy Approved Script - Recording 6/26/2001

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1479	AVMDL10809888	AVMDL10809888		Goldstein, B.J., Fuell, D., et al, article titled "Rosiglitazone in Combination With Glibenclamide: Effect on PAI-1 Antigen, PAI-1 Activity, and tPA in Patients With Type 2 Diabetes Mellitus"
1480	AVMDL10545348	AVMDL10545356	11/9/2004	Email to GCS-Avandia-International, et al., from Harrison dated 11/9/2004, re: Announcement of Actos vs. Avandia head to head study at American Heart Association Policy Issues - A publication of GlaxoSmithKline Government Affairs, Europe & Corporate, Global Public
1481			March, 2009	Policy Issues - pages 1-5
1482	AVMDL10942729	AVMDL10942736	7/27/2004	Email with Study No. 49653/234 attached, sent to Tuttle, et al., dated 7/27/2004, re: Fifth batch of Avandia summaries
1483			3/31/2003	Martin, L.R., Vettee-Dadey, M.B. et al., Report 133 Phase IIIB, Final Clinical Report - BRL 49653C - An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of Rosiglitazone (BRL 49653C) When Administered Twice Daily in Combination with Glyburide to Patients with Type 2 Diabetes Mellitus Who Are Inadequately Controlled on Maximum Dose Glyburide, pages 1-83
1484			11/2/2004	Study No. 49653/133 pages 1-3
1485	AVMDL04105324	AVMDL04105324	8/3/2001	Email to Harrison, et al., from Freed, dated 8/3/2001 re: PST meeting 7th August
1486	AVMDL06116244	AVMDL06116248	6/6/2002	PST Teleconference - Action - Review of minutes and actions/updates
1487	AVMDL00295235	AVMDL00295238	4/27/2001	memo To Bernadette A Mansi/SPD/PHRD/SB_PLC, from Martin I Freed/DEV/PHRD/SB_PLC, dated 4/27/2001, re: STP-GSK Proposed Publication Policy
1488	AVMDL10810288	AVMDL10810293	6/12/2001	Email to Arvind Agrawal, et al., from Harrison, dated 6/12/2001 re: Avandia key messages
1489	AVMDL11622229	AVMDL11622229		Lipids/Metabolism - Get to Goal With Durable Control, Avandia has an impressive long-term effect on HDL
1490				Avandia CV Event Modelling Communication Strategy Scenarios - Draft, pages 1-14
1491	AVMDL10949023	AVMDL10949053	3/1/2006	Email to Stuart Magargee, et al., from Heise, dated 3/1/2006, re: Privileged and Confidential - CV modelling
1492	AVMDL11325317	AVMDL11325323	5/23/2006	Draft minutes of Avandia Project Team Meeting Held, Tuesday, 23 May 2006

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1493	AVMDL12742110	AVMDL12742111	11/19/2008	Email to Noriko N Nishi et al., from Ryutaro Ishii, dated 11/19/2008, re: Avandia Japan update
1494	AVMDL10261538	AVMDL10261538	7/31/2007	Email to Mark Heise from Masato Suzuki, dated 7/31/2007, re: KCB result H2H Study against Actos
1495	AVMDL10608314	AVMDL10608315	9/13/2004	Patients with Myocardial Ischemia in Avandia Double-Blind Studies Study No.: 49653/113, pages 1-5
1496				
1497			7/1/2007	2007 FDA AdCom Minutes Vote - Summary minutes of the joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held on July 30, 2007. Pages 1-7
1498			7/1/2010	2010 AdCom Vote - Summary minutes of the joint meeting of the Endocrinology and metabolic drugs advisory committee and the drug safety and risk management advisory committee location: Hilton Washington DC North/Gaithersburg July 13-14, 2010. Pages 1-14.
1499	AVMDL09755272	AVMDL09755344	4/15/2004	Briefing Document FOR Lp-PLA2 Inhibitor Clinical Development Program
1500			2007	Document from diaDexus entitled The PLAC Test
1501	AVMDL06752574	AVMDL06752591	4/15/2004	Slides prepared for the FDA meeting of 4/15/2004, Re: Lp-PLA2 Inhibitor Clinical Development
1502	AVMDL00223650	AVMDL00223651	1/16/2004	Draft of a "Briefing Document"
1503			9/2/2008	GSK Press Release entitled "GSK's darapladib modifies coronary plaque composition and lowers Lp-PLA2 activity, a biomarker predictive of heart attack risk"
1504	AVMDL04677051	AVMDL04677089	5/1/2002	CV Markers in Study 143
1505	AVMDL04273432	AVMDL04273434	1/21/2003	Freed response re: inquiry by Lawson McCartney of whether GSK assessed Avandia's affect on Lp-PLA2
1506	AVMDL0033862	AVMDL00033871	3/5/2002	Haffner response letter
1507	AVMDL00443050	AVMDL00443051	10/11/2002	GSK Publication Strategy Article circulated by Manager David Harrisor
1508	AVMDL00103208	AVMDL00103209	8/6/2002	Email Shapowal to Letendre Re: Haffner Publications circulation
1509	AVMDL00457119	AVMDL00457173	5/12/2003	Glyburide Monotherapy/Lp-PLA2 Levels Study
1510	AVMDL00612044	AVMDL00612045	1/7/2004	GLY Monotherapy Study: Lp-PLA2 one of the biomarkers studied
1511	AVMDL00612046	AVMDL00612048	1/7/2004	GLY Monotherapy study: Overall, changes in CV markers were positive in the Avandia plus glyburide group in that there were no deleterious changes in the CV markers
1512	AVMDL00039621	AVMDL00039623	11/21/2001	Lawson Macartney requests a review of LpPLA2 activity from 100 study 143 samples.
1513	AVMDL00269670	AVMDL00269674	2001	"Avandia Kicks off Cardio-Alliance"
1514	AVMDL0508699	AVMDL0508699	8/15/2001	Email from K. Connors Re: Funding for your region for Avandia Cardiology Dinner Programs!
1515	AVMDL05090848	AVMDL05090848	10/2/2001	GSK Memo from Avandia Product Management Re: AHA Convention
1516	AVMDL05082666	AVMDL05082671	11/21/2001	GSK Presentation at AHA Convention titled "The Clock is Ticking..."

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1517	AVMDL09328275	AVMDL09328542	12/5/2001	Avandia 2002 Tactical Plan Presentation
1518	AVMDL01444593	AVMDL01444598	10/5/1999	HPB's Request for the Addition of Cardiac Disease to the Avandia Product Monograph (Canada)
1519	AVMDL00511507	AVMDL00511511	5/23/2007	Dear Doctor Letter from Cobitz with GSK press release attached
1520	AVMDL11273090	AVMDL11273098	12/21/1999	Tabona Complaint
1521	AVMDL11273072	AVMDL11273074	11/26/1999	Letter from Claypool to Tabona
1522	Public Document	Public Document	2010	GSK Annual Report 2010
1523	AVMDL0742139	AVMDL07742156	3/00/2007	Sales Aid
				Representative Messages and Resource Reminder - Rep Oral Responses to Unsolicited Questions from Physicians Regarding Nissen.
1524	AVMDL07547734	AVMDL07547734	5/22/2007	Email sending Avandia materials.
1525	AVMDL01947822	AVMDL01947823	5/22/2007	Dear HCP Letter re Nissen.
1526	AVMDL01947824	AVMDL01947828	5/22/2007	Memo to sales force re Responsive Healthcare Provider Letter enclosing the Dear HCP letter.
1527	AVMDL01947829	AVMDL01947835	5/22/2007	Avandia Package Insert AV-119 (March 2007)
1528	AVMDL01947830	AVMDL01947829	5/22/2007	Representative Messages and Resource Reminder - Rep Oral Responses to Unsolicited Questions from Physicians Regarding Nissen.
1529	AVMDL01947836	AVMDL01947836	5/22/2007	Q&A to Current Events about Avandia
1530	AVMDL01947837	AVMDL01947838	5/22/2007	Avandia patient information (March 2007).
1531	AVMDL01947839	AVMDL01947839	5/22/2007	Dear HCP re Nissen signed by Cobitz.
1532	AVMDL0742487	AVMDL07742494	5/30/2007	Avandia in the News: Q&A
1533	AVMDL0747468	AVMDL07747476	6/00/2007	Dear Avandia patient letter.
1534	AVMDL0747342	AVMDL07747343	6/1/2007	Dear HCP Letter re Nissen.
1535	AVMDL0742601	AVMDL07742608	6/6/2007	GSK Website Content.
1536	AVMDL0747346	AVMDL07747433	6/8/2007	"Update on Avandia" slide deck.
1537	AVMDL0742495	AVMDL07742559	7/00/2007	Dear HCP re 2007 AdCom results.
1538	AVMDL00500054	AVMDL00500059	7/31/2007	Diabetes Franchise - Sales Training Update for Avandia family.
1539	AVMDL07548219	AVMDL07548230	8/00/2007	Email from Coccoffito re Feedback on draft sales aid.
1540	AVMDL10681088	AVMDL10681089	8/2/2007	Myocardial Ischemic Safety sales aid.
1541	AVMDL10676334	AVMDL10676338	8/2/2007	Email from Cobitz and Schell.
1542	AVMDL10666084	AVMDL10666086	8/3/2007	2007 Town Hall Meeting slide deck.
1543	AVMDL03335716	AVMDL03335738	8/3/2007	Memo to sales management re: recent publications
1544	AVMDL07548208	AVMDL07548209	8/7/2007	2007 Town Hall Meeting slide deck.
1545	AVMDL10476343	AVMDL10476383	8/13/2007	Update: Avandia CHF Label Change - August 2007 slide deck.
1546	AVMDL07548237	AVMDL07548250	8/14/2007	Representative Messages and Resource Reminder - CHF Label Changes.
1547	AVMDL07548251	AVMDL07548256	8/14/2007	Myocardial Ischemia Deck.
1548	AVMDL0742662	AVMDL07742673	8/14/2007	Cover email re: draft Reactive Slide Deck.
1549	AVMDL10728593	AVMDL10728593	8/20/2007	Draft Reactive Slide Deck.
1550	AVMDL10728594	AVMDL10728601	8/20/2007	

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1551	AVMDL10159600	AVMDL10159603	8/21/2007	Cover email re: comments on draft Reactive Slide Deck
1552	AVMDL10159604	AVMDL10159611	8/21/2007	Attachment draft Reactive Slide Deck.
1553	AVMDL10677566	AVMDL10677566	8/23/2007	Email re "Final Non-Affirmative Pio Slide Deck."
1554	AVMDL10677567	AVMDL10677576	8/23/2007	Attachment re "Final Non-Affirmative Pio Slide Deck."
1555	AVMDL10677578	AVMDL10677579	8/24/2007 (1:38pm)	Email re not sending out "Final Non-Affirmative Pio Slide Deck."
1556	AVMDL10666412	AVMDL10666412	8/24/2007	Email from Phillips to Cobitz re "Final Non-Affirmative Pio Slide Deck".
1557	AVMDL10666413	AVMDL10666422	8/24/2007	Attachment to Email from Phillips to Cobitz.
1558	AVMDL10699146	AVMDL10699148	8/24/2007	Email from Dube re: comments on "Final Non-Affirmative Pio Slide Deck."
1559	AVMDL10677687	AVMDL10677687	8/29/2007	Email re: posting of final Reactive Slide Deck.
1560	AVMDL10677683	AVMDL10677685	8/29/2007	Email from Coccochetto to Pugh.
1561	AVMDL07545877	AVMDL07550337	9/00/2007	2007 Avandia Field Development Trainer's Resource Guide.
1562	AVMDL07742611	AVMDL07742636	9/00/2007	Update on Avandia 2007 Fall Teleconference Series.
1563	AVMDL07743017	AVMDL07743057	9/00/2007	Update on Avandia 2007 Fall Webcast.
1564	AVMDL10677832	AVMDL10677833	9/4/2007	Email from Pugh to Coccochetto.
1565	AVMDL10677834	AVMDL10677845	9/4/2007	Attachment of Reactive Slide Deck.
1566	AVMDL07742993	AVMDL07742996	9/11/2007	Dear HCP Letter - "Response About Recent Publications on TZDs" for reactive use only.
1567	AVMDL08281055	AVMDL08281055	9/19/2007	Email from Pugh attaching FINAL reactive slide deck.
1568	AVMDL08281056	AVMDL08281090	9/19/2007	Attachment: FINAL reactive slide deck.
1569	AVMDL10668494	AVMDL10668495	9/20/2007	Email re updates to FINAL reactive slide deck from Paul Stober
1570	AVMDL10668496	AVMDL10668530	9/20/2007	Attachment re updates to FINAL reactive slide deck from Paul Stober
1571	AVMDL10668630	AVMDL10668632	9/21/2007	Email attaching updated reactive slide deck noting changes made
1572	AVMDL10668633	AVMDL10668666	9/21/2007	Attachment of updated reactive slide deck
1573	AVMDL10668667	AVMDL10668670	9/21/2007	Email from Stober re edit to slide deck.
1574	AVMDL03380055	AVMDL03380055	9/21/2007	Email to Collier and Lammers attaching "near-final" rosi and pio reactive slide deck.
1575	AVMDL03380056	AVMDL03380089	9/21/2007	Attachment of "near-final" rosi and pio reactive slide deck.
1576	AVMDL03380090	AVMDL03380091	9/21/2007	Email re: PCDM Training Materials for Diabetes Franchise.
1577	AVMDL03380092	AVMDL03380093	9/21/2007	Attachment 1: PCDM Training Materials for Diabetes Franchise
1578	AVMDL03380094	AVMDL03380110	9/21/2007	Attachment 2: Participant Guide
1579	AVMDL03380111	AVMDL03380114	9/21/2007	Attachment 3: Supplemental Workshop - ADOPT and EMPIRE Participant Guide
1580	AVMDL03380115	AVMDL03380121	9/21/2007	Attachment 4: Supplemental Workshop - ADOPT and EMPIRE Leaders Guide.
1581	AVMDL03380122	AVMDL03380139	9/21/2007	Attachment 4: Supplemental Workshop Leaders Guide.
1582	AVMDL10679577	AVMDL10679580	9/22/2007	Email from Coccochetto re FINAL slide deck.
1583	AVMDL10679581	AVMDL10679614	9/22/2007	Attachment re FINAL slide deck.
1584	AVMDL00500669	AVMDL00500669	9/24/2007	Email from Collier re providing sales reps with reactive slide deck
1585	AVMDL00500670	AVMDL00500671	9/24/2007	Email from Lammers.
1586	AVMDL10708087	AVMDL10708090	9/26/2007	Email from Pugh seeking comments on reactive slide deck.

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1587	AVMDL10708091	AVMDL10708142	9/26/2007	Attachment of slide deck.
1588	AVMDL07410166	AVMDL07410166	9/28/2007	Email from Puigh circulating "FINAL reactive slide deck."
1589	AVMDL07410167	AVMDL07410201	9/28/2007	Attachment of "FINAL reactive slide deck."
1590	AVMDL07548631	AVMDL07548635	10/5/2007	Department of VA- CV safety of Avandia.
1591	AVMDL07750708	AVMDL07750712	11/0/2007	Avandia FAQ re November black box warning change.
1592	AVMDL07743223	AVMDL07743238	11/0/2007	November 2007 Sales Aid.
1593	AVMDL07743253	AVMDL07743258	11/0/2007	November 2007 Sales Aid.
1594	AVMDL10179524	AVMDL10179526	11/0/2007	Dear HCP Letter from Cobitz.
1595	AVMDL07743132	AVMDL07743168	11/0/2007	"Gain Control - Sustain Control" slide deck.
1596	AVMDL07548895	AVMDL07548905	11/0/2007	November 2007 annotated label change information.
1597	AVMDL13188537	AVMDL13188547	11/0/2007	November 2007 annotated label change information.
1598	AVMDL07743206	AVMDL07743222	11/0/2007	"November 2007 Label Updates for Avandia" slide deck.
1599	AVMDL11626845	AVMDL11626854	11/0/2007	November 2007 reactive statements for reps to use when discussing Avandia and label changes.
1600	AVMDL13188728	AVMDL13188748	11/0/2007	November 2007 Sales Aid.
1601	AVMDL07747582	AVMDL07747583	11/13/2007	Krall video.
1602	AVMDL07548913	AVMDL07548914	11/14/2007	FDA Press Release re Avandia label Change.
1603	AVMDL07750762	AVMDL07750769	11/14/2007	GSK website content re Avandia label change.
1604	AVMDL10179527	AVMDL10179529	11/14/2007	GSK Press Release re Avandia label change.
1605	AVMDL13188526	AVMDL13188532	11/14/2007	FAQ for Representatives re Label Change.
1606	AVMDL10179506	AVMDL10179520	11/15/2007	"Update: Labeling Change for Avandia" for internal training
1607	AVMDL13188572	AVMDL13188600	11/28/2007	"Diabetes Franchise DSM Update" slide deck for internal training
1608			12/12/2007	JAMA article "TZDs and Cardiovascular Outcomes in Older Patients with Diabetes," Lipscombe et al.
1609	AVMDL13188669	AVMDL13188670	12/12/2007	Talking points for sales reps to use in response to questions about JAMA article.
1610	AVMDL13188996	AVMDL13189002	1/00/2008	Incentive Compensation 101 - Q&A for Managers.
1611	AVMDL14086299	AVMDL14086310	9/00/2008	September 2008 Sales Aid.
1612	AVMDL13180121	AVMDL13180122	10/22/2008	Email circulating sales rep material re consensus algorithm.
1613	AVMDL13180123	AVMDL13180124	10/22/2008	ADA/EASD Consensus Algorithm
1614	AVMDL13180136	AVMDL13180146	10/22/2008	Rep Call Slides re algorithm
1615	AVMDL13180125	AVMDL13180135	10/22/2008	ADA/EASD Consensus Algorithm article in Diabetes Care.
1616	AVMDL13180147	AVMDL13180148	10/22/2008	Key communication points to respond to updated ADA/EASD Consensus statement.
1617	AVMDL13180149	AVMDL13180151	10/22/2008	FAQ for Reps to respond to questions re: consensus algorithm
1618	AVMDL11777154	AVMDL11777155	6/8/2009	Email to sales team attaching materials for Avandia franchise teleconference 6/8/2009.
1619	AVMDL11777156	AVMDL11777181	6/8/2009	Avandia Franchise Conference Call: ADA results.
1620	AVMDL11777182	AVMDL11777184	6/8/2009	RECORD "leave-behind"
1621	AVMDL11777185	AVMDL11777195	6/8/2009	RECORD reprint article in the Lancet.

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1622	AVMDL111777196	AVMDL111777197	6/8/2009	Bari-2D "leave-behind"
1623	AVMDL111777198	AVMDL111777208	6/8/2009	Annotated RECORD article.
1624	AVMDL111777209	AVMDL111777211	6/8/2009	RECORD backgrounder.
1625	AVMDL111777212	AVMDL111777217	6/8/2009	RECORD FAQs for sales reps.
1626	AVMDL111777218	AVMDL111777219	6/8/2009	Talking points for sales reps to use for RECORD.
1627	AVMDL111777220	AVMDL111777221	6/8/2009	Bari-2D FAQs for sales reps
1628	AVMDL111777222	AVMDL111777222	6/8/2009	Talking points for sales reps to use for Bari-2D.
1629	AVMDL111777223	AVMDL111777224	6/8/2009	Bari-2D Backgrounder
1630	AVMDL111777225	AVMDL111777228	6/8/2009	Lunchtime Webconference Series invite
1631	AVMDL111777229	AVMDL111777234	6/8/2009	Avandia prescribing info (Dec 2008).
1632	AVMDL05095983	AVMDL05095983	4/26/2002	The Diabetes Literacy Board- Creative Brief
1633	AVMDL05066205	AVMDL05066205	4/3/2002	Avandia CV Game Plan
1634	AVMDL04345663	AVMDL04345666	5/4/2002	Email from Freed to DiMatteo
1635	AVMDL04335597	AVMDL04335600	5/6/2002	Email from Ganz to Freed
1636	STI 0013158	STI 0013172	6/25/2003	Letter from Romaniewicz to Chung
1637	STI 0003416	STI 0003416	10/10/2001	Email from Kistner to Phillips
1638	STI 0010410	STI 0010416	11/30/2005	Memo from Snyder to Huang
1639	AVMDL06015360	AVMDL06015364	2/5/2002	Meeting report re PST Teleconference
1640	AVMDL01713902	AVMDL0173907	11/13/2000	Study 175 Headline Results Summary
1641	AVMDL05097671	AVMDL05097702	7/2/2002	Email from Mooney re Haffner revised
1642	AVMDL03728190-R	AVMDL03728211-R	12/1/2002	Avandia Publication Plan 2003
1643	AVMDL03388169	AVMDL03388182	3/1/2004	Rosi or Pio for T2DM, GSK/Casper
1644	AVMDL05078461	AVMDL05078484	8/1/2002	Avandia Publication Status Report
1645	AVMDL07983621	AVMDL07983646	9/1/2002	Avandia Publication Status Report
1646	AVMDL03710570	AVMDL03710596	12/1/2002	Avandia Publication Status Report
1647	AVMDL12282798	AVMDL12282804		Avandia Publication Status Report
1648	AVMDL00000607	AVMDL00000622	Nov/Dec 2002	Journal of Diabetes and its Complications reprint
1649	AVMDL05324261	AVMDL05324269	8/00/2006	Marketing Advisory Board Meeting Approval Form
1650	AVMDL0066832	AVMDL0066835	11/16/2000	Email Rapaport to Freed re Status of Avandia Publications
1651	AVMDL08202547	AVMDL08202548	10/25/2008	Email Miller to Cobitz re Avandia Publications process meeting
1652	AVMDL10110699	AVMDL10110712	4/00/2007	Clinical Trial Publications and Presentations Audit
1653	AVMDL11389467	AVMDL11389469	10/3/2005	Email from Eroniu to Koenig re WSL & Sci Com
1654	AVMDL0062984	AVMDL0062989	2/3/2001	Email from DiMatteo to Cobitz re Long Term Avandia Study
1655	AVMDL07901062	AVMDL07901101	5/5/2006	Changing the paradigm in patients with uncontrolled diabetes
1656	AVMDL0509577	AVMDL05099618	8/19/2002	Draft II, Insulin resistance, inflammation, and the prediabetic state
1657	AVMDL05105623	AVMDL05105681	5/23/2003	Draft I, Evaluating the CV effects of TZDs and their place in the management of T2DM
1658	AVMDL0000570	AVMDL0000571		List of CD ROMs, supplements, reprints
1659	AVMDL01473813	AVMDL01473815		AVANDIA media alert
1660	AVMDL05067406	AVMDL05067407	3/13/2003	Strategic Platform Planning Meeting

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1661	AVMDL11389503	AVMDL11389508	10/3/2005	Evoniuik email
1662	AVMDL0933457	AVMDL0933458		Avandia 2000 PR Activities
1663	AVMDL04995878	AVMDL04995832	5/6/2007	Email from Nevine Zariffa
1664	AVMDL11684923	AVMDL11684942		Draft, CV Effects of Rosi: A Retrospective
1665	AVMDL03971471	AVMDL03971474		
1666				Study No. 49653/114
1667				Study No. 49653/136
1668	AVMDL04105324	AVMDL04105324	08/03/2001	Email from M. Freed to D. Harrison, et al.
1669	AVMDL0007411	AVMDL0007416	05/27/1994	U.S. Regulatory Affairs File Note
1670	GSK101_000058988	GSK101_000058990	06/08/2007	Letter from M. Kreider to M. Parks (FDA)
1671	AVMDLN0072054	AVMDLN0072073	06/04/2001	GSK Submission of NDA 21-071
1672	FDA Document	FDA Document		Approval Package for NDA 21-071/S-004
1673	TRANSCRIPT	TRANSCRIPT	11/12/2009	Deposition Transcript of Alastair Benbow
1674	TRANSCRIPT	TRANSCRIPT	8/6/2010	Deposition Transcript of Alexander Cobitz
1675	TRANSCRIPT	TRANSCRIPT	3/11/2009	Deposition Transcript of Andrew Verzilli
1676	TRANSCRIPT	TRANSCRIPT	12/12/2009	Deposition Transcript of Anna McClafferty
1677	TRANSCRIPT	TRANSCRIPT	5/10/2011	Deposition Transcript of Anne Phillips Vol. 2
1678	TRANSCRIPT	TRANSCRIPT	3/28/2011	Deposition Transcript of Anne Phillips Vol. 1
1679	TRANSCRIPT	TRANSCRIPT	4/14/2009	Deposition Transcript of Bernadette Mans
1680	TRANSCRIPT	TRANSCRIPT	4/15/2009	Deposition Transcript of Bonnie Rossello
1681	TRANSCRIPT	TRANSCRIPT	11/7/2008	Deposition Transcript of Collin Dillery
1682	TRANSCRIPT	TRANSCRIPT	10/14/2009	Deposition Transcript of Colleen Bennett
1683	TRANSCRIPT	TRANSCRIPT	7/1/2011	Deposition Transcript of Daniel Regard
1684	TRANSCRIPT	TRANSCRIPT	5/16/2011	Deposition Transcript of David Brand
1685	TRANSCRIPT	TRANSCRIPT	11/17/2009	Deposition Transcript of David Cochetto- Vol I
1686	TRANSCRIPT	TRANSCRIPT	3/15/2011	Deposition Transcript of David Cochetto- Vol II
1687	TRANSCRIPT	TRANSCRIPT	9/25/2009	Deposition Transcript of Elizabeth Peck
1688	TRANSCRIPT	TRANSCRIPT	10/1/2009	Deposition Transcript of Emma Meagher
1689	TRANSCRIPT	TRANSCRIPT	10/1/2009	Deposition Transcript of Eric Duke, Vol. 1
1690	TRANSCRIPT	TRANSCRIPT	1/15/2010	Deposition Transcript of Eric Duke, Vol. 2
1691	TRANSCRIPT	TRANSCRIPT	1/4/2011	Deposition Transcript of Geraldine Clare Kahn Vol. 1
1692	TRANSCRIPT	TRANSCRIPT	8/16/2011	Deposition Transcript of Geraldine Clare Kahn Vol. 2
1693	TRANSCRIPT	TRANSCRIPT	3/1/2011	Deposition Transcript of Grace Johnson
1694	TRANSCRIPT	TRANSCRIPT	3/23/2011	Deposition Transcript of Gregory Burkhardt
1695	TRANSCRIPT	TRANSCRIPT	5/20/2011	Deposition Transcript of James Carr
1696	TRANSCRIPT	TRANSCRIPT	1/5/2011	Deposition Transcript of James Stone
1697	TRANSCRIPT	TRANSCRIPT	8/17/2011	Deposition Transcript of Jasna Knezevic
1698	TRANSCRIPT	TRANSCRIPT	5/3/2011	Deposition Transcript of Jean-Pierre Garnier
1699	TRANSCRIPT	TRANSCRIPT	5/17/2011	Deposition Transcript of Jeffery Freid
1700	TRANSCRIPT	TRANSCRIPT	4/29/2011	Deposition Transcript of Jeffery Freid Vol. 2

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1701	TRANSCRIPT	TRANSCRIPT	8/27/2010	Deposition Transcript of Jeffrey Borer
1702	TRANSCRIPT	TRANSCRIPT	3/13/2009	Deposition Transcript of Jeffrey Freic
1703	TRANSCRIPT	TRANSCRIPT	6/16/2009	Deposition Transcript of Joanna Balarek
1704	TRANSCRIPT	TRANSCRIPT	7/21/2009	Deposition Transcript of John Romankiewicz
1705	TRANSCRIPT	TRANSCRIPT	8/31/2010	Deposition Transcript of John Warren, III Vol. 1
1706	TRANSCRIPT	TRANSCRIPT	11/30/2009	Deposition Transcript of John Warren, III Vol. 2
1707	TRANSCRIPT	TRANSCRIPT	12/9/2009	Deposition Transcript of Joshua Septimus
1708	TRANSCRIPT	TRANSCRIPT	9/9/2009	Deposition Transcript of Judy Melinek
1709	TRANSCRIPT	TRANSCRIPT	6/4/2009	Deposition Transcript of Judy Stewart
1710	TRANSCRIPT	TRANSCRIPT	8/27/2009	Deposition Transcript of Kristin Connors-Ral
1711	TRANSCRIPT	TRANSCRIPT	6/3/2009	Deposition Transcript of Laraine Caponi- Vol 1
1712	TRANSCRIPT	TRANSCRIPT	10/1/2009	Deposition Transcript of Laraine Caponi- Vol 1
1713	TRANSCRIPT	TRANSCRIPT	6/24/2009	Deposition Transcript of Laraine Caponi, Vol. 1
1714	TRANSCRIPT	TRANSCRIPT	7/17/2009	Deposition Transcript of Lawson Macartney
1715	TRANSCRIPT	TRANSCRIPT	11/12/2009	Deposition Transcript of Margaret Kreidler
1716	TRANSCRIPT	TRANSCRIPT	11/7/2008	Deposition Transcript of Margaret Sowell
1717	TRANSCRIPT	TRANSCRIPT	7/16/2009	Deposition Transcript of Mark Heise
1718	TRANSCRIPT	TRANSCRIPT	10/6/2009	Deposition Transcript of Mark Heise- Part 2
1719	TRANSCRIPT	TRANSCRIPT	4/17/2010	Deposition Transcript of Martin Freed
1720	TRANSCRIPT	TRANSCRIPT	3/31/2010	Deposition Transcript of Martin Freed
1721	TRANSCRIPT	TRANSCRIPT	3/11/2009	Deposition Transcript of Mary Money
1722	TRANSCRIPT	TRANSCRIPT	6/5/2009	Deposition Transcript of Melissa Fishman
1723	TRANSCRIPT	TRANSCRIPT	11/17/2009	Deposition Transcript of Michael DiMatteo
1724	TRANSCRIPT	TRANSCRIPT	10/1/2009	Deposition Transcript of Monsif Mohamed Slaoui, Ph.D.
1725	TRANSCRIPT	TRANSCRIPT	11/12/2009	Deposition Transcript of Murray Stewart
1726	TRANSCRIPT	TRANSCRIPT	11/20/2009	Deposition Transcript of Murray Stewart Vol. 2
1727	TRANSCRIPT	TRANSCRIPT	11/19/2009	Deposition Transcript of Nicholas DePace
1728	TRANSCRIPT	TRANSCRIPT	10/14/2009	Deposition Transcript of Nigel P. Jones
1729	TRANSCRIPT	TRANSCRIPT	7/14/2009	Deposition Transcript of Patrick Boyle
1730	TRANSCRIPT	TRANSCRIPT	10/10/2008	Deposition Transcript of Peter Lammers
1731	TRANSCRIPT	TRANSCRIPT	5/26/2010	Deposition Transcript of Peter Letendre
1732	TRANSCRIPT	TRANSCRIPT	7/22/2009	Deposition Transcript of Phillip Home
1733	TRANSCRIPT	TRANSCRIPT	9/25/2009	Deposition Transcript of Rita Stevens ^s
1734	TRANSCRIPT	TRANSCRIPT	11/13/2008	Deposition Transcript of Robin E. Buckingham
1735	TRANSCRIPT	TRANSCRIPT	12/21/2009	Deposition Transcript of Ron Krall
1736	TRANSCRIPT	TRANSCRIPT	7/2/2010	Deposition Transcript of Rosemary Johann-Liang
1737	TRANSCRIPT	TRANSCRIPT	12/18/2009	Deposition Transcript of Sharon Shapowal
1738	TRANSCRIPT	TRANSCRIPT	5/6/2010	Deposition Transcript of Stobhian Robinson
1739	TRANSCRIPT	TRANSCRIPT	8/5/2010	Deposition Transcript of Stephen Hobriger
1740	TRANSCRIPT	TRANSCRIPT	5/4/2010	Deposition Transcript of Stephen Lippman

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1741	TRANSCRIPT	TRANSCRIPT	3/17/2010	Deposition Transcript of Steven Haffner
1742	TRANSCRIPT	TRANSCRIPT	4/22/2010	Deposition Transcript of Stuart Pocock
1743	TRANSCRIPT	TRANSCRIPT	4/23/2009	Deposition Transcript of Suzette Osei
1744	TRANSCRIPT	TRANSCRIPT	4/15/2010	Deposition Transcript of Suzette Osei Vol. 2
1745	TRANSCRIPT	TRANSCRIPT	4/16/2010	Deposition Transcript of Tom Elasy
1746	TRANSCRIPT	TRANSCRIPT	7/2/2010	Deposition Transcript of Trevor Gibbs
1747	TRANSCRIPT	TRANSCRIPT	4/16/2010	Deposition Transcript of William Collier Vol. 1
1748	TRANSCRIPT	TRANSCRIPT	4/15/2010	Deposition Transcript of William Collier Vol. 2
1749	TRANSCRIPT	TRANSCRIPT	6/17/2009	Deposition Transcript of William DuMouchelle
1750	TRANSCRIPT	TRANSCRIPT	9/21/2011	Deposition Transcript of Winslow Tucker
1751	TRANSCRIPT	TRANSCRIPT	3/16/2012	Deposition Transcript of Charles Whitcomb
1752	TRANSCRIPT	TRANSCRIPT		Deposition Transcript of Eliot Brinton
1753	TRANSCRIPT	TRANSCRIPT		Deposition Transcript of Suzanne Parisian
1754	TRANSCRIPT	TRANSCRIPT		Deposition Transcript of Laura Plunkett
1755	TRANSCRIPT	TRANSCRIPT		Deposition Transcript of Allan Sniderman
1756	TRANSCRIPT	TRANSCRIPT		Deposition Transcript of Brian Swirsky
1757	TRANSCRIPT	TRANSCRIPT		Deposition Transcript of Joshua Septimus
1758	TRANSCRIPT	TRANSCRIPT		Deposition Transcript of Nicholas Jewell
1759	EXPERT REPORT	EXPERT REPORT		Expert Report of Charles Whitcomb
1760	EXPERT REPORT	EXPERT REPORT		Expert Report of Eliot Brinton
1761	EXPERT REPORT	EXPERT REPORT		Supplemental Expert Report of Eliot Brinton
1762	EXPERT REPORT	EXPERT REPORT		Expert Report of Suzanne Parisian
1763	EXPERT REPORT	EXPERT REPORT		Supplemental Expert Report of Suzanne Parisian
1764	EXPERT REPORT	EXPERT REPORT		Expert Report of Laura Plunkett
1765	EXPERT REPORT	EXPERT REPORT		Expert Report of Allan Sniderman
1766	EXPERT REPORT	EXPERT REPORT		Supplemental Expert Report of Allan Sniderman
1767	EXPERT REPORT	EXPERT REPORT		Expert Report of Nicholas Jewell
1768	EXPERT REPORT	EXPERT REPORT		Supplemental Expert Report of Nicholas Jewell
1769	EXPERT REPORT	EXPERT REPORT		Expert Report of Brian Swirsky
1770	EXPERT REPORT	EXPERT REPORT		Supplemental Expert Report of Brian Swirsky
1771	EXPERT REPORT	EXPERT REPORT		Expert Report of Peter Rost
1772	EXPERT REPORT	EXPERT REPORT		Supplemental Expert Report of Peter Rost
1773	EXPERT REPORT	EXPERT REPORT		Expert Report of Joshua Septimus
1774	EXPERT REPORT	EXPERT REPORT		Supplemental Expert Report of Joshua Septimus
1775	TRANSCRIPT	TRANSCRIPT	5/27/2010	Deposition Transcript of John F. Keaney
1776	TRANSCRIPT	TRANSCRIPT	5/27/2010	Deposition Transcript of John F. Keaney Vol. 2
1777	TRANSCRIPT	TRANSCRIPT	7/7/2010	Deposition Transcript of Elizabeth Mayer-Davis
				All expert reports, curriculum vitae and bibliographies of expert witnesses designated in <i>LaVoice v. SmithKline Beecham Corporation d/b/a GlaxoSmithKline, et al.</i> Case No. YC059911
1778				

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1779	TRANSCRIPT	TRANSCRIPT		Deposition Transcript of Nancy LaVoice
1780	AVMDL00276819	AVMDL00276838		Curriculum Vitae of Martin I. Freed, MD
1781	FREED DEPOSITION EXHIBIT 431	FREED DEPOSITION EXHIBIT 431		Various Charts
1782	FREED DEPOSITION EXHIBIT 436	FREED DEPOSITION EXHIBIT 436		diaDexus PLAC Test for lp-PLA2
1783	BUCKINGHAM DEPOSITION EXHIBIT 1710	BUCKINGHAM DEPOSITION EXHIBIT 1710		Hand-drawn diagram
1784	BUCKINGHAM DEPOSITION EXHIBIT 1703	BUCKINGHAM DEPOSITION EXHIBIT 1703		Biography of Robin Buckingham
1785	Resume			Resume of Donna Fucillo, CCMEP
1786	CV of Grace Johnson	CV of Grace Johnson		CV of Grace E. Sun Johnson, PharmD
1787	Romaniewicz CV	Romaniewicz CV		CV of John A Romaniewicz
1788	FREED DEPOSITION EXHIBIT 403	FREED DEPOSITION EXHIBIT 403		Handwritten Notes : Drug Development Priorities
1789	FREED DEPOSITION EXHIBIT 406	FREED DEPOSITION EXHIBIT 406		"The Lies of SmithKlineBeecham and the Truth About Avandia"
1790				All Exhibits attached to any Deposition
1791				GSK Recordtrak Request HEALTHNET Records
1792				GSK Recordtrak Request LA SHERIFF'S PERSONAL RECORDS DEPARTMENT Records
1793				GSK Recordtrak Request HEALTHCARE PARTNERS (Leonard Lipman, MD)
1794				GSK Recordtrak Request WALGREEN'S PHARMACIES CORPORATE OFFICE Records
1795				GSK Recordtrak Request WORKERS COMPENSATION Records
1796				GSK Recordtrak Request TORRANCE MEMORIAL MEDICAL CENTER Records
1797				GSK Recordtrak Request TORRANCE MEMORIAL MEDICAL CENTER BILLING Records
1798				GSK Recordtrak Request TORRANCE MEMORIAL MEDICAL CENTER RADIOLOGY Records
1799				GSK Recordtrak Request TORRANCE MEMORIAL MEDICAL CENTER PATHOLOGY Records
1800				GSK Recordtrak Request TORRANCE MEMORIAL MEDICAL CENTER (CATH) Records
1801				GSK Recordtrak Request KHATTAB SHERIF Records
1802				GSK Recordtrak Request HEALTHCARE PARTNERS (DR. LIPMAN) Records
1803				GSK Recordtrak Request DIGESTIVE CARE CONSULTANTS (THAI HA) Records
1804				GSK Recordtrak Request HUNTINGTON MEMORIAL HOSPITAL (MED) Records
1805				GSK Recordtrak Request HUNTINGTON MEMORIAL HOSPITAL (BILLING) Records

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1806				GSK Recordstrak Request HEALTHCARE PARTNERS (SOUTHBAY) Records
1807				GSK Recordstrak Request HEALTHCARE PARTNERS (SOUTHBAY-MED) Records
1808				Medical Records- HEALTHCARE PARTNERS- Leonard Lipman, MD/Susan Abelson, RN
1809				Medical Records- Torrance Memorial Hospital
1810				Medical Records- Dr. James Hall
1811				Medical Records- MedCo
1812				Medical Records- Walgreens Pharmacy
1813				Call Notes for Leonard Lipman, M.D.
1814				Call Notes for Marci Mamita, M.D.
1815	Clinical Trial Registry	Clinical Trial Registry	Various	All studies listed on the GSK Clinical Trial Registry for Rosiglitazone and Pioglitazone at www.gsk-clinicalstudyregister.com
1816	FDA website	FDA website	7/30/2007	Slideshow from 7/30/07 EMDAC meeting Murray W. Stewart
1817	FDA website	FDA website	7/30/2007	Slideshow from 7/30/07 EMDAC meeting J. Rick Turner
1818	FDA website	FDA website	7/30/2007	Slideshow from 7/30/07 EMDAC meeting Samuel Nussbaum
1819	FDA website	FDA website	7/30/2007	Slideshow from 7/30/07 EMDAC meeting Karen M. Mahoney
1820	FDA website	FDA website	7/30/2007	Slideshow from 7/30/07 EMDAC meeting David Egilman
1821	FDA website	FDA website	7/30/2007	Slideshow from 7/30/07 EMDAC meeting Sanjay Kaul
1822	FDA website	FDA website	7/30/2007	Slideshow from 7/30/07 EMDAC meeting Richard E. Ralston
1823	FDA website	FDA website	7/30/2007	Slideshow from 7/30/07 EMDAC meeting Ronald Krall (2)
1824	FDA website	FDA website	7/30/2007	Slideshow from 7/30/07 EMDAC meeting Ronald Krall
1825	FDA website	FDA website	7/30/2007	Slideshow from 7/30/07 EMDAC meeting Kate Galperin
1826	FDA website	FDA website	7/30/2007	Slideshow from 7/30/07 EMDAC meeting Richard Hellman
1827	FDA website	FDA website	7/30/2007	Slideshow from 7/30/07 EMDAC meeting Robert E. Ratner
1828	FDA website	FDA website	7/30/2007	Slideshow from 7/30/07 EMDAC meeting Sidney Wolfe
1829	FDA website	FDA website	7/30/2007	Slideshow from 7/30/07 EMDAC meeting Michael R. Peterson
1830	FDA website	FDA website	7/30/2007	Slideshow from 7/30/07 EMDAC meeting David J. Gordon
1831	2007 FDA Material	2007 FDA Material	10/7/2008	Letter from D. Graham to M. Parks, DMEP
1832	2007 FDA Material	2007 FDA Material	7/30/2007	"Assessment of the Cardiovascular Risks and Health Benefits of Rosiglitazone", slide set by, Dr. D. Graham, presented at the July, 2007, EMDAC meeting
1833	2010 FDA Material	2010 FDA Material	7/13/2010	Leibenthal, S., M.D., FDA Inspections of RECORD Trial, Slide Presentation, Division of Scientific Investigations, FDA Advisory Committee Meeting, July 13, 2010.
1834	2010 FDA Material	2010 FDA Material	7/13/2010	Laws, Ian, Glaxo SmithKline, Avandia Slide Presentation, Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety Risk Management Advisory Committee, July 13-14, 2010.

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1835	2010 FDA Material	2010 FDA Material	7/13/2010	Callaghan, Fiona, MA M.S PhD, Rosiglitazone Cardiovascular Safety Meta-Analysis, Slide Presentation, Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety Risk Management Advisory Committee, July 13-14, 2010.
1836	2010 FDA Material	2010 FDA Material	7/13/2010	Gerstein, TIDE: TZD Intervention with vitamin D Evaluation, Slide Presentation.
1837	2010 FDA Material	2010 FDA Material	7/13/2010	Nissen, Steven, M.D., Rosiglitazone: A Critical Overview, Slide Presentation, Dept. of Cardiovascular
1838	2010 FDA Material	2010 FDA Material	7/13/2010	Mahoney, K., MD, FACE, RECORD: Topics Related to Interpretability, Slide Presentation, Division of Metabolism and Endocrinology Products.
1839	2010 FDA Material	2010 FDA Material	7/13/2010	Marciniak, T. M.D., Cardiovascular Events in the RECORD Trial, Slide Presentation, FDA, Division of Cardiovascular and Renal Products.
1840	2010 FDA Material	2010 FDA Material	7/13/2010	Parks, Mary, M.D., Advisory Committee Meeting Avandia®, Slide Presentation, FDA, Division of Metabolism and Endocrinology Products, July 13-13, 2010.
1841	2010 FDA Material	2010 FDA Material	7/13/2010	FDA Briefing Document: Advisory Committee Meeting for NDA 21071 Avandia (rosiglitazone maleate) tablet
1842	2010 FDA Material	2010 FDA Material	7/13/2010	FDA, Center for Drug Evaluation and Research, Draft Agenda, Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety Risk Management Advisory Committee, July 13-14, 2010.
1843	2010 FDA Material	2010 FDA Material	7/13/2010	Graham, David J., Gelperin, Kate, TIDE and benefit-risk considerations, Slide Presentation, Office of Surveillance and Epidemiology, July 13, 2010.
1844	2010 FDA Material	2010 FDA Material	7/13/2010	FDA, Pre-Meeting Posting of Slides for the July 13-14, 2010 Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee, http://fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials , accessed July 09, 2010.
1845	2010 FDA Material	2010 FDA Material	7/13/2010	Moritz, Thomas, M.S., Impact of the use of Rosiglitazone in VADT, Slide Presentation, VA Cooperative Studies Program Coordinating Center, Edward Hines Jr. VA Hospital, Hines, IL.

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1846	2010 FDA Material	2010 FDA Material	7/13/2010	McMurray, J., Komajda, M., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Pocock, S., Curtis, P., Jones, N., and Home, P., Effect of rosiglitazone on coronary events in the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes (RECORD) study, Slide Presentation.
1847	2010 FDA Material	2010 FDA Material	7/14/2010	GlaxoSmithKline, Statement in response to FDA Advisory Committees' vote on safety of Avandia® (rosiglitazone), http://www.GlaxoSmithKline.com/media/pressreleases/2010/14_2010 .
1848	2010 FDA Material	2010 FDA Material	7/13/2010	FDA, Cardiovascular Safety of Rosiglitazone, Advisory Committee Briefing Document, Briefing Document, July 13-14, 2010.
1849	2010 FDA Material	2010 FDA Material	7/13/2010	Graham, David J., Quelliet-Hellstrom, Rita, MacCurdy, Thomas E., Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated with Rosiglitazone or Pioglitazone, JAMA, June 28, 2010.
1850	2010 FDA Material	2010 FDA Material	7/13/2010	FDA, Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety Risk Management Advisory Committee, Questions to the Committee, July 13-14, 2010.
1851	2010 FDA Material	2010 FDA Material	7/13/2010	McEvoy, B, MS, DrPH, Pioglitazone and Rosiglitazone Cardiovascular Safety Meta-Analyses, Slide Presentation, FDA, Division of Biometrics VI, Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety Risk Management Advisory Committee, July 13-14, 2010.
1852	2010 FDA Material	2010 FDA Material	7/13/2010	Brooks, Maria Mori, PhD, Rosiglitazone Use and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial, Slide Presentation.
1853	2010 FDA Material	2010 FDA Material	7/13/2010	Hoberman, D., Ph.D., Statistical issue in the rosiglitazone RECORD trial, Slide Presentation, FDA, Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety Risk Management Advisory Committee, July 13-14, 2010.
1854	2010 FDA Material	2010 FDA Material	7/13/2010	Unger, Ellis, M. D., FDA Cardiologist's Perspective on RECORD, Slide Presentation, FDA, Office of Drug Evaluation-1, Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety Risk Management Advisory Committee, July 13-14, 2010.

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1855	2010 FDA Material	2010 FDA Material	7/13/2010	Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety Risk Management Advisory Committee, July 13-14, 2010, Meeting Roster.
1856	2010 FDA Material	2010 FDA Material	7/13/2010	Gelperin, Kate, Systematic review of epidemiologic studies of cardiovascular risk in patients treated with rosiglitazone or pioglitazone, Slide Presentation, Office of Surveillance and Epidemiology, CDER, FDA.
1857	2010 FDA Material	2010 FDA Material	7/13/2010	FDA Briefing Information: Avandia (Rosiglitazone Maleate) Tablets, for the July 13-14, 2010 Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety Risk Management Advisory Committee, June 09, 2010, http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials .
1858	2010 FDA Material	2010 FDA Material	7/13/2010	Follman, Dean, Synthesizing information from Different Study Designs, Slide Presentation, National Institutes of Health.
1859	2010 FDA Material	2010 FDA Material	7/13/2010	McCoy, Christopher, M.D., Restoring Trust and Integrity in Medicine: Addressing Rosiglitazone, National Physicians Alliance, July 14, 2010.
1860	Press Release	Press Release	7/9/2010	Press Release: GlaxoSmithKline EU regulatory update on Avandia (rosiglitazone)
1861	Press Release	Press Release	2/20/2010	Press Release: GlaxoSmithKline rejects conclusions reported in The New York Times story on Avandia
1862	Press Release	Press Release	5/21/2007	Press Release: GlaxoSmithKline response to NEJM article
1863	Press Release	Press Release	2/20/2010	Press Release: GlaxoSmithKline rejects conclusions of Senate Committee on Finance Staff Report on Avandia
1864	Press Release	Press Release	6/28/2010	Press Release: GlaxoSmithKline statement in response to JAMA publications on rosiglitazone
1865	Press Release	Press Release	6/5/2007	Press Release: GlaxoSmithKline response to New England Journal of Medicine editorials thiazolidinediones to treatment guidelines for the management of type 2 diabetes mellitus by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA)
1866	Press Release	Press Release	12/4/2007	
1867	Press Release	Press Release	7/9/2010	Press Release: Data support Avandia (rosiglitazone maleate) cardiovascular safety profile
1868	Press Release	Press Release	6/24/2007	Press Release: Data shows Avandia patients incur lower medical costs and use fewer healthcare resources
1869	Press Release	Press Release	7/30/2007	Press Release: FDA advisory Panel votes 22 to 1 for Avandia to remain available to patients in the US

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1870	Press Release	Press Release	9/6/2010	Press Release: GlaxoSmithKline responds to British Medical Journal article regarding Avandia (rosiglitazone)
1871	Press Release	Press Release	9/6/2010	Press Release: GlaxoSmithKline pre-broadcast statement: BBC Panorama, 6 September 2010"
1872	Press Release	Press Release	6/5/2007	Press Release: Data from GlaxoSmithKline's RECORD study published in NEJM
1873	Press Release	Press Release	2/6/2008	Press Release: GlaxoSmithKline responds to findings in ACCORD study,
1874	Press Release	Press Release	9/11/2007	Press Release: GlaxoSmithKline responds to JAMA articles
1875	Press Release	Press Release	5/30/2007	Press Release: Data affirms Avandia cardiovascular safety profile
1876	Press Release	Press Release	7/21/2010	Press Release: GlaxoSmithKline statement in response to FDA announcement on TIDE trial
1877	Press Release	Press Release	4/8/2008	Press Release: GlaxoSmithKline confirms receipt of FDA letter on regulatory reporting.
1878	Press Release	Press Release	7/27/2007	Press Release: GlaxoSmithKline statement in diabetes care study thiazolidinediones and heart failure: a teleo-analysis
1879	Press Release	Press Release	8/14/2007	Press Release: GlaxoSmithKline updates prescribing information for Avandia in the US
1880	Press Release	Press Release	9/23/2010	Press Release: European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim
1881	Press Release	Press Release	12/11/2007	Press Release: GlaxoSmithKline responds to JAMA article on the ICES thiazolidinediones and cardiovascular outcomes in older patients with diabetes
1882	Press Release	Press Release	6/5/2009	Press Release: Large, long-term study, RECORD, shows Avandia has no increased overall cardiovascular risk compared to other commonly used diabetes medicines."
1883	Press Release	Press Release	5/21/2007	Press Release: GlaxoSmithKline response to US Senate Committee on Finance Avandia following EMA and FDA reviews
1884	Press Release	Press Release	9/23/2010	Press Release: Stock Exchange Announcement: GlaxoSmithKline regulatory update on Right of Reply Statement"
1885	Press Release	Press Release	9/6/2010	Press Release: BBC Panorama "A Risk Worth Taking?" Programme, GlaxoSmithKline Committee letter of 12 July to FDA
1886	Press Release	Press Release	7/13/2010	Press Release: GlaxoSmithKline (GlaxoSmithKline) responds to Senate Finance Committee letter of 12 July to FDA
1887	Press Release	Press Release	12/3/2007	Press Release: GlaxoSmithKline response to Nature Medicine article on rosiglitazone and bone in mice

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1888	Press Release	Press Release	7/14/2010	Press Release: GlaxoSmithKline statement in response to FDA Advisory Committee's vote on safety of Avandia (rosiglitazone)
1889	Press Release	Press Release	7/16/2007	Press Release: GlaxoSmithKline responds to reviews of oral diabetes medications
1890	Press Release	Press Release	7/17/2007	Press Release: GlaxoSmithKline responds to online review of rosiglitazone by the Cochrane collaboration
1891	Press Release	Press Release	3/23/2010	Press Release: GlaxoSmithKline responds to JAMA editorial and comment
1892	Press Release	Press Release	11/14/2007	Press Release: GlaxoSmithKline revises US labeling for Avandia
1893	Press Release	Press Release	7/30/2007	Press Release: GlaxoSmithKline presents Avandia data to FDA
1894	Press Release	Press Release	1/24/2008	Press Release: GlaxoSmithKline to revise Avandia (rosiglitazone maleate) label in Europe following assessment by CHMP.
1895	Press Release	Press Release	7/16/2007	Press Release: GlaxoSmithKline responds to reviews of oral diabetes medications
1896	Press Release	Press Release	6/6/2007	Press Release: Newly published data from large study support cardiovascular safety of Avandia (rosiglitazone maleate)
1897	Press Release	Press Release	2/24/2010	Press Release: GlaxoSmithKline responds to US Senate Committee on Finance report on Avandia
1898	Press Release	Press Release	5/21/2007	Press Release: "GlaxoSmithKline strongly defends its record on Avandia"
1899	Public - Literature	Public - Article	5/24/2007	WSJ, Diabetes Expert Raised Issue of Avandia Heart Risk in 2002
1900	Public - Literature	Public - Article	5/21/2007	WSJ, Congress Steps Up Scrutiny of FDA
1901	Public - Literature	Public - Article	7/25/2007	Philly Enquirer, Top Officer reviews GlaxoSmithKline
1902	Public - Literature	Public - Literature	2003	Article - Braunstein MD, S. Clinical Therapeutics, Vol. 25, No. 7, 2003 "New developments in Type 2 Diabetes Mellitus: Combination Therapy with a Thiazolidinedione"
1903	Public - Literature	Public - Literature		Introduction by Clinical Therapeutics
1904	Public - Literature	Public - Literature		Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med (2008) 359:21:1295-2207 (Abstract)
1905	Public - Literature	Public - Literature		Tack CJ, Goudswaard AN, Smits P. Thiazolidinedione in Type 2 diabetes mellitus. GeBu (2005) 39:107-115
1906	Public - Literature	Public - Literature		Berhanu P, Kipnes MS, Khan MA, et al. Effects of Pioglitazone on Lipid and Lipoprotein Profiles in Patients with Type 2 Diabetes And Dyslipidemia After Treatment Conversion From Rosiglitazone While Continuing Stable Statin Therapy. Diab Vasc Dis Res (2006) 3:39-44

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1907	Public - Literature	Public - Literature		Osei K, Miller E, Everitt D, Ilgenfritz J, Porter L, Freed MI. Rosiglitazone is Effective and Well Tolerated as Monotherapy in African Americans with Type 2 Diabetes. <i>Diabetes</i> (2001) 50 (Suppl. 1):A127 512-P and poster presented at ADA 2001 [Abstract]
1908	Public - Literature	Public - Literature		Park SE, Kang ES, Kim DH, et al. Effect of ABCA1 Variant on Atherogenic Dyslipidaemia in Patients with Type 2 Diabetes Treated with Rosiglitazone. <i>Diabet Med</i> (June 2009) 26(6):577-81
1909	Public - Literature	Public - Literature	6/7/2007	Clinical Therapeutics, "A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study of the Efficacy and Tolerance of Combination Therapy with Rosiglitazone and Sulfonylurea in African American and Hispanic American Patients with Type 2 Diabetes inadequately Controlled with Sulfonylurea Monotherapy" by J. A. Davidson et al.
1910	Public - Literature	Public - Literature		Khan MA, St. Peter JV, Xue JL. A Prospective, Randomized Comparison of the Metabolic Effects of Pioglitazone or Rosiglitazone in Patients with Type 2 Diabetes who were Previously Treated with Troglitazone. <i>Diabetes Care</i> (2002) 5:708-711
1911	Public - Literature	Public - Literature		Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive Glucose Lowering in Type 2 Diabetes. <i>N Engl J Med</i> (2008) 358:24 2545-2559
1912	Public - Literature	Public - Literature		Finfer S, Chittock DR, et al. Intensive versus Conventional Glucose Control in Critically Ill Patients. <i>N Engl J Med</i> (2009) 360:1289-1297
1913	Public - Literature	Public - Literature	10/19/2000	New England Journal of Medicine, "Lipoprotein-Associated Phospholipase A2 as an Independent Predictor of Coronary Heart Disease" by C.J. Packard et al.
1914	Public - Literature	Public - Literature	5/15/2009	BMJ "Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study" By, David N Jurlin et al.
1915	Public - Literature	Public - Literature	5/23/2002	Circulation article: "Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus"
1916	Public - Literature	Public - Literature		Lipscombe LL, Gomes T, Levesque LL, et al. Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes. <i>JAMA</i> (2007) 298 (22):2634-2643
1917	Public - Literature	Public - Literature		Wang CP, Haffner S, DeFrango R, Pugh J. Add-on Oral Agents and Cardiovascular Diseases in VA Patients. 590-P Presented at ADA 2008 [Abstract]
1918	Public - Literature	Public - Literature		Alaupovic P. Concept of Apolipoprotein-Defined Plasma Lipoproteins. 2009 International Symposium on Atherosclerosis [Abstract]

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1919	Public - Literature	Public - Literature		Sakamoto J, Kimura H, Moriyama S, et al. Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by Pioglitazone. <i>J Biochem Biophysics Res Commun.</i> (2000) 278:704-711
1920	Public - Literature	Public - Literature		Owen S, Charbonnel B, Lonnqvist F, Patwardhan R. Rosiglitazone is an Effective Alternative to Glibenclamide as First-Line Therapy in Type 2 Diabetic Patients. <i>Diabetologia</i> (1999) 42(Suppl. 1):A231. Abs 868 presented at EASD 1999 [Abstract]
1921	Public - Literature	Public - Literature		Samaha FF, Szapary PO, Iqbal N, Williams MM, Bloedon LT, Kocher A, Wolfe ML, Rader DJ. Effects of Rosiglitazone on Lipids, Adipokines, and Inflammatory Markers in Non-diabetic Patients with Low High-Density Lipoprotein Cholesterol and Metabolic Syndrome. <i>Arterioscler Thromb Vasc Biol</i> (2006) 26(3):624-630
1922	Public - Literature	Public - Literature		BARI2D Study Group. A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. <i>N Engl J Med</i> (2009) 360:2503-2515
1923	Public - Literature	Public - Literature		Margolis DJ, Hoffstad O, Strom BL. Association Between Serious Ischemic Cardiac Outcomes and Medications Used to Treat Diabetes. <i>Pharmacoepidem Drs</i> (2008) 17:753-759
1924	Public - Literature	Public - Literature		Yu D, Murdoch SJ, Marcovina SM, Chen H, Cobitz AR, Porter LE, Brunzell JD. Effects of Rosiglitazone on Lipid Metabolism in Type 2 Diabetes Mellitus Patients Who Were Predominant Type B LDL and on Statins. <i>Diabetes</i> (2004) 53 (Suppl. 2):A233 951 [Abstract]
1925	Public - Literature	Public - Literature	10/??/00	Molecular Aspects of Medicine "Atherosclerosis: from lesion formation to plaque activation and endothelial dysfunction" By, John F. Keaney, Jr.
1926	Public - Literature	Public - Literature		Diamond GA, et al. Balance of Evidence: Is Rosiglitazone Associated with cardiovascular Risk? . <i>Ann of Intern Med</i> (2007) 147 :578-581. Slide Source lipids Online Slide Library. www.lipidsonline.org
1927	Public - Literature	Public - Literature		Kawakami A, Yoshida M. Apolipoprotein CIII Links Dyslipidemia with Atherosclerosis. <i>Atheroscler Thromb</i> (2009) 16:6-11.
1928	Public - Literature	Public - Literature		Derosa G, Cicero AFG, D'Angelo A, et al. Effects of 1 Year of Treatment with Pioglitazone or Rosiglitazone Added to Glimepiride on Lipoprotein (a) and Homocysteine Concentrations in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome. <i>Clin Therapeutics</i> (2006) 5:679-688

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1929	Public - Literature	Public - Literature		Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed M. Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes. <i>J Clin Endocrinol Metab</i> (2001) 86:280-288
1930	Public - Literature	Public - Literature		Turner RC, Holman RR, Cull CA, et al. Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33). <i>The Lancet</i> (1998) 352:837-853
1931	Public - Literature	Public - Literature	6/25/2010	ADA, PPAR CV Effects, 70th Session, June 25, 2010.
1932	Public - Literature	Public - Literature		Ziyadeh N, McAfee AT, Koro C, et al. The Thiazolidinediones Rosiglitazone and Pioglitazone and the Risk of Coronary Heart Disease: A Retrospective Cohort Study Using a US Health Insurance Database. <i>Clin Ther</i> (2009) 31:2665-2677
1933	Public - Literature	Public - Literature		Inzucchi SE, Siegel MD. Glucose Control in the ICU - How Tight is Too Tight? [Editorial] <i>New Eng J Med</i> (Mar 2009) 360:13-1346-1349
1934	Public - Literature	Public - Literature		McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM. Coronary Heart Disease Outcomes in Patients Receiving Antidiabetic agents. <i>Pharmacoepidemiol Dr S</i> (2007) 16:711-725
1935	Public - Literature	Public - Literature		Kahn SE, Freed MI, Porter LE, et al. Proinsulin/Insulin Ratio Reduced and -Cell Function Improved in Type 2 Diabetes with Rosiglitazone. <i>Diabetes Res Clin Pract</i> (2000) 50 (Suppl. 1):S6263 and poster P305 presented at IDF 2000 [Abstract]
1936	Public - Literature	Public - Literature		Serrys PW, Garcia-Garcia HM, Bussman P, et al. Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque. <i>Circulation</i> (2008) 118:1172-1182
1937	Public - Literature	Public - Literature	6/5/2009	Herper M. Glaxo Falls to Learn Lesson of Avandia. <i>Forbes</i> (June 5, 2009). Found at http://www.forbes.com/2009/06/05/avandia-glaxosmithkline-business-healthcare-avandia.html
1938	Public - Literature	Public - Literature		Juurink DN, Gomes T, Lipscombe LL, et al. Adverse Cardiovascular Events during Treatment with Pioglitazone and Rosiglitazone: Population Based Cohort Study. <i>BMJ</i> (2009) 339:1-6 and corresponding press release
1939	Public - Literature	Public - Literature		RECORD Trial Limitations Slide
1940	Public - Literature	Public - Literature	9/15/2006	Article: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial" by, The DREAM Trial Investigators
1941	Public - Literature	Public - Literature	9/12/2007	JAMA, "Long-term Risk of Cardiovascular Events with Rosiglitazone, A Meta-analysis" By S. Singh, et al.

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1942	Public - Literature	Public - Literature		Lebovitz HE, Patel J, Dole J, Patwardhan R. Rosiglitazone (BRL49653) Monotherapy Has Significant Glucose Effect in Type 2 Diabetic Patients. <i>Diabetologia</i> (1998) 41 (Suppl. 1):A238 and poster presented at EASD 1998 [Abstract]
1943	Public - Literature	Public - Literature	5/23/2002	Circulation article, "Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus"
1944	Public - Literature	Public - Literature		Drazen JM, Morrissey S, Curfman GD. Rosiglitazone- Continued Uncertainty About Safety. <i>N Engl J Med</i> (Jul 2007) 357:1-63-64
1945	Public - Literature	Public - Literature	5/10/2010	Archives of Internal Medicine, "Rosiglitazone Revisited: An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality" By, S. Nissen, MD and K. Wolski, MPH
1946	Public - Literature	Public - Literature		RECORD Slides - ADA PowerPoint 2009. www.recdsstudyresults.org
1947	Public - Literature	Public - Literature	3/28/2008	Pharmacoepidemiology and Drug Safety, "Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007" By, A. Walker et al.
1948	Public - Literature	Public - Literature	07/??/05	Diabetes Care, "A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia" By, R. B. Goldberg, MD, et al.
1949	Public - Literature	Public - Literature		Koro CE, Fu Q, Stender M. An Assessment of the Effect of Thiazolidinedione Exposure on the Risk of Myocardial Infarction in Type 2 Diabetic Patients. <i>Pharmacopidemiol Dr S</i> (2008) 17(10):989-996
1950	Public - Literature	Public - Literature		Pasaty BM, Furberg CD. The Record on Rosiglitazone and the Risk of Myocardial Infarction. (Editorial) <i>N Engl J Med</i> (Jun 2007) 357:67-69
1951	Public - Literature	Public - Literature		Abbas F, Lima NK, Reaven GM. Relationship between Changes in Insulin Sensitivity and Associated Cardiovascular Disease Risk Factors in Thiazolidinedione Treated, Insulin-Resistant, Nondiabetic Individuals: Pioglitazone versus Rosiglitazone. <i>Metab. Clin Exp.</i> (2009) 58:373-378
1952	Public - Literature	Public - Literature		Cohen BR, Kreider M, Biswas N, Brunzell J, Ratner RE, Freed MI. Rosiglitazone in Combination with HMG CoA Reductase Inhibitor: Safety and Effects on Lipid Profile in Patients with Type 2 Diabetes. <i>Diabetes</i> (2001) 50 (Suppl 2);A451. Abs 1884-PO presented at ADA 2001 [Abstract]
1953	Public - Literature	Public - Literature		Rosen CJ. The Rosiglitazone Story - Lessons from an FDA Advisory Committee Meeting. <i>N Engl J Med</i> (Aug 2007) 357:9 844-846
1954	Public - Literature	Public - Literature	1/1/2001	Contemporary Diagnosis and Management of Lipid Disorders By, Antonio M. Gotto, Jr., MD, DPhil

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1955	Public - Literature	Public - Literature		Brunzell J, Cohen BR, Kreider M, Biswas N, Ratner RE, Freed MI, Marcovina S. Rosiglitazone Favorably Affects LDL-C and HDL-C Heterogeneity in Type 2 Diabetes. Diabetes (2001) 50(Suppl. 2) A141. Abs 567- P Presented at ADA 2001 [Abstract]
1956	Public - Literature	Public - Literature		Komaida M, Curtis P, Hanefeld M, et al. Effect of the Addition of Rosiglitazone to Metformin or Sulfonylureas Versus Metformin/Sulfonylurea Combination Therapy on Ambulatory Blood Pressure in People with Type 2 Diabetes: A Randomized Controlled Trial (the RECORD study). Cardiovas Diabet (2008) 7:10
1957	Public - Literature	Public - Literature		Balfour Barman JA and Plosker GL. Rosiglitazone. Drugs (1999) 57:921-930
1958	Public - Literature	Public - Literature		Nathan DM. The Role of Glycemia Management in the Prevention of Cardiovascular Disease - Starting Over? Ann Intern Med (2009) 151:888-889
1959	Public - Literature	Public - Literature		Scheffer PG, Teerlink T, Dekker JM, et al. Increased Plasma Apolipoprotein C-III Concentration Independently Predicts Cardiovascular Mortality: The Hoorn Study. Clinical Chemistry (2008) 1-7
1960	Public - Literature	Public - Literature		Fox, CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal Trends in Coronary Heart Disease Mortality and Sudden Cardiac Death from 1950 to 1999: The Framingham Heart Study. Circulation (2004) 110:522-527
1961	Public - Literature	Public - Literature	12/21/2009	BMJ, "Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review" by, A. T. Wang, C. McCoy, et al.
1962	Public - Literature	Public - Literature		Rebuck AS, Weil S, Patwardhan R. Rosiglitazone Given Once or Twice Daily is Effective First-Line Treatment for Type 2 Diabetes Mellitus. Diabetologia (1999) 42 [Suppl. 1]:A231 867 and poster presented at EASD 1999 [Abstract]
1963	Public - Literature	Public - Literature		Institute of Medicine, Ethical Issues in Studying the Safety of Approved Drugs: A Letter Report, Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs, Board on Population Health and Public Health Practice, The National Academies Press, Washington, D.C., www.nap.edu.
1964	Public - Literature	Public - Literature		Osman A, Otero J, Brizolara A, et al. Effect of Rosiglitazone on Restenosis after Coronary Stenting in Patients with Type 2 Diabetes. Am Heart J (May 2004) 27:5:829.e21-e25
1965	Public - Literature	Public - Literature		DeAngelis CD, Fontanarosa PB. Ensuring Integrity in Industry-Sponsored Research: Premium Non Nocere, Revisited. JAMA (2010);303(12):1196-1198
1966	Public - Literature	Public - Literature	5/1/2010	The Lancet, "Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies" by, The LpPLA2 Studies Collaboration

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1967	Public - Literature	Public - Literature		Jarvinen H. Thiazolidiones. <i>N Engl J Med</i> (Sep 2004) 351:11:1106-1110
1968	Public - Literature	Public - Literature		ACCORD slides, sponsored by National Heart, Lung, and Blood Institute
1969	Public - Literature	Public - Literature		Hennekens CH, DeMets D. The Need for Large-Scale Randomized Evidence Without Undue Emphasis on Small Trials, Meta-Analyses, or Subgroup Analyses.
1970	Public - Literature	Public - Literature		Walker AM, Koro CE, Landon J. Coronary Heart Disease Outcomes in Patients Receiving Antidiabetic Agents in the Pharmetrics Database 2000-2007. <i>Pharmacoepidemiol Drug Saf.</i> (2008) 17(8):760-768
1971	Public - Literature	Public - Literature		Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, Komajda M, Gubb J, Biswas N, Jones NP. Rosiglitazone Evaluated for Cardiac Outcomes- An Interim Analysis. <i>N Engl J Med</i> (2007) 357:1:28-38
1972	Public - Literature	Public - Literature		Gerstein HC, Ratner RE, Cannon CP, et al. Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease. The Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients with Cardiovascular History Trial. <i>Circulation</i> (2010) 121:1176-1187
1973	Public - Literature	Public - Literature		Bakris GL, Dole JF, Porter LE, Huang C, Freed MI. Rosiglitazone Improves Blood Pressure in Patients with Type 2 Diabetes Mellitus. <i>Diabetes</i> (2000) 49 (Suppl. 1):A96. Abs 388 presented at ADA 2000 [Abstract]
1974	Public - Literature	Public - Literature		Rosenstock J, Baron MA, DeJager S, et al. Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients with Type 2 Diabetes: A 24-Week, Double-Blind, Randomized Trial. <i>Diabetes Care</i> 2007;30:217-223
1975	Public - Literature	Public - Literature		Van Wijk JPH, de Koning JP, et al. Comparison of Rosiglitazone and Metformin for Treating HIV Lipodystrophy. <i>Ann Intern Med</i> (2005) 143:337-346
1976				Intentionally Omitted
1977	Public - Literature	Public - Literature	2/23/2009	Pharmacoepidemiology and Drug Safety "Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis" By, Z. A. Habib, MD, et al.
1978	Public - Literature	Public - Literature		Inzuchi SE, Masoudi FA, Wang Y, et al. Insulin-Sensitizing Antihyperglycemic Drugs and Mortality After Acute Myocardial Infarction. <i>Diabetes Care</i> (2005) 28:1680-1689

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1979	Public - Literature	Public - Literature		Haffner SM, Greenberg AS, Weston WM, et al. Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus. <i>Circulation</i> (2002) 106:679-684
1980	Public - Literature	Public - Literature		Turner RC, Cull CA, Frighi V, et al. Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49) <i>JAMA</i> (Sept 1999) 281(21):2005-2012
1981	Public - Literature	Public - Literature	6/28/2010	JAMA, "Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated with Rosiglitazone or Pioglitazone" By, D. Graham; R. Ouellet-Hellstrom; T.E. MacCurdy; et al.
1982	Public - Literature	Public - Literature		O'Donnell CJ, Elousa R. Cardiovascular Risk Factors. Insights from Framingham Heart Study. <i>Rev Esp Cardiol</i> (2008) 61(3):299-310
1983	Public - Literature	Public - Literature	??/??/1994	Natural Antioxidants in Human Health and Disease "Antioxidant Protection of Low-Density Lipoprotein and Its Role in the Prevention of Atherosclerotic Vascular Disease" By, J. F. Keaney, Jr., and B. Frei
1984	Public - Literature	Public - Literature	6/28/2010	Juurink, David, Rosiglitazone and the Case for Safety over Certainty, <i>JAMA</i> , June 28, 2010.
1985	Public - Literature	Public - Literature	October, 2002	The American Journal of Managed Care, Vol 8, No. 16, supplement - October 2002 Article - Wyne MD, K., The Endocrinologist, 2003 vol 13, suppl 1, "Trends in Management of Type 2 Diabetes: Role of Thiazolidinediones"
1986	Public - Literature	Public - Literature	2003	Article - Hsueh MD, W., The American Journal of Cardiology, "A Symposium: New Insight into Understanding the Relation of Type 2 Diabetes Mellitus, Insulin Resistance, and Cardiovascular Disease"
1987	Public - Literature	Public - Literature	8/18/2003	Article - Goldstein MD, B., The American Journal of Cardiology, "A Symposium: Evolution of Type 2 Diabetes Mellitus Management: Assessment and Clinical Application of Newer Findings"
1988	Public - Literature	Public - Literature	9/5/2002	Article - The American Journal of Medicine, "Evaluating the Cardiovascular Effects of the Thiazolidinediones and Their Place in the Management of Type 2 Diabetes Mellitus"
1989	Public - Literature	Public - Literature	12/8/2003	Article - The American Journal of Medicine, "Evaluating the Cardiovascular Effects of the Thiazolidinediones and Their Place in the Management of Type 2 Diabetes Mellitus"

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
1990	Public - Literature	Public - Literature		Mun DJ, Engelson ES, Albu JB, et al. Effects of Diet and Exercise and/or Rosiglitazone on Body Composition and Lipids including Oxidized LDL in HIV+ and HIV- Men and Women, 15th CROI 2008 Feb3-6
1991	Public - Literature	Public - Literature		Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. Once-and Twice-Daily Dosing with Rosiglitazone Improves Glycemic Control in Patients with Type 2 Diabetes. <i>Diabetes Care</i> (2001) 24:308-315. Erratum: <i>Diabetes Care</i> (2001) 24:973
1992	Public - Literature	Public - Literature		Bobik A. Apolipoprotein CII and Atherosclerosis: Beyond Effects on Lipid Metabolism. <i>Circulation</i> (2008) 118:702-704
1993	Public - Literature	Public - Literature		Nissen SE, Wolski K. Nissen and Wolski Meta-Analysis: Rates of Myocardial Infarction and Death from Cardiovascular Causes. <i>N Engl J Med</i> (2007) 356:24:2457-2472. Slide Source Lipids Online Slide Library. www.lipidsonline.org
1994	Public - Literature	Public - Literature	6/25/2010	Stiles, Steve, BARI 2D analysis enters rosiglitazone debate, finds no MI hazard, http://www.theheart.org/article/1093045 , accessed June 29, 2010.
1995	Public - Literature	Public - Literature		ADA, BARI 2D Slide Presentation, June 25-29, 2010.
1996	Public - Literature	Public - Literature		Porter L, Freed M, Jones N, Biswas N. Rosiglitazone Improves -Cell Function as Measured by Proinsulin/Insulin Ratio in Patients with Type 2 Diabetes. <i>Diabetes</i> (2000) 49 (Suppl. 1):A122 and poster presented at ADA 2000 [Abstract]
1997	Public - Literature	Public - Literature		Hedblad B, Zambanini A, Nilsson P, et al. Rosiglitazone and Carotid IMT Progression Rate in a Mixed Cohort of Patients with Type 2 Diabetes and the Insulin Resistance Syndrome: Main Results from the Rosiglitazone Atherosclerosis Study. <i>J Intern Med</i> (2007) 261:293-305
1998	Public - Literature	Public - Literature		Lago R, Singh P, Nesto R. Congestive Heart Failure and Cardiovascular Death in Patients with Prediabetes and Type 2 Diabetes Given Thiazolidinediones: A Meta-Analysis of Randomized Clinical Trials. <i>Lancet</i> (2007) 370:1129-36
1999	Public - Literature	Public - Literature	??/?/04	Abstract of "Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Ischemic Stroke in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities Study" by C. M. Ballantyne et al.
2000	Public - Literature	Public - Literature		Gerstein HC, Yusuf S, Holman RR, et al. Effects of Rosiglitazone on the Frequency of Diabetes in Patients with Impaired Glucose Tolerance or Impaired Fasting Glucose: A Randomized Controlled Trial. <i>Lancet</i> (2006) published online September 15, 2006

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2001	Public - Literature	Public - Literature		"The Environment and Disease: Association or Causation?" by Sir Austin Bradford Hill
2002	Public - Literature	Public - Literature		Horne PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, Komajda M, Gubb J, Biswas N, Jones NP. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): Study Design and Protocol. Diabetologia (2005) 48:1726-1735
2003	Public - Literature	Public - Literature	??/??/07	Clinical Trial Report: "Choice of monotherapy in newly diagnosed Type 2 diabetic patients: clinical perspective of ADOPT" By, Janaka Karallidde & Robin E. Buckingham Wolfenbuttel BHR, Gomist R, Squarrito S, et al. Addition of Low-Dose Rosiglitazone to Sulphonylurea Therapy Improves Glycaemic Control in Type 2 Diabetic Patients. Diabetic Med (2000) 17:40-47
2004	Public - Literature	Public - Literature		Clinical Therapeutics: "The Thiazolidinediones Rosiglitazone and Pioglitazone and the Risk of Coronary Heart Disease: A Retrospective Cohort Study Using a US Health Insurance Database" By, N. Ziyadeh, MA, MPH et.al.
2005	Public - Literature	Public - Literature	11/11/2009	ACCORD Protocol, May 11, 2005 Version
2006	Public - Literature	Public - Literature		Karallidde J, Buckingham R, Starkie M, et al Effect of Various Diuretic Treatments on Rosiglitazone-Induced Fluid Retention. J Am Soc Nephrol (2006) 17(12):3482-3490 Intentionally Omitted
2007	Public - Literature	Public - Literature		Strickler, Laura, Avandia Drug Trials Shut Down in India, CBS News Investigates, http://www.cbsnews.com/, accessed July 16, 2010.
2008				Baucus, Max and Grassley, Chuck, Press Release: Baucus, Grassley Release Finance Committee Report on Diabetes Drug Avandia, Express Concern About FDA's Role in Protecting Patients in Ongoing Avandia Study, U.S. Senate, Committee on Finance, February 20, 2010.
2009	Public - Literature	Public - Literature		Olsansky L, Marchetti A, et al. "Multi Center Retrospective Assessment of TZD Monotherapy and Combination Therapy in Patients with Type 2 Diabetes: Comparative Subgroup Analyses of Glycemic Control and Blood Lipid Levels. Clinical Therapy" (2003) 25 Suppl B:B 64-80
2010	Public - Literature	Public - Literature		Dhangana MD, et al. Prevalence of low ankle-brachial index, elevated plasma fibrinogen and CRP among those otherwise at low-intermediate cardiovascular events risk: data from the National Health and Nutrition Examination Survey (NHANES) 1999-2004 (2009) JVIR; Oral presentation at SIR annual scientific meeting 2009
2011	Public - Literature	Public - Literature		
2012	Public - Literature	Public - Literature		

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2013	Public - Literature	Public - Literature		Dhangana MD, et al. Prevalence of low ankle-brachial index, elevated plasma fibrinogen and CRP among those otherwise at low-intermediate cardiovascular events risk: data from the National Health and Nutrition Examination Survey (NHANES) 1999-2004 (2009) JVIR; Oral presentation at SIR annual scientific meeting 2009
2014	Public - Literature	Public - Literature		Pedersen TR, Faergeman O, Kastlein JP, et al. Design and Baseline Characteristics of the Incremental Decrease in End Points Through Aggressive Lipid Lowering Study. Am J Cardiol (2004) 94:720-724
2015	Public - Literature	Public - Literature		Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combinations (RECORD)
2016	Public - Literature	Public - Literature		DREAM: Study Design. The DREAM Trial Investigators. Diabetologia 2004 47:151S-1527. Lipids Online Slide Library www.lipidsonline.org
2017	Public - Literature	Public - Literature		Natali A, Toschi E, Sirone A, Camastra S, Ferrannini E. Effect of Essential Hypertension on Endothelial Function in Type 2 Diabetic Patients. Diabetes (2001) 50 (Suppl. 2):A161. 653 Poster presented at ADA [Abstract]
2018	Public - Literature	Public - Literature		Nissen SE. The Rise and Fall of Rosiglitazone. Eur Heart (2010) published online February 12, 2010. DOI: 10.1093/eurheartj/ehq016
2019	Public - Literature	Public - Literature		Nissen SE. Setting the RECORD Straight. JAMA (2010) 303(12):1194-1195
2020	Public - Literature	Public - Literature		Gomis R, Jones NP, Vallance SE, Patwardhan R. Low-Dose Rosiglitazone Enhances Glycemic Control When Combined with Sulfonylureas in Type 2 Diabetes. Diabetologia (1999) 42 (Suppl. 1):A851. Poster presented at EASD 1999 [Abstract]
2021	Public - Literature	Public - Literature		Bakris G, Weston WM, Rappaport EB, Freed MI. Rosiglitazone Produces Long-Term Reductions in Urinary Albumin Excretion in Type 2 Diabetes. Diabetologia (1999) 42 (Suppl. 1):A230. 865 and poster presented at EASD 1999 [Abstract]
2022	Public - Literature	Public - Literature	12/15/2009	Diabetes Care, "Rapid identification of myocardial infarction risk associated with diabetic medications using electronic medical records", By J.S. Brownstein, PhD, et al.
2023	Public - Literature	Public - Literature		McConnell JP, Jaffe AS. The Spin Stops Here: Inhibition of Lipoprotein-Associated Phospholipase A2-A Promising Target but a Negative Initial Trial? Clin Chem (2009) 55:1 21-23
2024	Public - Literature	Public - Literature		Szapary PO, Bloedon LJ, Samaha FF, et al. Effects of Pioglitazone on Lipoproteins, Inflammatory Markers, and Adipokines in Nondiabetic Patients with Metabolic Syndrome. Arterioscler Thromb Vasc Biol (2006) 26:182-188
2025	Public - Literature	Public - Literature	5/21/2007	Press Release. "GlaxoSmithKline Strongly Defends its Record on Avandia"

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2026	Public - Literature	Public - Literature		Nissen, S., Wolski, K., Rosiglitazone Revisited: An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality, AMA, www.archinternmed.com , (reprinted) June 28, 2010.
2027	Public - Literature	Public - Literature		Stocker DJ, Taylor AJ, Langley RW, et al. A Randomized Trial of the Effects of Rosiglitazone and Metformin on Inflammation and Subclinical Atherosclerosis in Patients with Type 2 Diabetes. <i>Am Heart J</i> (2007) 153:445.e1-245.e6
2028	Public - Literature	Public - Literature	5/21/2007	New England Journal of Medicine, "Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes" by S. Nissen & Wolski ([2007]356:2457-2472. Published online first: May 21, 2007)
2029	Public - Literature	Public - Literature		Salzman A, Murphy KJ. Rosiglitazone: Cardiac Safety with Long-Term Treatment in Patients with Type 2 Diabetes. <i>Res Clin Pract</i> (2000) 50 (Suppl. 1):A64-309 and poster presented at IDF 2000 [Abstract]
2030	Public - Literature	NONE	7/30/2007	"Observational Studies: Effect of Antidiabetic Agent Choice on Cardiovascular Morbidity and Mortality in Type 2 Diabetes Mellitus" Slide Set
2031	Public - Literature	Public - Literature		Duckworth W, Abraira C, Moritz T, et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. <i>N Engl J Med</i> (Jan 2009) 360:2 129-141 [Abstract]
2032	Public - Literature	Public - Literature	2/8/2009	"The Risk of Both Stroke and Coronary Heart Disease (CHD) Nearly Doubles With Elevated LP-PLA2 Activity", prnewswire.com
2033	Public - Literature	Public - Literature		Cobitz A, Zambanini A, Sowell M, Heise M, Louridas B, McMorn S, Semigran M, Koch G. A Retrospective Evaluation of Congestive Heart Failure and Myocardial Ischemia Events in 14237 Patients with Type 2 Diabetes Mellitus Enrolled in 42 Short-Term, Double-Blind, Randomized Clinical Studies with Rosiglitazone. <i>Pharmacoeepim Dr S</i> (2008) 17 :769-781
2034	Public - Literature	Public - Literature		Ko SH, Song KH, Yoo SJ, et al. The Effect of Rosiglitazone on Serum Lipoprotein(a) Levels in Korean Patients With Type 2 Diabetes Mellitus. <i>Metabolism</i> 2003 52:731-734
2035	Public - Literature	Public - Literature		Miller, Reed, European Atherosclerosis Society recommends screening for Lp(a), http://www.theheart.org/article/1090493 , accessed July 19, 2010.
2036	Public - Literature	Public - Literature		

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2037	Public - Literature	Public - Literature	7/12/2006	Chaitman BR, Hardison RM, Adler D, et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus with Stable Ischemic Heart Disease - Impact of Treatment Strategy on Cardiac Mortality and Myocardial Infarction. Circulation (2009) published online November 17, 2009; DOI: 10.1161/CIRCULATIONAHA.109.913111
2038	Public - Literature	Public - Literature	7/12/2006	The American Journal of Cardiology, "Risk of Cardiovascular Events in Patients Receiving Celecoxib A Meta-Analysis of Randomized Clinical Trials" By, V.W. White, C.R. West, et al.
2039	Public - Literature	Public - Literature		Freed MI, Weston WM, Viberti G. Rosiglitazone Reduces Urinary Albumin Excretion in Type 2 Diabetes. Diabetologia (1999) 42 (Suppl. 1):A230 866 and poster presented at EASD 1999 [Abstract]
2040	Public - Literature	Public - Literature		Aljada A, Shah KA, Mousa SA. Peroxisome Proliferator-Activated receptor Agonists: Do They Increase Cardiovascular Risk? PPAR Research Vol 2009, Article ID 460764
2041	Public - Literature	Public - Literature		Natali A, Toschi E, Baldeweg S, Casolari A, Baldi S, Sironi AM, Yudkin JS, Ferrannini E. Haematoцит, Type 2 Diabetes and Endothelium-Dependent Vasodilation of Resistance Vessels. Eur Heart J. (Mar 2005) 26(5):464-71
2042	Public - Literature	Public - Literature		Information on the Plac Test and DiaDexus. www.diadexus.com
2043	Public - Literature	Public - Literature		Goldstein B, Salzman A. Rosiglitazone is Effective in Poorly Controlled Type 2 Diabetes Patients. Diabetologia (1999) 42 (Suppl. 1):A229 861 and poster presented at EASD 1999 [Abstract]
2044	Public - Literature	Public - Literature		Chaitman BR, BARI-2D - Impact of Treatment Strategy on Cardiac Mortality and Myocardial Infarction slides
2045	Public - Literature	Public - Literature		Ray KK, Seshasai SRK, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized controlled trials. Lancet 2009; 373: 1765-72
2046	Public - Literature	Public - Literature		Campos H, Moye LA, Glasser SP, et al. Low-Density Lipoprotein Size, Pravastatin Treatment and Coronary Events. JAMA 286:1468-1474 September 26, 2001 (MI re LDL particle size)
2047	Public - Literature	Public - Literature		Yu D, Murdoch SJ, Parikh SJ, et al. Rosiglitazone Increases LDL Particle Size and Buoyancy and Decreases C-Reactive Protein in Patients with Type 2 Diabetes on Statin Therapy. Diab Vasc Dis Res (2006) 3:189-196

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2048	Public - Literature	Public - Literature		Chahill TJ, et al. Effects of Pioglitazone and Rosiglitazone on Lipid Metabolism. Columbia University Medical Center
2049	Public - Literature	Public - Literature		Kawakami A, Osaka M, Tani M, Azuma H, Sacks FM, Shimokado K, Yoshida M. Apolipoprotein CII Links Hyperlipidemia with Vascular Endothelial Cell Dysfunction. Circulation (2008) 118:731-742
2050	Public - Literature	Public - Literature		Diamond GA, Bax L, Kaul S. Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death. Ann of Intern Med (2007) 147, 578-581
2051	Public - Literature	Public - Literature		Freedman DS, et al. Lipoprotein Subclasses. Arterioscler Thromb Vasc Biol. 1998 18:1046-1053. Slides
2052	Public - Literature	Public - Literature		Krumholz HM. A Perspective on the American Heart Association Presidential Commission: Advisory on Thiazolidinedione Drugs. Circ Cardiovasc Qual Outcomes (2010) 3:00-00. Published online ahead of print. DOI: 10.1161/CIRCOUTCOMES.110.936070
2053	Public - Literature	Public - Literature	10/22/2008	Diabetes Care, "Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy" By, D.M. Nathan, J. Buse, et al.
2054	Public - Literature	Public - Literature	6/21/2002	Freed MI, Ratner R, Marcovina SM, Kreider MM, Biswas N, Cohen BR, Brunzell JD. Effects of Rosiglitazone Alone and in Combination with Atorvastatin on the Metabolic Abnormalities in Type 2 Diabetes Mellitus. Am J Cardiol (2002) 90:947-952
2055	Public - Literature	Public - Literature		Article: Thiazolidinediones and Cardiovascular Events In Patient With Type 2 Diabetes Mellitus
2056	Public - Literature	Public - Literature		Kaul S, Bolger AF, Herrington D, et al. Thiazolidinedione Drugs and Cardiovascular Risks: A Science Advisory From the American Heart Association and American College of Cardiology Foundation. J Am Coll Cardiol (2010) published online ahead of print
2057	Public - Literature	Public - Literature		Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones, NP, Komajda M, McMurry JV. Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes (RECORD): A Multicentre, Randomized, Open-Label Trial. Lancet, published online June 5, 2009
2058	Public - Literature	Public - Literature		Bertrand OF, Poirier P, Després JP. VICTORY: A Cardiometabolic Trial. Slides

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2059	Public - Literature	Public - Literature		Miller AK, Inglis AL, Thompson K, et al. Effect of Hepatic Impairment on the Pharmacokinetics (PK) of Rosiglitazone (RSG). 1999 American Society for Clinical Pharmacology and Therapeutics [Abstract]
2060	Public - Literature	Public - Literature		McGuire DK, Inzucchi SE. New Drugs for the Treatment of Diabetes Mellitus: Part I: Thiazolidinediones and Their Evolving Cardiovascular Implications. Circulation (2008) 117: 440-449
2061	Public - Literature	Public - Literature		Chiquette E, Ramirez G, DeFronezo R. A Meta-analysis Comparing the Effect of Thiazolidinediones on Cardiovascular Risk Factors. Arch Intern Med (2004) 164:2097-2014
2062	Public - Literature	Public - Literature		Hirschler, Ben, Avandia, Reuters, www.reutersreprints.com, March 22, 2010.
2063	Public - Literature	Public - Literature		Rosenstock J, Niggl M, Maldonado-Lutomirsky M. Long-Term 2-Year Safety and Efficacy of Vildagliptin Compared with Rosiglitazone in Drug-Naïve Patients with Type 2 Diabetes Mellitus. Diabetes Obes Metab 2009 11:571-578
2064	Public - Literature	Public - Literature	11/15/2008	Journal of American College of Cardiology, "Lipoprotein Management in Patients with Cardiometabolic Risk", by J.D. Brunzell et al.
2065	Public - Literature	Public - Literature		Burger, Ludwig, German drugs gatekeeper rejects GlaxoSmithKline's Avandia Pill, Reuters, June 18, 2010.
2066	Public - Literature	Public - Literature		Raskin P, McGill J, Cappleman JM, Kayes W, Khutoryansky N, Hale PM. Combination Therapy for Type 2 Diabetes: Repaglinide plus Rosiglitazone. Diabetes UK. Diabetic Medicine (2004) 21:321-335
2067	Public - Literature	Public - Literature	2/3/2003	Cardiovascular Research, "The PPAR-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction" By C.A. Lygate et al.
2068	Public - Literature	Public - Literature		Johannes CB, Koro CE, Quinn SG, et al. The Risk of Coronary Heart Disease in Type 2 Diabetic Patients Exposed to Thiazolidinediones Compared to Metformin and Sulfonylurea Therapy. Pharmacopidem Dr S (2007) 16(5):504-512
2069	Public - Literature	Public - Literature		Duez H, Lamarche B, Uffelman KD, et al. Dissociation between the InsulinSensitivity Effect of Rosiglitazone and Its Effect on Hepatic and Intestinal Lipoprotein Production. J Clin Endocrinol Metab (May 2008) 93:1722-1729

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2070	Public - Literature	Public - Literature		Deeg MA, Buse JB, Goldberg RB, et al. Pioglitazone and Rosiglitazone Have Different Effects on Serum Lipoprotein Particle Concentration and Sizes in Patients with Type 2 Diabetes and Dyslipidemia. <i>Diabetes Care</i> (2007) 30:2458-2464
2071	Public - Literature	Public - Literature		Lonnqvist F, Charbonnel B, Jones NP, Abel MG, Patwardhan R. Rosiglitazone is Superior to Glyburide in Reducing Fasting Plasma Glucose in Type 2 Diabetic Patients. <i>Diabetologia</i> (1999) 42 (Suppl. 1):A231. 869 presented at EASD 1999 [Abstract]
2072	Public - Literature	Public - Literature		Ratner RE, Cannon CP, Gerstein HC, et al. Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients with Cardiovascular History (APPROACH): Study Design and Baseline Characteristics. <i>Am Heart J</i> (Dec 2008) 156:1074-1079
2073	Public - Literature	Public - Literature		European Medicines Agency, European Medicines Agency starts review of rosiglitazone containing medicines, Press Release, Press Office, July 09, 2010.
2074	Public - Literature	Public - Literature		Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. <i>New England Journal of Medicine</i> 2006 355:2427-43
2075	Public - Literature	Public - Literature	8/12/2010	"After Avandia: Does the FDA Have a Drug Problem?", Time Magazine, Massimo Calabresi
2076	Public - Literature	Public - Literature		Article: Thiazolidinediones and Cardiovascular Outcomes in Older Patients With Diabetes Gerrits CM, Bhattacharya M, Manthina S, et al. A Comparison of Pioglitazone and Rosiglitazone for Hospitalization for Acute Myocardial Infarction in Type 2 Diabetes. <i>Pharmacoepidem Dis S</i> (2007) 16:1065-1071
2077	Public - Literature	Public - Literature		ABSTRACT: <i>Circulation</i> , "Lipoprotein-Associated Phospholipase A2 (Lp-PLA2). A Marker of Risk for Coronary Events and Strokes" By, H.S. Oei, I. van der Meer, et al.
2078	Public - Literature	Public - Literature	11/15/2004	Singh S, Loke Y, Furberg C. Long-term Risk of Cardiovascular Events with Rosiglitazone. <i>JAMA</i> (2007) 298(10):1189-1195
2079	Public - Literature	Public - Literature		Starner CL. Rosiglitazone and Pioglitazone Utilization from January 2007 through May 2008 Associated with Five Risk-Warming Events. <i>JMCP</i> (2008) 14:523-529
2080	Public - Literature	Public - Literature		

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2081	Public - Literature	Public - Literature		Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM: Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. <i>Circulation</i> (2005) 111(5):583-90
2082	Public - Literature	Public - Literature	4/15/2008	Pharmacoepidemiology and Drug Safety, "A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14 237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone", By A. Cobitz, MD, PhD, et al.
2083	Public - Literature	Public - Literature		Grunberger G, Weston WM, Patwardhan R, Rappaport EB, Rosiglitazone Once or Twice Daily Improves Glycemic Control in Patients with Type 2 Diabetes. <i>Diabetologia</i> (1999) 42 (Suppl. 1): A4. Poster presented at EASD 1999 [Abstract]
2084	Public - Literature	Public - Literature		Kawakami A, Alcaide M, Alcaide P, Luscinskas FW, Libby P, Sacks FM. Apolipoprotein CII Induces Expression of Vascular Cell Adhesion Molecule-1 in Vascular Endothelial Cells and Increases Adhesion of Monocytic Cells. <i>Circulation</i> (2006) 114:681-687
2085	Public - Literature	Public - Literature		Choi D, Kim S-K, Choi S-H, et al. Preventative Effects of Rosiglitazone on Restenosis after Coronary Stent Implantation in Patients with Type 2 Diabetes. <i>Diabetes Care</i> 2004 27:2654
2086	Public - Literature	Public - Literature	??/?/01	Abstracts from the ADA 61st Scientific Sessions: Mannucci E, Monami M, Di Bari M, Lamanna C, Gori F, Gensini GF, Marchionni N. Cardiac Safety Profile of Rosiglitazone: A Comprehensive Meta-Analysis of Randomized Clinical Trials. <i>Int J Cardiol</i> (2009) Mar 26 [Epub ahead of print]
2087	Public - Literature	Public - Literature		Lebovitz HE, Kreider M, Freed M. Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials. <i>Diabetes Care</i> (2002) 25:815-821
2088	Public - Literature	Public - Literature		Kawakami A, Osaka M, Aikawa M, Uematsu S, Akira S, Libby P, Shimokado K, Sacks FM, Yoshida M, Toll-Like 2 Receptor Mediates Apolipoprotein CII-Induced Monocyte Activation. <i>Circ Res</i> (2008)
2089	Public - Literature	Public - Literature		Mendivil C. ApoC-III Containing Lipoproteins and Risk of Coronary Heart Disease. 2009 International Symposium on Atherosclerosis [Abstract]
2090	Public - Literature	Public - Literature		Saudi Food and Drug Authority Drug Sector: Evaluation of the Safety and Efficacy Avandia compared to Actos
2091	Public - Literature	Public - Literature	2/27/2010	

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2092	Public - Literature	Public - Literature	??/??/1999	Owen S, Jones NP, Patwardhan R. Rosiglitazone Treatment Reduces Gamma-Glutamyltransferase Levels, a Marker for Visceral and Hepatic Fat. Diabetes (2000) presented at ADA 2000 [Abstract]
2093	Public - Literature	Public - Literature	??/??/1999	Cardiovascular Disease in the Elderly Patient
2094	Public - Literature	Public - Literature	??/??/1999	Dluhy RG, McMahon GT. Intensive Glycemic Control in the ACCORD and ADVANCE Trials. N Engl J Med (2008) 358:24 2630-2633
2095				Intentionally Omitted
2096	Public - Literature	Public - Literature	??/??/1999	Kawakami A, Alkawa M, Libby P, Alcaide P, Lusinskas FW, Sacks FM. Apolipoprotein CII in Apolipoprotein B Lipoproteins Enhances the Adhesion of Human Monocytic Cells to Endothelial Cells. Circulation (Feb 2006) 113:691-700
2097	Public - Literature	Public - Literature	??/??/1999	Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone Reduces Urinary Albumin Excretion in Type II Diabetes. J Hum Hypertens (2003) 17:7-12
2098	Public - Literature	Public - Literature	??/??/1999	Stewart M, Jones NP, Kreider M, Cohen B, Freed M, Biswas N, Ratner R, Brunzell J. Combined Effects of Rosiglitazone and Atorvastatin on the Dyslipidaemia Associated with Type 2 Diabetes. Diabetologia (2001) 44 (Suppl. 1):A222. 854 presented at EASD 2001 [Abstract]
2099	Public - Literature	Public - Literature	??/??/1999	Pantalone KM, Kattan MW, Yu C, et al. The Risk of Developing Coronary Artery Disease or Congestive Heart Failure, and Overall Mortality, in Type 2 Diabetic Patients Receiving Rosiglitazone, Pioglitazone, Metformin, or Sulfonylureas: A Retrospective Analysis. Acta Diabetol (2009) 46:145-154
2100	Public - Literature	Public - Literature	??/??/1999	Rosak C, Petzoldt R, Wolf R, et al. Rosiglitazone Plus Metformin is Effective and Well Tolerated in Clinical Practice: Results from Large Observational Studies in People with Type 2 Diabetes. Int J Clin Pract (2005) 59(10):1131-1136
2101	Public - Literature	Public - Literature	??/??/1999	Bhatt DL, Chew DP, Grines C, et al. Peroxisome Proliferator-Activated Receptor [gamma] Agonists for the Prevention of Adverse Events Following Percutaneous Coronary Revascularization - Results of the PPAR Study. Am Heart J (2007) 154:137-143
2102	Public Literature	Public Literature	??/??/1999	Rosiglitazone added to Soltfonylurea improves glycemic Control
2103	Public Literature	Public Literature	3/1/2006	Webb DR, Davies MJ, Gray LJ, Abrams KR, Srinivasan B, Das S, Taub N, Lawrence J, Sutton S, Khunti K.
2104	Public Literature	Public Literature	3/1/2006	Marfella, et al. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes. 2006 Mar; 55(3):622-32.

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2105	Public Literature	Public Literature	5/26/2006	Marfella, et. al. increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment. J Am Coll Cardiol. 2006 Jun 20;47(12):2444-55 Epub 2006 May 26
2106	Public-Literature	Public-Literature	2008	Editorial article in FUTURE MEDICINE "Have the risks of rosiglitazone been exaggerated?"
2107	Public-Literature	Public-Literature	Dec-07	Nature Clinical Practice Volume 3, No. 12, "Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus"
2108	Public-Literature	Public-Literature	7/14/2010	"Article in Press" Elsevier Letter to the Editor <i>Inaccuracy in meta-analysis on rosiglitazone and myocardial infarction</i>
2109	Public-Literature	Public-Literature	10/17/2007	Annals of Internal Medicine, Volume 147 Number 8, Perspective, "Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death"
2110	Public-Literature	Public-Literature	10/16/2007	Annals of Internal Medicine, Volume 147, Number 8 Editorial "Rosiglitazone: A Thunderstorm from Scarce and Fragile Data"
2111	Public-Literature	Public-Literature	4/27/2010	AHA/ACCF Science Advisory, "Thiazolidinedione Drugs and Cardiovascular Risks"
2112	Public-Literature	Public-Literature	2/10/2010	European Heart Journal (2010) 31, 773-776, Editorial, "The rise and fall of rosiglitazone"
2113	Public - Literature	Public - Literature	2003	Article - Braunstein MD, S, Clinical Therapeutics/Vol. 25, No. 7, 2003, "New Development in Type 2 Diabetes Mellitus: Combination Therapy with a Thiazolidinedione"
2114	Public - Literature	Public - Literature	2006	Scientific Therapeutics Information, Inc. (STI) "Welcome to STI", dated 9/2006, http://www.stimedinfo.com/
2115	Public - Literature	Public - Literature	2011	Article - Notes & Theories "How drug companies' PR tactics skew the presentation of medical research"
2116	Public - Literature	Public - Literature	May, 2005	Article - Smith, R., Plos Medicine, May 2005 Volume 2, Issue 5, e138 "Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies"
2117	Public - Literature	Public - Literature		Article - Layton, J., A Discovery Company, http://money.howstuffworks.com/money-laundering.htm/printable , "How Money Laundering Works"
2118	Public - Literature	Public - Literature	May, 2005	The Diabetes Prevention Program Research Group, Diabetes, Vol. 54, May 2005 "Intensive Lifestyle Intervention or Metformin on Inflammation and Coagulation in Participants With Impaired Glucose Tolerance"
2119	Public - Literature	Public - Literature	1/30/2008	GSK response to Grassley's letter dated 1/30/2008

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2120	Public - Literature	Public - Literature	2008	Haffner, British Journal of Nutrition (2000), 83, Suppl, 1, S67-S70, "Obesity and the metabolic syndrome: the San Antonio Heart Study"
2121	Public - Literature	Public - Literature	4/28/2010	Haffner, www.nejm.org on April 28, 2010 "Mortality From Coronary Heart Disease in Subjects With Type 2 Diabetes and in Nondiabetic Subjects With and Without Prior Myocardial Infarction"
2122	Public Document	Public Document	10/20/2000	Letter from B. Chong, Division of Drug Marketing, Advertising and Communications to S. Shapowal
2123	Public Document	Public Document	4/16/1999	Center for Drug Evaluation and Research, Application #021071, Medical Reviews Statement of Moncef Slaoui, PhD, before the House Committee on Oversight and Government Reform
2124	Public Document	Public Document	6/6/2007	Line Graph: Percent Study Reports Over Time
2125	Public Document	Public Document	10/31/2009	"Cardiovascular Events in the RECORD Trial" slide set
2126	Public Document	Public Document	NA	Letter to Clare Kahn from J. Jenkins, Office of Drug Evaluation I
2127	Public Document	Public Document	05/??/09	Line Graph: Percent Spontaneous Reports Over Time (ischaemic coronary artery disorders)
2128	Public Document	Public Document	10/31/2009	Testimony of Murray Stewart at the FDA Advisory Committee in 2007
2129	Public Document	Public Document	07/??/07	Handwritten Notes - Dr. Freed's Drug Development Priorities
2130	Public Document	Public Document	NA	An Analysis of FDA AERS for Thiazolidinedione Derivatives and Incretins- Anti-Diabetic Therapeutics for Type 2 Diabetes
2131	Public Document	Public Document	NA	Center for Drug Evaluation and Research, Application #021071, Medical Reviews
2132	Public Document	Public Document	4/16/1999	Center for Drug Evaluation and Research, Application #021071, Medical Reviews
2133	Public Document	Public Document	3/27/2003	Letter from L. Keenan, STA Health Care Communications, to Dr. S. Haffner
2134	Public Document	Public Document	9/17/2002	Email from J. Fiori to S. Haffner
2135	Public Document	Public Document	8/23/2002	Letter from M. Quinn, Medicalliance, to Dr. S. Haffner
2136	Public Document	Public Document	NA	Murray Stewart, DM FRCP, Slide Presentation
2137	Public Document	Public Document	NA	Fax from C. Kahn to J. Weber re Request for Revised Annotated Labeling and Outline of Phase IV Commitments
2138	Public Document	Public Document	5/5/1999	
2139	Public Document	Public Document	9/23/2010	Letter from J. Woodcock, Center for Drug Evaluation and Research to Margaret Kreider
2140	Public Document	Public Document	9/23/2010	Questions and answers on the suspension of rosiglitazone-containing medicines (Avandia, Avandamet, and Avaglim)
2141	Public Document	Public Document	5/21/2007	GlaxoSmithKline response to US Senate Committee on Finance
2142	Public Document	Public Document	3/28/2003	GlaxoSmithKline 2002 Annual Report
2143	Public Document	Public Document		73 Fed. Reg. 49605 - RULES and REGULATIONS DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2144	Public Document	Public Document	3/3/2006	GlaxoSmithKline 2005 Annual Report
2145	Public Document	Public Document	3/26/2004	GlaxoSmithKline 2003 Annual Report
2146	Public Document	Public Document	4/12/2001	GlaxoSmithKline 2000 Annual Report
2147	Public Document	Public Document	11/??/07	Committee Staff Report U.S. Committee on Finance silive.com: 'FDA issues safety alert on diabetes drug' By, M. Marchione
2148	Public Document	Public Document	5/21/2007	GlaxoSmithKline Press Release: GlaxoSmithKline initiates phase III programme for novel cardiovascular medication, darapladib
2149	Public Document	Public Document	12/18/2008	
2150	Public Document	Public Document	01/??/10	Baucus, M. and Grassley, C., Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia, Committee on Finance United States Senate, January 2010.
2151	Public Document	Public Document	2/25/2010	GlaxoSmithKline 2009 Annual Report
2152	Public Document	Public Document	7/6/2007	FDA Review of protocol for RECORD
2153	Public Document	Public Document	7/30/2007	FDA Summary of Minutes
2154	Public Document	Public Document	2/18/2010	Letter to FDA from Baucus and Grassley
2155	Public Document	Public Document	3/4/2009	GlaxoSmithKline 2008 Annual Report
2156	Public Document	Public Document	TBD	21 CFR § 314.70 - Supplements and other changes to an approved application Saudi Food and Drug Authority Drug Sector, Evaluation of the Safety and Efficacy Rosiglitazone (Avandia) Compared to Pioglitazone (Actos)
2157	Public Document	Public Document	2/27/2010	Committee Staff Report: The Intimidation of Dr. John Buse and the Diabetes Drug Avandia
2158	Public Document	Public Document	11/??/07	21 CFR § 314.80 - Post-marketing reporting of adverse drug experiences
2159	Public Document	Public Document		Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee
2160	Public Document	Public Document	7/30/2007	
2161	Public Document	Public Document	10/??/02	Prescription Drugs: FDA Oversight of Direct-to-Consumer Advertising Has Limitations
2162	Public Document	Public Document	9/2/2008	GlaxoSmithKline press release
2163	Public Document	Public Document	7/30/2007	GlaxoSmithKline Briefing Document for July 30, 2007 AdComm Meeting
2164	Public Document	Public Document		21 CFR § 201.80 Specific requirements on content and format of labeling for human prescription drug and biological products
2165	Public Document	Public Document	1/30/2008	U.S. Finance Committee: Senator Grassley's letter to GlaxoSmithKline
2166	Public Document	Public Document	3/28/2002	GlaxoSmithKline 2001 Annual Report
2167	Public Document	Public Document	3/2/2007	GlaxoSmithKline 2006 Annual Report
2168	Public Document	Public Document	7/30/2007	FDA Briefing Document
2169	Public Document	Public Document	2/28/2008	GlaxoSmithKline 2007 Annual Report
2170	Public Document	Public Document	3/4/2005	GlaxoSmithKline 2004 Annual Report
2171	Public Document	Public Document	3/1/2005	Guidance for Industry: Good Pharmacovigilance Practices and Pharacoepidemiologic Assessment

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2172	Public Document	Public Document	N/A	FDA HHS §201.57
2173	Public Document	Public Document		Food and Drug Administration Regulation 201.80 Specific requirement on content and format of labeling for human prescription drug and biological products
2174	Public Document	Public Document	January, 2010	Staff Report on Glaxosmithkline And The Diabetes Drug Avandia, 111th Congress 2d Session, dated January 2010
2175	Public Document	Public Document	7/12/2010	letter to The Honorable Margaret A. Hamburg from United States Senate Committee on Finance, dated 7/12/2010 and supporting materials
2176	Public Document	Public Document	6/28/2010	http://abciocal.go.com Diabetes drug risks reported ahead of FDA hearing Monday, June 28, 2010, by Graham
2177	Publicly Available	Publicly Available	Various	U.S. Lovaza Labels
2178	Publicly Available	Publicly Available	6/30/2006	FDA Warning Letter- Zovirax
2179	Publicly Available	Publicly Available	6/19/2003	FDA Warning Letter- Flonase
2180	Publicly Available	Publicly Available	5/13/2002	FDA Warning Letter- Imritex
2181	Publicly Available	Publicly Available	6/28/2001	FDA Warning Letter- Navelbine
2182	Publicly Available	Publicly Available	6/9/2000	FDA Warning Letter- Famvir
2183	Publicly Available	Publicly Available	11/20/2000	FDA Warning Letter Argatoban
2184	Publicly Available	Publicly Available	5/9/2000	FDA Warning Letter- Flovent
2185	Publicly Available	Publicly Available	4/28/2000	FDA Warning Letter- Lotronex
2186	Publicly Available	Publicly Available	3/10/2000	FDA Warning Letter- Flonase
2187	Publicly Available	Publicly Available	3/13/2000	FDA Warning Letter- Relenza
2188	Publicly Available	Publicly Available	2/9/1999	FDA Warning Letter- Coreg
2189	Publicly Available	Publicly Available	9/9/1999	FDA Warning Letter Bactroban
2190	Publicly Available	Publicly Available	2/1/1999	FDA Warning Letter- Valtrex
2191	Publicly Available	Publicly Available	3/9/1999	FDA Warning Letter- Zofran
2192	Publicly Available	Publicly Available	4/23/1999	FDA Warning Letter- Combivir
2193	Publicly Available	Publicly Available	6/4/1999	FDA Warning Letter- Agenerase
2194	Publicly Available	Publicly Available	6/21/1999	FDA Warning Letter- Navelbine
2195	Publicly Available	Publicly Available	9/17/1999	FDA Warning Letter- Flonase
2196	Publicly Available	Publicly Available	8/18/1999	FDA Warning Letter- Flonase
2197	Publicly Available	Publicly Available	11/30/1999	FDA Warning Letter- Flovent
2198	Publicly Available	Publicly Available	11/23/1999	FDA Warning Letter- Relenza
2199	Publicly Available	Publicly Available	1/31/2005	FDA Warning Letter- Coreg
2200	Publicly Available	Publicly Available	6/9/2004	FDA Warning Letter- Paxil
2201	Publicly Available	Publicly Available	7/6/2004	FDA Warning Letter- Erygeix
2202	Publicly Available	Publicly Available	11/14/2007	FDA News Release: FDA adds boxed warning for Heart-related risks to Anti-Diabetes Drug Avandia.

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2203	Publicly Available	Publicly Available	5/21/2007	FDA safety Alert on Avandia.
2204	Publicly Available	Publicly Available	March, 2008	What is Avandia - http://www.avandia.com/
2205	Publicly Available	Publicly Available	October, 2007	What is Avandia - http://web.archive.org/web/20080306045731/http://www.avandia.com/index.html
2206	Publicly Available	Publicly Available	November, 2006	What is Avandia - http://web.archive.org/web/20071019042113/http://www.avandia.com/
2207	Publicly Available	Publicly Available	December, 2010	Important Safety Information for Avandia - Update on Avandia - http://www.avandia.com/
2208	Regulatory Material	Regulatory Material	6/28/2001	Letter from B. Chong, Division of Drug Marketing, Advertising and Communication, to S. Shapowal
2209	Regulatory Material	Regulatory Material	7/17/2001	Letter from B. Chong, Department of Drug Marketing, Advertising and Communication, to J.P. Garnier
2210	Regulatory Material	Regulatory Material	3/25/2008	Letter from M. Wholeske, Department of Health and Human Services, to J.P. Garnier
2211	Regulatory Materials	Regulatory Materials		Approval Package - Medical Officer Reviews
2212	Regulatory Materials	Regulatory Materials	04/??/1999	Medical Officer Review
2213	Regulatory Materials	Regulatory Materials	7/13/2010	July 2010 AdComm Transcript
2214	Regulatory Materials	Regulatory Materials	7/29/2005	2005-07-29 - Approval Letter
2215	Regulatory Materials	Regulatory Materials	5/12/2005	2005-05-12 - Approval Letter
2216	Regulatory Materials	Regulatory Materials	5/12/2005	2005-05-12 - Label
2217	Regulatory Materials	Regulatory Materials	11/14/2007	2007-11-14 Label
2218	Regulatory Materials	Regulatory Materials	5/19/2004	2004-05-19 - Approval Letter
2219	Regulatory Materials	Regulatory Materials	4/28/1999	Letter from M. Askin, Division of Drug Marketing, Advertising and Communications, to C Kahn
2220	Regulatory Materials	Regulatory Materials	10/20/2008	2008-10-20 Approval Letter
2221	Regulatory Materials	Regulatory Materials	10/20/2008	2008-10-20 Label
2222	Regulatory Materials	Regulatory Materials	7/13/2010	July 2010 AdComm Transcript
2223	Regulatory Materials	Regulatory Materials	8/14/2007	2007-08-14 - Approval Letter
2224	Regulatory Materials	Regulatory Materials	2/28/2005	2005-02-28 Label
2225	Regulatory Materials	Regulatory Materials	5/25/1999	1999-05-25 Label - Initial
2226	Regulatory Materials	Regulatory Materials	4/21/2006	2006-04-21 - Label
2227	Regulatory Materials	Regulatory Materials	8/18/1999	Department of Health & Human Services Warning Letter to Morrow
2228	Regulatory Materials	Regulatory Materials	1/16/2008	2008-01-16 Label
2229	Regulatory Materials	Regulatory Materials	7/7/2007	FDA - Mele July 2007 AdComm Slides
2230	Regulatory Materials	Regulatory Materials		Procedural Steps Taken from EMEA website
2231	Regulatory Materials	Regulatory Materials	1/16/2008	2008-01-16 Approval Letter
2232	Regulatory Materials	Regulatory Materials	4/21/2006	2006-04-21 - Approval Letter
2233	Regulatory Materials	Regulatory Materials	7/30/2007	July 2007 Ad Comm Transcript

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
22234	Regulatory Materials	Regulatory Materials	7/29/2005	2005-07-29 - Label
22235	Regulatory Materials	Regulatory Materials	2/27/2003	2003-02-27 Approval Letter
22236	Regulatory Materials	Regulatory Materials	1/4/2005	2005-01-04 Approval Letter
22237	Regulatory Materials	Regulatory Materials	7/10/2008	2008-07-10 Label - ADAPT
22238	Regulatory Materials	Regulatory Materials	7/30/2007	2007-07-30 AC Meeting Minutes
22239	Regulatory Materials	Regulatory Materials	4/23/2007	2007-04-23 - Label
22240	Regulatory Materials	Regulatory Materials	6/16/2006	2006-06-16 - Label
22241	Regulatory Materials	Regulatory Materials	4/23/2007	2007-04-23 - Approval Letter
22242	Regulatory Materials	Regulatory Materials	4/4/2000	2000-04-04 - Approval Letter
22243	Regulatory Materials	Regulatory Materials	1/4/2005	2005-01-04 Label
22244	Regulatory Materials	Regulatory Materials	7/10/2008	2008-07-10 Approval Letter
22245	Regulatory Materials	Regulatory Materials	2/27/2003	2003-02-27 Label
22246	Regulatory Materials	Regulatory Materials	2/22/2008	2008-02-22 Label
22247	Regulatory Materials	Regulatory Materials	4/3/2000	2000-04-03 - Label - sNDA
22248	Regulatory Materials	Regulatory Materials	5/25/1999	1999-05-25 Final Labeling - Initial
22249	Regulatory Materials	Regulatory Materials	9/20/2007	2007-09-20 - Label
22250	Regulatory Materials	Regulatory Materials	9/20/2007	2007-09-20 - Approval Letter
22251	Regulatory Materials	Regulatory Materials	2/22/2008	2008-02-22 Approval Letter
22252	Regulatory Materials	Regulatory Materials		Avandia SmPC 2007 - October
22253	Regulatory Materials	Regulatory Materials	11/14/2007	2007-11-14 Approval Letter
22254	Regulatory Materials	Regulatory Materials	02/??/01	2001-02 Label
				2010 Senate Letter to FDA with attachments (including Letter from David J. Graham to Mary Parks dated October 7, 2008)
22255	Regulatory Materials	Regulatory Materials	2/18/2010	Mary Parks dated October 7, 2008
22256	Regulatory Materials	Regulatory Materials	2/28/2005	2005-02-28 Approval Letter
22257	Regulatory Materials	Regulatory Materials	8/14/2007	2007-08-14 - Label
22258	Regulatory Materials	Regulatory Materials	6/16/2006	2006-06-16 - Approval Letter
22259	Regulatory Materials	Regulatory Materials	12/3/2002	2002-12-03 Approval Letter
22260	Regulatory Materials	Regulatory Materials	5/25/1999	1999-05-25 Approval Letter
22261	Regulatory Material	Regulatory Material	3/19/2000	3/19/00 MOR for sNDA
22262	Regulatory Material	Regulatory Material	10/00/2006	Avandia Summary of Product Characteristics
22263	Regulatory Materials	Regulatory Materials	5/23/2007	Press Release - "EMEA statement on recent publication on cardiac safety of rosiglitazone (Avandia, Avandamet, Avaglim)"
22264	Regulatory Materials	Regulatory Materials	9/30/2007	EMEA SmPC - Annex 1 Summary of Product Characteristics
				Confidential UIM2008/00311/01 - update European Union Risk Management Plan for Avandia
22265	Regulatory Materials	Regulatory Materials	2009	Product Monograph Avandia
22266	Regulatory Materials	Regulatory Materials	3/12/2009	Annex 1 Summary of Product Characteristics
22267	Regulatory Materials	Regulatory Materials	2009	Background information of the procedure
22268	Regulatory Materials	Regulatory Materials	3/16/2000	Letter to all health care professionals from GSK Important Safety Information Regarding Avandia
22269	Regulatory Materials	Regulatory Materials	11/13/2001	

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2270	Regulatory Materials	Regulatory Materials	9/1/2003	Scientific Discussion - Avandia
2271	Regulatory Materials	Regulatory Materials	9/30/2003	EMEA Chart - Scientific information and changes made before Sept. 2003
2272	Regulatory Materials	Regulatory Materials	5/26/2005	Scientific Discussion - Avandia
2273	Regulatory Materials	Regulatory Materials	12/20/2005	GSK memo re: an association between Avandia and Avandamet and vision problems in diabetics
2274	Regulatory Materials	Regulatory Materials	2007	2007 EMEA Chart - scientific information and changes made after Sept 2003
2275	Regulatory Materials	Regulatory Materials	2/27/2010	Saudi Arabia's food & drug authority drug sector
2276	Regulatory Materials	Regulatory Materials	7/10/2010	Annex 1 Summary of Product Characteristics
2277	Regulatory Materials	Regulatory Materials	7/7/2006	Summary of Product Characteristics
2278	Regulatory Materials	Regulatory Materials	10/7/2006	Summary of Product Characteristics
2279	Regulatory Materials	Regulatory Materials	2/7/2007	Summary of Product Characteristics
2280	Regulatory Materials	Regulatory Materials	7/7/2007	Summary of Product Characteristics
2281	Regulatory Materials	Regulatory Materials	6/7/2007	Summary of Product Characteristics
2282	Regulatory Materials	Regulatory Materials	10/7/2007	Summary of Product Characteristics
2283	GSK Annual Report	GSK Annual Report	2000	GSK Annual Report
2284	GSK Annual Report	GSK Annual Report	2001	GSK Annual Report
2285	GSK Annual Report	GSK Annual Report	2002	GSK Annual Report
2286	GSK Annual Report	GSK Annual Report	2003	GSK Annual Report
2287	GSK Annual Report	GSK Annual Report	2004	GSK Annual Report
2288	GSK Annual Report	GSK Annual Report	2005	GSK Annual Report
2289	GSK Annual Report	GSK Annual Report	2006	GSK Annual Report
2290	GSK Annual Report	GSK Annual Report	2007	GSK Annual Report
2291	GSK Annual Report	GSK Annual Report	2008	GSK Annual Report
2292	GSK Annual Report	GSK Annual Report	2009	GSK Annual Report
				The ALLHAT officers and coordinators for the ALLHAT collaborative Research Group journal article - JAMA-Express
2293	Public - Literature	Public - Literature	12/18/2002	Ferreira article in BMJ
2294	Public - Literature	Public - Literature	4/2/2007	Montori article in BMJ
2295	Public - Literature	Public - literature	10/5/2007	Psaty article in The New England Journal of Medicine
2296	Public - Literature	Public - literature	6/14/2007	article from Harvard University Biostatistics Working Paper Series, 2007-10 Wei Meta Paper, Paper 6, #9
2297	Public - Literature	Public - Literature	2007	- 14 pages, by L. Tian, T. Cai, N. Pian Kov, P. Cremieux and L. Wei article - Dormuth, C.R., et al., published in Plos One June 2009, volume 4, Issue 6, "Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin"
2298	Public - Literature	Public - Literature	6/7/2009	Abassi article "Comparison of Three Treatment Approaches to Decreasing Cardiovascular Disease Risk in Non-diabetic Insulin-Resistant Dyslipidemic Subjects"
2299	Public - Literature	Public - Literature	2008	

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2300	Public - Literature	Public - Literature	10/10/2002	ADOPT publication - Epidemiology/Health Services/Psychosocial Research (ADOPT)
2301	Public - Literature	Public - Literature	1997	Agewall article
2302	Public - Literature	Public - Literature	7/3/2007	Aguilar article in JACC Journal of the American College of Cardiology
2303				Intentionally Omitted
2304	Public - Literature	Public - Literature	5/11/2010	Jonas article in AHA Medical/Scientific Statement
2305	Public - Literature	Public - Literature	11/8/2000	Zhong Chen article "Troglitazone Inhibits Atherosclerosis in Apolipoprotein E-Knockout Mice"
2306	Public - Literature	Public - Literature	12/4/2008	Roland Stocker and John F. Keaney Jr., article
2307	Public - Literature	Public - Literature	1/7/2001	article - Chinetti et al., Nature Publishing Group "PPAR-x and PPAR-y activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA 1 pathway
2308	Public - Literature	Public - Literature	12/1/2000	article - Collins, A.R., et al., Arterioscler Thromb Vasc Biol 2001; 21:365-371, "Troglitazone Inhibits Formation of Early Atherosclerotic Lesions in Diabetic and Nondiabetic Low Density Lipoprotein Receptor - Deficient Mice"
2309	Public - Literature	Public - Literature	9/8/2007	Eurich article "Benefits of harms of antidiabetic agents in patients with diabetes and heart failure: systematic review
2310	Public - Literature	Public - Literature	11/10/2005	article - Bailey, C.J., Bagdonas, A., Clinical Therapeutics/VOLUME 27 "Rosiglitazone/Metformin Fixed-Dose Combination Compared with Up titrated Metformin Alone in Type 2 Diabetes Mellitus: A 24-week, Multicenter, Randomized, Double-Blind, Parallel-Group Study"
2311	Public - Literature	Public - Literature	3/31/1990	MacMahon article - The Lancet
2312	Public - Literature	Public - Literature	1992	Kannel article "Left Ventricular Hypertrophy and Mortality - Results from the Framingham Study"
2313	Public - Literature	Public - Literature	12/28/2005	Meisner article "Effect of Rosiglitazone Treatment on Plaque Inflammation and Collagen Content in Nondiabetic Patients"
2314	Public - Literature	Public - Literature	9/29/2007	Editorial, www.thelancet.com Vol 370 "Ensuring drug safety: lessons from the thiazolidinediones"
2315	Public - Literature	Public - Literature	6/2/2007	Editorial, www.thelancet.com Vol 369 "The deteriorating health situation in Iraq" "Rosiglitazone: seeking a balanced perspective"
2316				Intentionally Omitted
2317	Public - Literature	Public - Literature	1/8/1994	BMJ volume 308 [abstract], Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients"

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2318	Public - Literature	Public - Literature	5/2/2010	Carey PhD, V.J., Bishop BS, L, Laranjo BA, N, et al. article www.ajconline.org "Contribution of High Plasma Triglycerides and Low High-Density Lipoprotein Cholesterol to Residual Risk of Coronary Heart Disease After Establishment of Low-Density Lipoprotein Cholesterol Control"
2319	Public - Literature	Public - Literature	10/27/2008	Selvin PhD, E., Bolen MD, S., et al., Review Article, Arch Intern Med/Vol 168 (no. 19) www.archinternmed.com "Cardiovascular Outcomes in Trials of Oral Diabetes Medications"
2320	Public - Literature	Public - Literature	2008	Assayag, E.B., Bova, I., Kesler, A, et al, IOS Press "Erythrocyte aggregation as an early biomarker in patients with asymptomatic carotid stenosis"
2321	Public - Literature	Public - Literature	5/16/2001	Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, JAMA, Vol 285 No. 19 "Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)"
2322	Public - Literature	Public - Literature	6/7/2003	Publication - Rose, N., & Afanasyeva, M., Nature Medicine Volume 9, Number 6 "Autoimmunity: busting the atherosclerotic plague"
2323	Public - Literature	Public - Literature	12/19/2007	Study No. AVD104742
2324	Public - Literature	Public - Literature	8/7/2005	article - Babaev, V.R., Yancey, P.G., Ryzhov, S.V., et al, Arterioscler Thromb Vasc Biol, "Conditional Knockout of Macrophage PPAR γ Increases Atherosclerosis in C57BL/6 and Low-Density Lipoprotein Receptor-Deficient Mice"
2325	Public - Literature	Public - Literature	9/3/2006	article - Bahia, L., Aguilal, L.G.K., et al., Atherosclerosis 195 (2007) 138-146, "Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome"
2326	Public - Literature	Public - Literature	2006	article - Bakris, G.L., Ruilope, L.M., McMorn, S.O., et al., Journal of Hypertension 2006, Vol 24 No. 10 "Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria"
2327	Public - Literature	Public - Literature	4/10/1991	article - Barrett-Conner & Bush, JAMA - Vol 265, No.14 "Estrogen and Coronary Heart Disease in Women"
2328	Public - Literature	Public - Literature	11/22/2007	article - Barter MD, P.J., Caulfield MD, M., et al., The New England Journal of Medicine, "Effects of Torcetrapib in Patients at High Risk for Coronary Events"

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2329	Public - Literature		2008	article - Berneis, K., Rizzo, M., Stettler, C., et al., Expert Opinion "Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with type 2 diabetes"
2330	Public - Literature		2008	article - Betteridge, J., et al., European Heart Journal (2008) 29, 969-983, "PROactive: time for a critical appraisal!"
2331	Public - Literature		7/18/2008	article - Beyens, C., Murphy E.J., et al., Journal of Lipid Research Volume 49, (2008), "A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes"
2332	Public - Literature		6/7/1992	article - Edwin L. Bierman, Arteriosclerosis and Thrombosis Vol 12, No. 6 June 1992 "Atherogenesis in Diabetes"
2333	Public - Literature		7/14/2010	article - Bilik, D., McEwan, L.N., Brown, M.B., et al., J Clin Endocrinol Metab, October 2010, 95(10):0000-0000 "Thiazolidinediones and Fractures: Evidence from translating research into action for diabetes"
2334	Public - Literature	AVMDL07915180	2007 10/13/2003	editorial - Bilous, 2007 Diabetes UK. Diabetic Medicine, 24, 931-933 "Rosiglitazone and myocardial infarction: cause for concern or misleading meta-analysis?" email from Nigel P. Jones to Hubert S. Chou re: Draft of FDA Briefing Document for review
2335	AVMDL07915154		11/1/2001	article - Blake et al., JACC Vol. 38, No. 5, 2001, "A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women"
2336	Public - Literature		9/7/2007	article - Bloomgarden, Diabetes Care, Volume 30 Number 9, September 2007 "The Avandia Debate"
2337	Public - Literature		6/11/2009	editorial - Boden, W.E., & Taggart, D.P., N Engl J Med 360; 24 NEJM.ORG "Diabetes with Coronary Disease - A Moving Target Amid Evolving Therapies?"
2338	Public - Literature		3/30/2010	article - Bohm, M.B., Baumhakel, M., et al., Circulation "Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both"
2339	Public - Literature		11/7/2007	article - Boyle MD P.J., Southern Medical Journal, Volume 100, Number 11, November 2007 "Thiazolidinediones and Clinical Diabetes Management: New Challenges for the Fall of 2007"
2340	Public - Literature		8/30/2007	article - Bracken, N Engl J Med 357;9 www.NEJM.org, "Rosiglitazone and Cardiovascular Risk"

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2342	Public - Literature		3/26/2009	abstract - Brackenridge, A.L., Jackson, N., et al., Diabetic Medicine, 26, 532-539 "Original article: Treatment effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with type 2 diabetes and normal lipids"
2343	Public - Literature		8/6/2008	article - Buse, J.B., Ginsberg, H.N., et al., Circulation, "Primary prevention of cardiovascular diseases in people with diabetes mellitus"
2344	Public - Literature		4/24/2008	commentary - Calif, R.M., Framer, J.M., Pharmacoepidemiology and Drug Safety 2008; 17: 782-786, "the balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment"
2345	Public - Literature		7/8/2009	article - Lamarche, B., Tchernof, A., et al., Circulation, "Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men"
2346	Public - Literature		8/26/2001	article - St. Pierre, A.C., Ruel, I.L. et al., Circulation www.circulationaha.org "Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease"
2347	Public - Literature		2006	article - Zheng, CAO, Yu-jie, Z., Ying-xin, Z., et al., Chinese Medical Journal 2006; 119(14):1171-1175, Rosiglitazone could improve clinical outcomes after coronary stent implantation in nondiabetic patients with metabolic syndrome"
2348	Public - Literature		2008	article - Petrazzi, L., Grassi D., Polidoro, L., et al., Jnephrol 2008; 21: 826-835 "Cardiovascular risk and cardiometabolic protection: role of glitazones"
				letter to the editor - Shuster, J.J., Jones, L.S., et al., Statistics in Medicine Statist. Med 2008; 27, 3910-
				3924 "Comments on fixed vs. random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death"
2349	Public - Literature		2008	article - Carr, A., Workman, C., Carey, D., et al., The Lancet, Vol 363 "No effect of rosiglitazone for treatment of HIV-1 lipodistrophy: randomised, double-blind, placebo-controlled trial!"
2350	Public - Literature		2/7/2004	article - Casas, J.P., Ninio, E., et al., Circulation. 2010; 121: 2284-2293 "PLA267 Genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European ancestry"
2351	Public - Literature		4/5/2010	article - Casscells, S.W., Granger, E., et al., American Journal of Therapeutics, "A comparison of select cardiovascular outcomes by antidiabetic prescription drug classes used to treat type 2 diabetes among military health system beneficiaries, fiscal year 2003-2006"
2352	Public - Literature		2008	

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2353	Public - Literature	Public - Literature	1988	abstract - Castelli, W., The Canadian Journal of Cardiology Vol. 4 Supplement A, July 1988 "Cholesterol and lipids in the risk of coronary artery disease - The Framingham Heart Study"
2354	Public - Literature	Public - Literature	6/29/2007	article - BMJ.com rapid responses for Kazi, 334 (7606) 1233-1234 "How big is the increase in myocardial infarction risk with rosiglitazone"
2355	Public - Literature	Public - Literature	1/8/2007	article - Chappuis, et al., Diabetes/Metabolism Research and Reviews diabetes metab rev 2007; 23: 392-399 "Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study"
2356	Public - Literature	Public - Literature	1/7/2001	article - Chawla, A., Boisvert, A.A., et al, Molecular Cell, vol 7, 161-171, 'A PPARY-LXR-ABCA1 Pathway in Macrophages is involved in Cholesterol Efflux and Atherogenesis'
2357	Public - Literature	Public - Literature	5/21/2003	article - Chobanian et al., JAMA, vol 289, No. 19 (reprinted), "the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:
2358	Public - Literature	Public - Literature	2/7/2005	abstract - Chu, J.W., Abbasi, F., et al., Diabetes Vasc Dis Res Volume 2 issue 1 "Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects"
2359	Public - Literature	Public - Literature	2006	article - Chu, C., Lee, K., et al., www.AJConline.org "Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus"
2360	Public - Literature	Public - Literature	9/29/2007	John GF Cleland - www.thelancet.com Vol 370 September 29, 2007 "Thiazolidinediones, deadly sins, surrogates, and elephants
2361	Public - Literature	Public - Literature	8/5/2008	article - Staflas, P.C., Sarafidis, P.A., and Lasaridis, A.N., International Journal of Cardiology 131 (2009) 298-304 "The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality"
2362	Public - Literature	Public - Literature	7/2/2007	article - Couzin, J., www.sciencemag.org vol 316, "Heart Attack Risk Overshadows A Popular Diabetes Therapy"
2363	Public - Literature	Public - Literature	5/3/2003	article - King, D.E., Muchanan, T.A., et al., Diabetes Care, Vol 26, Number 5 "C-Reactive Protein and Glycemic Control in Adults With Diabetes"
2364	Public - Literature	Public - Literature	2008	article - Dahabreh, I.J., Clinical Trials 2008; 5: 116-120 "Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone"

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2365			2007	article - Dargie, H.J., Hildebrandt, R., Journal of the American College of Cardiology, vol 49, No. 16, 2007, "A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart failure"
2366	Public - Literature	Public - Literature	1999	report - 1999 Surveillance report, Data & Trends, Diabetes Surveillance System - Table 3.16 Death Rates for Diabetes as Underlying Cause per 100,000 Population, Males, by Age, United States, 1980-1996
2367	Public - Literature	Public - Literature	4/22/2005	article - Dekker, J.M., Girman, C., et al., Circulation, "Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study"
2368	Public - Literature	Public - Literature	2007	article - Derosa, G., D'Angelo, A., et al., Internal Medicine Journal 37 (2007) 79-86, "Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin"
2369	Public - Literature	Public - Literature	2006	article - Derosa, G., D'Angelo, A., et al., Journal of Clinical Pharmacy and Therapeutics (2006) 31, 375-383, "Metformin - pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factor plasma level in type 2 diabetic patients with metabol syndrome"
2370	Public - Literature	Public - Literature	12/26/2006	article - Derosa, G., et al., Department of Internal Medicine and Therapeutics, University of Pavia, "Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin"
2371	Public - Literature	Public - Literature	2004	abstract - Derosa, G., et al., Clinical Therapeutics/Vol 26 No. 5., 2004 "Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve-month multicenter, double-blind, randomized, controlled, parallel-group trial"
2372	Public - Literature	Public - Literature	2002	article - Diep, Q.N., et al., Circulation, "Structure, Endothelial Function, Cell Growth, and Inflammation in Blood Vessels of Angiotensin II-Infused Rats"
2373	Public - Literature	Public - Literature	2007	article - Doggrell, S.A., Expert Opin. Pharmacotherapy (2007) 8(15):2665-2669 "Does rosiglitazone increase cardiovascular outcomes?"
2374	Public - Literature	Public - Literature	11/10/1956	article - Doll, R., Hill, A.B., British Medical Journal, "Lung Cancer and Other Causes of Death in Relation to Smoking"
2375	Public - Literature	Public - Literature	2009	article - Dore, D.D., Trivedi, A.N., et al., Pharmacotherapy volume 29, number 7, 2009 "Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction"

Nancy LaVoice v. GSK
Plaintiff's Exhibit List

#	Bates Start	Bates End	Date	Exhibit Description
2376	Public - Literature	Public - Literature	10/8/2005	article - Dormandy, J.A., Charbonne, D.J.A., et al., www.thelancet.com vol 366 October 8, 2005 "Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitazone clinical trial in macroVascular events); a randomised controlled trial"
2377	Public - Literature	Public - Literature	9/15/2006	article - published online 9/15/2006, The Lancet, "Glucose lowering and diabetes prevention: are they the same?"
2378	Public - Literature	Public - Literature	12/9/2006	article - www.thelancet.com vol 368, "Correspondence"
2379	Public - Literature	Public - Literature	11/18/2006	article - www.thelancet.com vol 368, "Correspondence"
2380	Public - Literature	Public - Literature	9/24/2007	article - Dagenais, G.R., "Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People with Impaired Glucose Tolerance or Impaired Fasting Glucose: A Randomised, Controlled Trial. Results of the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) Study
2381	Public - Literature	Public - Literature		Study No. AVD113985
2382	Public - Literature	Public - Literature	11/7/2008	editorial - Malik, N.N., Drug Discovery Today, volume 13, number 21/22, November 2008, "Drug discovery: past, present and future"
2383	Court Record	Court Record		Pre-Trial Pleadings and Filings by Plaintiff
2384	Court Record	Court Record		Pre-Trial Pleadings and Filings by Defendants
2385	Court Record	Court Record		Any document attached as an exhibit to any motion, order, brief filed by Plaintiff or Defendant
2386	Court Record	Court Record		Any document offered as an exhibit at any hearing held in this case
2387	Court Record	Court Record		Any document relied upon by any expert witness endorsed by Plaintiff or Defendants
2388	Court Record	Court Record		All hearing transcripts in this matter
2389	Court Record	Court Record		Any discovery responses by Defendant in this matter.
2390	Court Record	Court Record		All transcripts and video of any testimony given under oath by any witness in LaVoise v. SmithKlineBeecham Corporation d/b/a GlaxoSmithKline, et al.; Case No. YC059911.
2391	Demonstrative	Demonstrative		Avandia Pills and Bottle
2392	Demonstrative	Demonstrative		Demonstrative exhibits, including but not limited to timelines, enlargements of exhibits or compilations of evidence.
2393				All video, deposition transcripts and deposition exhibits of expert witnesses designated in Johnson v. SmithKlineBeecham Corp., Case No. INCO072316.
2394				Any document necessary for rebuttal, sur-rebuttal, or impeachment purposes
2395				Any exhibit endorsed by Defendant